Olefinic compounds, process for their preparation and their use in medicine

Abstract

This disclosure relates to olefin compounds, methods for their preparation, and their pharmaceutical applications. Specifically, this disclosure relates to an olefin compound of general formula (I), methods for its preparation, pharmaceutical compositions containing such compounds, and its use as a therapeutic agent, particularly as an IL-17 inhibitor, and its use in the preparation of medicaments for the treatment and / or prevention of cancer, inflammation, or autoimmune diseases. The groups in general formula (I) are as defined in the specification.

Description

Olefin compounds, preparation methods thereof and their applications in medicine Technical Field

[0001] The present disclosure relates to the field of medicine and relates to an olefin compound, a method for preparing the same, and its use in medicine. In particular, the present disclosure relates to an olefin compound represented by general formula (I), a method for preparing the same, and a pharmaceutical composition containing the same, as well as its use as an IL-17 inhibitor and its use in the preparation of a medicament for treating and / or preventing cancer, inflammation, or autoimmune diseases. Background Art

[0002] IL-17 is a proinflammatory cytokine primarily produced by Th17 cells. IL-17 can act on epithelial cells, prompting them to secrete antimicrobial peptides and cytokines and promoting damage repair. Therefore, IL-17 plays a crucial role in the body's defense against foreign pathogens. However, excessive or abnormal IL-17 can induce chronic inflammation and contribute to various autoimmune diseases, such as psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. The IL-17 family includes six members, IL-17A-F. IL-17A and IL-17F are Th17-associated cytokines. IL-17A and IL-17F can form three active dimers: IL-17AA, IL-17AF, and IL-17FF. IL-17AA exhibits the strongest proinflammatory activity. Compared to IL-17AA, IL-17AF is 10-fold less active, and IL-17FF is 100-fold less active. In addition, IL-17AA is the most important IL-17 cytokine mediating the occurrence of psoriasis, and the IL-17AA content in psoriasis patients is positively correlated with the severity of the disease.

[0003] Currently, the FDA has approved three IL-17 drugs. Novartis's Secukinumab is the first approved IL-17 (IL-17A) drug, with indications including psoriasis, psoriatic arthritis, axial spondyloarthritis, and juvenile atopic arthritis. Eli Lilly's Ixekizumab (IL-17A) is approved for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis. Valeant's Brodalumab (IL 17RA) is approved for the treatment of psoriasis, but patients taking the drug are at risk of suicide, and the FDA has added a black box warning. UCB's Bimekizumab (dual inhibition of IL-17A and F) has been approved for the treatment of psoriasis in the European Union and Japan, and is awaiting FDA approval in the United States.

[0004] IL-17 biological agents have differentiated designs. Secukinumab and Ixekizumab are traditional antibodies that are selective for IL-17A; Bimekizumab is a traditional antibody that dually inhibits IL-17A and F; Sonelokimab is a nanobody that dually inhibits IL-17A and F, with a molecular weight of 40kD and a human albumin-binding domain; Izokibep is an IL-17A-selective Affibody fusion protein with a molecular weight of 18.6kD and a human albumin-binding domain.

[0005] Overall, IL-17 antibodies have demonstrated excellent efficacy in psoriasis, with PASI 75 response rates reaching 75-90% after 12 weeks of treatment. The IL-17A-selective drugs secukinumab and ixekizumab have similar safety and efficacy profiles. In a head-to-head Phase 3 clinical trial of IL17A / F versus IL-17A antibodies, both IL17A / F antibodies demonstrated superior efficacy compared to IL-17A antibodies, but the side effect of oral Candida infections was significantly higher in IL17A / F than in IL-17A antibodies. Gene knockout studies in mice and human genetic studies have also demonstrated that both IL-17A and IL-17F play important roles in the body's defense against fungal infections such as Candida albicans, and that complete inhibition of IL-17A and IL-17F can increase Candida infection. Furthermore, psoriasis disease characteristics differ between Asians and Westerners: Westerners have larger lesions, while Asians have smaller lesions. However, Asian lesions contain higher concentrations of IL-17A. IL-17A antibodies are more effective in treating psoriasis in Asians. Therefore, selective inhibition of IL-17A is the most appropriate option for psoriasis.

[0006] Hidradenitis suppurativa is a difficult-to-treat autoimmune disease. Currently, only adalimumab is approved. Tissue damage and inflammation in hidradenitis suppurativa occur more deeply, requiring therapeutic agents with good tissue penetration. Furthermore, studies have shown that both IL-17A and IL-17F are enriched to a certain extent in hidradenitis suppurativa lesions, suggesting that both IL-17A and IL-17F play a role in disease pathogenesis. In a Phase 3 clinical trial for hidradenitis suppurativa, secukinumab increased HiSCR50 by 11% compared to placebo, while bimekizumab increased it by 26%, and sonelokimab by 38%. Izokibep, with a HiSCR50 of 71%, is currently the most effective IL-17 drug, but lacks a placebo control. For hidradenitis suppurativa, sonelokimab and izokibep, with their smaller molecular weight and better permeability, are more effective.

[0007] Targeting the combination of IL-17A and IL-17RA is an effective strategy for treating IL-17A-mediated autoimmune inflammatory diseases. Currently approved IL-17A neutralizing antibodies, secukinumab and ixekizulmab, can effectively treat IL-17A-mediated autoimmune inflammatory diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis.

[0008] Although there are many IL-17A antibodies, due to the cost of producing antibodies and the limitation of administration route (injection), the development of oral small molecule inhibitor drugs specific for IL-17A has good research and development prospects. Summary of the Invention

[0009] The present invention aims to provide a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.

[0010] in:

[0011] Ring A is selected from aryl, heteroaryl, cycloalkyl and heterocyclyl;

[0012] Ring B is a cycloalkyl group or a heterocyclic group;

[0013] R 1 is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkylalkyl group, and a heterocyclylalkyl group;

[0014] R 2 is selected from hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, -C(O)R a 、-C(S)R a 、-C(O)OR a and -C(O)NR b R c The alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl groups are each independently optionally substituted by one or more R A replace;

[0015] R a 、R b and R c are the same or different and are each independently selected from a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group and a heteroarylalkyl group; the alkyl group, the alkenyl group, the alkynyl group, the cycloalkyl group, the heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group and a heteroarylalkyl group are each independently optionally replaced by one or more RA replace;

[0016] Or, R b and R c Together with the nitrogen atom to which it is attached, it forms a heterocyclic group, which is optionally substituted by one or more R A replace;

[0017] R 3 A hydrogen atom or

[0018] n4 is 0, 1, 2, or 3;

[0019] n5 is 0, 1, 2, or 3;

[0020] R 3a 、R 3b 、R 3c and R 3d are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, hydroxyl, cyano, amino, nitro, -(CR x R y ) s OR d 、-(CR x R y ) s NR e R f 、-C(O)R d 、-C(S)R d 、-C(O)OR d 、-C(S)OR d 、-OC(O)R d 、-OC(O)NR e R f 、-C(O)NR e R f 、-C(S)NR e R f 、-NR g C(O)R d 、-NR g C(S)R d 、-NR g C(O)OR d 、-NR g C(S)OR d 、-NR g C(O)NR e R f 、-NR gC(S)NR e R f 、-S(O) v R d 、-S(O) v OR d 、-S(O) v NR e R f 、-NR g S(O) v NR e R f 、-NR g S(O) v R d and P(O)R h R i The alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl groups are each independently optionally substituted by one or more R B replace;

[0021] Or, R 3a and R 3b and the carbon atoms connected to it together form a cycloalkyl or heterocyclic group, wherein the cycloalkyl and heterocyclic groups are each independently optionally substituted by one or more R B replace;

[0022] Alternatively, R on the same carbon atom 3a and R 3b Together they form =O;

[0023] R d 、R e and R f are the same or different and are each independently selected from a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group and a heteroarylalkyl group; the alkyl group, the alkenyl group, the alkynyl group, the cycloalkyl group, the heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group and a heteroarylalkyl group are each independently optionally replaced by one or more R B replace;

[0024] Or, R e and R f Together with the nitrogen atom to which it is attached, it forms a heterocyclic group, which is optionally substituted by one or more R B replace;

[0025] R g is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkylalkyl group, and a heterocyclylalkyl group;

[0026] R h and R i are the same or different and are each independently selected from a hydrogen atom, a hydroxyl group, an alkyl group, an alkenyl group, an alkynyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxy group, a haloalkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group and a heteroaryl group; wherein the alkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, the aryl group and the heteroaryl group are each independently optionally replaced by one or more R B replace;

[0027] R 4 =O or =S;

[0028] Or, R 4 connected to ring A to form a heterocyclic group or heteroaryl group fused to ring A; the heterocyclic group and heteroaryl group are each independently optionally substituted by one or more R 7 replace;

[0029] R 5 R 5a ; or R 5 does not exist;

[0030] R 5a is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group, and a heteroarylalkyl group;

[0031] X is a key or CR m R n ;

[0032] R m and R n are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, hydroxyl, cyano, amino and nitro; wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl are each independently optionally replaced by one or more R 0 replaced by;

[0033] R A 、R B 、R 6 and R 7 are the same or different and are each independently selected from halogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, hydroxy, cyano, amino, nitro, -(CRx R y ) s OR 10 、-(CR x R y ) s NR 11 R 12 、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)NR 11 R 12 、-C(O)NR 11 R 12 、-NR 13 C(O)R 10 、-NR 13 C(O)OR 10 、-NR 13 C(O)NR 11 R 12 、-S(O) v R 10 、-S(O) v OR 10 、-S(O) v NR 11 R 12 、-NR 13 S(O) v R 10 , oxo, =S, =NR 14 、=CR 15 R 16 and P(O)R 17a R 17b wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl are each independently optionally substituted by one or more R 0 replaced by;

[0034] Or, two R 6 and the atoms to which they are attached together form a cycloalkyl or heterocyclic group, wherein the cycloalkyl and heterocyclic groups are each independently optionally substituted by one or more R 0 replace;

[0035] R 8 and R 9 are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, -OR 10 、-C(O)R10 、-C(O)OR 10 and cyano, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl are each independently optionally substituted by one or more R 0 replace;

[0036] Or, R 8 and R 9 and the carbon atoms to which they are attached together form a cycloalkyl or heterocyclic group, wherein the cycloalkyl and heterocyclic groups are each independently optionally substituted by one or more R 0 replace;

[0037] R 10 、R 11 and R 12 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group and a heteroarylalkyl group; the alkyl group, the alkenyl group, the alkynyl group, the cycloalkyl group, the heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group and a heteroarylalkyl group are each independently optionally replaced by one or more R 0 replace;

[0038] Or, R 11 and R 12 Together with the nitrogen atom to which it is attached, it forms a heterocyclic group, which is optionally substituted by one or more R 0 replace;

[0039] R 13 is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkylalkyl group, and a heterocyclylalkyl group;

[0040] R 14 is selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, hydroxy, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, cycloalkyloxy and heterocyclyloxy; wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, cycloalkyloxy and heterocyclyloxy are each independently optionally replaced by one or more R 0 replace;

[0041] R 15 and R 16are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, -C(O)alkyl, -C(O)Oalkyl and cyano, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl are each independently optionally replaced by one or more R 0 replace;

[0042] Or, R 15 and R 16 Together with the carbon atom to which it is attached, it forms a cycloalkyl or heterocyclic group, wherein the cycloalkyl and heterocyclic groups are each independently optionally substituted by one or more R 0 replace;

[0043] R 17a and R 17b are the same or different and are each independently selected from a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a hydroxyl group, an alkoxy group, a haloalkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group and a heteroaryl group; wherein the alkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, the aryl group and the heteroaryl group are each independently optionally replaced by one or more R 0 replace;

[0044] R 0 are the same or different and are each independently selected from oxo, =S, =NR 18 、=CR 19 R 20 , halogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, hydroxy, cyano, amino, nitro, -(CR x R y ) s OR 21 、-(CR x R y ) s NR 22 R 23 、-C(O)R 21 、-C(O)OR 21 、-OC(O)R 21 、-OC(O)NR 22 R 23 、-C(O)NR 22 R 23 、-NR 24 C(O)R21 、-NR 24 C(O)OR 21 、-NR 24 C(O)NR 22 R 23 、-S(O) v R 21 、-S(O) v OR 21 、-S(O) v NR 22 R 23 and -NR 24 S(O) v R 21 wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl are each independently optionally substituted by one or more R t replace;

[0045] R 18 is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a hydroxyl group, an alkoxy group, a haloalkoxy group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, a cycloalkyloxy group, and a heterocyclyloxy group;

[0046] R 19 and R 20 are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, and heteroarylalkyl;

[0047] Or, R 19 and R 20 Together with the carbon atom to which it is attached, it forms a cycloalkyl or heterocyclic group, wherein the cycloalkyl and heterocyclic groups are each independently optionally substituted by one or more R t replace;

[0048] R 21 、R 22 and R 23 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclic group, an aryl group and a heteroaryl group; the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group and the heteroaryl group are each independently optionally replaced by one or more R t replace;

[0049] Or, R 22 and R 23 Together with the carbon atom to which it is attached, it forms a heterocyclic group, which is optionally substituted by one or more R t replace;

[0050] R 24 is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkylalkyl group, and a heterocyclylalkyl group;

[0051] Each R t are the same or different and are each independently selected from the group consisting of oxo, =S, =NH, halogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkoxy, haloalkoxy, cyano, nitro, hydroxy, amino, -NHalkyl, -N(alkyl), -C(O)alkyl, -C(O)OH, -C(O)Oalkyl, -C(O)NH, -C(O)NH(alkyl), -C(O)N(alkyl), -S-alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl;

[0052] R x and R y are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, hydroxy, cyano, amino, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl;

[0053] s is 0, 1, or 2;

[0054] n1 is 0, 1, or 2;

[0055] n2 is 0, 1, 2, 3, 4, or 5;

[0056] n3 is 0, 1, 2, 3, 4, or 5;

[0057] v is 0, 1, or 2.

[0058] The purpose of the present disclosure is to provide a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof:

[0059] in:

[0060] Ring A is selected from aryl, heteroaryl, cycloalkyl and heterocyclyl;

[0061] Ring B is a cycloalkyl group or a heterocyclic group;

[0062] R 1 is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkylalkyl group, and a heterocyclylalkyl group;

[0063] R 2 is selected from hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, -C(O)R a、-C(O)OR a and -C(O)NR b R c The alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl groups are each independently optionally substituted by one or more R A replace;

[0064] R a 、R b and R c are the same or different and are each independently selected from a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group and a heteroarylalkyl group; the alkyl group, the alkenyl group, the alkynyl group, the cycloalkyl group, the heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group and a heteroarylalkyl group are each independently optionally replaced by one or more R A replace;

[0065] Or, R b and R c Together with the nitrogen atom to which it is attached, it forms a heterocyclic group, which is optionally substituted by one or more R A replace;

[0066] R 3 A hydrogen atom or

[0067] n4 is 0, 1, 2, or 3;

[0068] n5 is 0, 1, 2, or 3;

[0069] R 3a 、R 3b 、R 3c and R 3d are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, hydroxyl, cyano, amino, nitro, -(CR x R y ) s OR d 、-(CR x R y ) s NR e R f 、-C(O)R d 、-C(O)OR d 、-OC(O)R d 、-OC(O)NRe R f 、-C(O)NR e R f 、-NR g C(O)R d 、-NR g C(O)OR d 、-NR g C(O)NR e R f 、-S(O) v R d 、-S(O) v OR d 、-S(O) v NR e R f 、-NR g S(O) v NR e R f 、-NR g S(O) v R d and P(O)R h R i The alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl groups are each independently optionally substituted by one or more R B replace;

[0070] Or, R 3a and R 3b and the carbon atoms connected to it together form a cycloalkyl or heterocyclic group, wherein the cycloalkyl and heterocyclic groups are each independently optionally substituted by one or more R B replace;

[0071] Alternatively, R on the same carbon atom 3a and R 3b Together they form =O;

[0072] R d 、R e and R f are the same or different and are each independently selected from a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group and a heteroarylalkyl group; the alkyl group, the alkenyl group, the alkynyl group, the cycloalkyl group, the heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group and a heteroarylalkyl group are each independently optionally replaced by one or more R B replace;

[0073] Or, R e and R fTogether with the nitrogen atom to which it is attached, it forms a heterocyclic group, which is optionally substituted by one or more R B replace;

[0074] R g is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkylalkyl group, and a heterocyclylalkyl group;

[0075] R h and R i are the same or different and are each independently selected from a hydrogen atom, a hydroxyl group, an alkyl group, an alkenyl group, an alkynyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxy group, a haloalkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group and a heteroaryl group; wherein the alkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, the aryl group and the heteroaryl group are each independently optionally replaced by one or more R B replace;

[0076] R 4 =O or =S;

[0077] Or, R 4 connected to ring A to form a heterocyclic group or heteroaryl group fused to ring A; the heterocyclic group and heteroaryl group are each independently optionally substituted by one or more R 7 replace;

[0078] R 5 R 5a ; or R 5 does not exist;

[0079] R 5a is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group, and a heteroarylalkyl group;

[0080] X is a key or CR m R n ;

[0081] R m and R n are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, hydroxyl, cyano, amino and nitro; wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl are each independently optionally replaced by one or more R 0 replaced by;

[0082] R A 、RB 、R 6 and R 7 are the same or different and are each independently selected from halogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, hydroxy, cyano, amino, nitro, -(CR x R y ) s OR 10 、-(CR x R y ) s NR 11 R 12 、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)NR 11 R 12 、-C(O)NR 11 R 12 、-NR 13 C(O)R 10 、-NR 13 C(O)OR 10 、-NR 13 C(O)NR 11 R 12 、-S(O) v R 10 、-S(O) v OR 10 、-S(O) v NR 11 R 12 、-NR 13 S(O) v R 10 , oxo, =S, =NR 14 、=CR 15 R 16 and P(O)R 17a R 17b wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl are each independently optionally substituted by one or more R 0 replaced by;

[0083] Or, two R 6 and the atoms to which they are attached together form a cycloalkyl or heterocyclic group, wherein the cycloalkyl and heterocyclic groups are each independently optionally substituted by one or more R 0 replace;

[0084] R 8 and R 9 are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, -OR 10 、-C(O)R 10 、-C(O)OR 10 and cyano, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl are each independently optionally substituted by one or more R 0 replace;

[0085] Or, R 8 and R 9 and the carbon atoms to which they are attached together form a cycloalkyl or heterocyclic group, wherein the cycloalkyl and heterocyclic groups are each independently optionally substituted by one or more R 0 replace;

[0086] R 10 、R 11 and R 12 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group and a heteroarylalkyl group; the alkyl group, the alkenyl group, the alkynyl group, the cycloalkyl group, the heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group and a heteroarylalkyl group are each independently optionally replaced by one or more R 0 replace;

[0087] Or, R 11 and R 12 Together with the nitrogen atom to which it is attached, it forms a heterocyclic group, which is optionally substituted by one or more R 0 replace;

[0088] R 13 is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkylalkyl group, and a heterocyclylalkyl group;

[0089] R 14 is selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, hydroxy, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, cycloalkyloxy and heterocyclyloxy; wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, cycloalkyloxy and heterocyclyloxy are each independently optionally replaced by one or more R 0 replace;

[0090] R 15 and R 16 are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, -C(O)alkyl, -C(O)Oalkyl and cyano, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl are each independently optionally replaced by one or more R 0 replace;

[0091] Or, R 15 and R 16 Together with the carbon atom to which it is attached, it forms a cycloalkyl or heterocyclic group, wherein the cycloalkyl and heterocyclic groups are each independently optionally substituted by one or more R 0 replace;

[0092] R 17a and R 17b are the same or different and are each independently selected from a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a hydroxyl group, an alkoxy group, a haloalkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group and a heteroaryl group; wherein the alkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, the aryl group and the heteroaryl group are each independently optionally replaced by one or more R 0 replace;

[0093] R 0 are the same or different and are each independently selected from oxo, =S, =NR 18 、=CR 19 R 20 , halogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, hydroxy, cyano, amino, nitro, -(CR x R y ) s OR 21 、-(CR x R y ) s NR 22 R 23 、-C(O)R 21 、-C(O)OR 21 、-OC(O)R 21 、-OC(O)NR 22 R 23 、-C(O)NR22 R 23 、-NR 24 C(O)R 21 、-NR 24 C(O)OR 21 、-NR 24 C(O)NR 22 R 23 、-S(O) v R 21 、-S(O) v OR 21 、-S(O) v NR 22 R 23 and -NR 24 S(O) v R 21 wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl are each independently optionally substituted by one or more R t replace;

[0094] R 18 is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a hydroxyl group, an alkoxy group, a haloalkoxy group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, a cycloalkyloxy group, and a heterocyclyloxy group;

[0095] R 19 and R 20 are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, and heteroarylalkyl;

[0096] Or, R 19 and R 20 Together with the carbon atom to which it is attached, it forms a cycloalkyl or heterocyclic group, wherein the cycloalkyl and heterocyclic groups are each independently optionally substituted by one or more R t replace;

[0097] R 21 、R 22 and R 23 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclic group, an aryl group and a heteroaryl group; the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group and the heteroaryl group are each independently optionally replaced by one or more R t replace;

[0098] Or, R 22 and R 23Together with the carbon atom to which it is attached, it forms a heterocyclic group, which is optionally substituted by one or more R t replace;

[0099] R 24 is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkylalkyl group, and a heterocyclylalkyl group;

[0100] Each R t are the same or different and are each independently selected from the group consisting of oxo, =S, =NH, halogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkoxy, haloalkoxy, cyano, nitro, hydroxy, amino, -NHalkyl, -N(alkyl), -C(O)alkyl, -C(O)OH, -C(O)Oalkyl, -C(O)NH, -C(O)NH(alkyl), -C(O)N(alkyl), -S-alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl;

[0101] R x and R y are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, hydroxy, cyano, amino, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl;

[0102] s is 0, 1, or 2;

[0103] n1 is 0, 1, or 2;

[0104] n2 is 0, 1, 2, 3, 4, or 5;

[0105] n3 is 0, 1, 2, 3, 4, or 5;

[0106] v is 0, 1, or 2.

[0107] The present disclosure aims to provide a compound represented by the general formula (G), (G-1) or (G-2) or a pharmaceutically acceptable salt thereof:

[0108] in:

[0109] R 7c 、R 7d 、R 7e and R 7f are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen and an alkyl group;

[0110] R 2c 、R 2d 、R 2e 、R 2f and R 2gare the same or different and are each independently a hydrogen atom or a deuterium atom; or, R 2f and R 2g and the atoms to which they are attached together form a cycloalkyl group;

[0111] R 3b is selected from the group consisting of alkyl, cycloalkyl, alkoxyalkyl and cycloalkylalkyl.

[0112] In some embodiments of the present disclosure, the compound represented by the general formula (G), (G-1) or (G-2) or a pharmaceutically acceptable salt thereof, wherein R 7c Halogen or C 1-6 alkyl; in some embodiments, R 7c is halogen; in some embodiments, R 7c For F.

[0113] In some embodiments of the present disclosure, the compound represented by the general formula (G) or (G-1) or a pharmaceutically acceptable salt thereof is a compound represented by (B), (B-1), (B-2), (B-3) or (B-4) or a pharmaceutically acceptable salt thereof,

[0114] in:

[0115] R 7d 、R 7e and R 7f are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen and an alkyl group;

[0116] R 2c 、R 2d 、R 2e 、R 2f and R 2g are the same or different and are each independently a hydrogen atom or a deuterium atom; or, R 2f and R 2g and the atoms to which they are attached together form a cycloalkyl group;

[0117] R 3b is selected from the group consisting of alkyl, cycloalkyl, alkoxyalkyl and cycloalkylalkyl.

[0118] The purpose of the present disclosure is to provide a compound represented by general formula (C), (C-1) or (C-2) or a pharmaceutically acceptable salt thereof,

[0119] in:

[0120] R 7d 、R 7e and R 7f are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen and an alkyl group;

[0121] R 2c 、R 2d 、R 2e 、R 2f and R 2g are the same or different and are each independently a hydrogen atom or a deuterium atom; or, R 2f and R 2g and the atoms to which they are attached together form a cycloalkyl group;

[0122] R 3b is an alkyl group or a cycloalkyl group, wherein the alkyl group is optionally substituted by one or more substituents selected from the group consisting of a cycloalkyl group, a cycloalkyloxy group, an alkoxy group, and a haloalkoxy group;

[0123] R bb is a hydrogen atom or an alkyl group;

[0124] R 3e is a hydrogen atom or an alkyl group.

[0125] In some embodiments of the present disclosure, the compound represented by the general formula (C), (C-1) or (C-2) or a pharmaceutically acceptable salt thereof, wherein R 3e A hydrogen atom or C 1-6 alkyl; in some embodiments, R 3e is a hydrogen atom or a methyl group; in some embodiments, R 3e is a hydrogen atom; in some embodiments, R 3e It is a methyl group.

[0126] In some embodiments of the present disclosure, the compound represented by the general formula (G), (G-1), (G-2), (B), (B-1), (B-2), (B-3), (B-4), (C), (C-1) or (C-2) or a pharmaceutically acceptable salt thereof, wherein R 2c 、R 2d 、R 2e 、R 2f and R 2g are the same or different and are each independently a hydrogen atom or a deuterium atom; in some embodiments, R 2c 、R 2d 、R 2e 、R 2f and R 2g are all deuterium atoms; in some embodiments, R 2c 、R 2d 、R 2e 、R 2f and R 2g All are hydrogen atoms.

[0127] In some embodiments of the present disclosure, the compound represented by the general formula (G), (G-1), (G-2), (B), (B-1), (B-2), (B-3), (B-4), (C), (C-1) or (C-2) or a pharmaceutically acceptable salt thereof, wherein R 7d 、R 7e 、R 7f 、R 2c 、R 2d 、R 2e 、R 2f and R 2g At least one of them is a deuterium atom.

[0128] In some embodiments of the present disclosure, the compound represented by the general formula (G), (G-1), (G-2), (B), (B-1), (B-2), (B-3), (B-4), (C), (C-1) or (C-2) or a pharmaceutically acceptable salt thereof, wherein R 7d 、R 7e 、R 7f 、R 2c 、R 2d 、R 2e 、R 2f and R 2g are each independently a hydrogen atom or a deuterium atom; in some embodiments, R 7d 、R 7e and R 7f All are hydrogen atoms.

[0129] In some embodiments of the present disclosure, the compound represented by the general formula (G), (G-1), (G-2), (B), (B-1), (B-2), (B-3), (B-4), (C), (C-1) or (C-2) or a pharmaceutically acceptable salt thereof, wherein R 2f and R 2g and the attached atoms together form a 3- to 6-membered cycloalkyl group; in some embodiments, R 2f and R 2g and the attached atoms together form a cyclopropyl group.

[0130] In some embodiments of the present disclosure, the compound represented by the general formula (G), (G-1), (G-2), (B), (B-1), (B-2), (B-3), (B-4), (C), (C-1) or (C-2) or a pharmaceutically acceptable salt thereof, wherein R 3b Selected from C 1-6 Alkyl, 3 to 6 membered cycloalkyl, C 1-6 Alkoxy C 1-6 Alkyl and 3 to 6 membered cycloalkyl C 1-6 alkyl; in some embodiments, R 3b C1-6 alkyl; in some embodiments, R 3b is a 3- to 6-membered cycloalkyl group; in some embodiments, R 3b C 1-6 Alkoxy C 1-6 alkyl; in some embodiments, R 3b is a 3- to 6-membered cycloalkyl C 1-6 alkyl; in some embodiments, R 3b is selected from methyl, methoxymethyl, cyclopropyl and cyclopropylmethyl; in some embodiments, R 3b is methyl; in some embodiments, R 3b is cyclopropyl; in some embodiments, R 3b is methoxymethyl; in some embodiments, R 3b It is cyclopropylmethyl.

[0131] In some embodiments of the present disclosure, the compound represented by the general formula (G), (G-1), (G-2), (B), (B-1), (B-2), (B-3), (B-4), (C), (C-1) or (C-2) or a pharmaceutically acceptable salt thereof, wherein R 7d is a deuterium atom; in some embodiments, R 7e is a deuterium atom; in some embodiments, R 7f is a deuterium atom; in some embodiments, R 7d and R 7e is a deuterium atom; in some embodiments, R 7e and R 7f is a deuterium atom; in some embodiments, R 7d and R 7f is deuterium; in some embodiments, R 2c and R 2d is a deuterium atom; in some embodiments, R 2e 、R 2f and R 2g is a deuterium atom; in some embodiments, R 2c 、R 2d 、R 2e 、R 2f and R 2g A deuterium atom.

[0132] In some embodiments of the present disclosure, the compound represented by the general formula (G), (G-1) or (G-2) or a pharmaceutically acceptable salt thereof, wherein R 7c F; R 7d 、R 7e 、R 7f 、R 2c 、R 2d 、R 2e、R 2f and R 2g are each independently a hydrogen atom or a deuterium atom, and R 7d 、R 7e 、R 7f 、R 2c 、R 2d 、R 2e 、R 2f and R 2g At least one of them is a deuterium atom; R 3b It is a methyl group.

[0133] In some embodiments of the present disclosure, the compound represented by the general formula (B), (B-1), (B-2), (B-3) or (B-4) or a pharmaceutically acceptable salt thereof, wherein R 7d 、R 7e 、R 7f 、R 2c 、R 2d 、R 2e 、R 2f and R 2g are each independently a hydrogen atom or a deuterium atom, and R 7d 、R 7e 、R 7f 、R 2c 、R 2d 、R 2e 、R 2f and R 2g At least one of them is a deuterium atom; R 3b It is a methyl group.

[0134] In some embodiments of the present disclosure, the compound represented by the general formula (B), (B-1), (B-2), (B-3) or (B-4) or a pharmaceutically acceptable salt thereof, wherein R 2c 、R 2d 、R 2e 、R 2f and R 2g is a deuterium atom; R 7d 、R 7e and R 7f is a hydrogen atom; R 3b It is a methyl group.

[0135] In some embodiments of the present disclosure, the compound represented by the general formula (C), (C-1), (C-2) or a pharmaceutically acceptable salt thereof, wherein R 2c 、R 2d 、R 2e 、R 2f and R 2g is a deuterium atom; R 7d 、R 7e and R 7f is a hydrogen atom; R3b is methyl; R 3e is a hydrogen atom or a methyl group; R bb is a hydrogen atom or a methyl group.

[0136] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (E) or the general formula (E-1) or a pharmaceutically acceptable salt thereof:

[0137] in:

[0138] R B1 is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, and a cycloalkyl group;

[0139] R B3 is selected from the group consisting of a hydrogen atom, a halogen, an alkyl group, a haloalkyl group, an alkoxy group, and a cycloalkyl group;

[0140] R 7c is selected from the group consisting of a hydrogen atom, a halogen, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxy group, a haloalkoxy group, a cycloalkyl group, and a cyano group;

[0141] Ring B, R a 、R 3c 、R 6 、n2、R 8 and R 9 As defined in general formula (I).

[0142] In some embodiments of the present disclosure, the compound represented by the general formula (E) or (E-1) or a pharmaceutically acceptable salt thereof, wherein R B1 is a hydrogen atom; R B3 is halogen; R 3c C 1-6 Alkyl or C 1-6 Alkoxy C 1-6 Alkyl; R 7c is a hydrogen atom or a halogen; Ring B is a cyclohexyl group or a cycloheptyl group; n2 is 0; R a Selected from R 8 and R 9 are the same or different and are each independently selected from hydrogen, halogen and C 1-6 alkyl.

[0143] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (I-1) or (I-2) or a pharmaceutically acceptable salt thereof:

[0144] in:

[0145] ○ indicates that the ring where G1 and G2 are located is aromatic;

[0146] G1 is N or NR 5a ;

[0147] G2 is selected from O, S, N, NR 7a and CR 7b ;

[0148] R 7a is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group, and a heteroarylalkyl group;

[0149] R 7b is a hydrogen atom or R 7 ;

[0150] Ring A, Ring B, R 1 -R 3 、R 5a 、R 6 -R 9 , n1, n2 and n3 are as defined in the general formula (I).

[0151] In some embodiments of the present disclosure, the compound represented by general formula (I) or a pharmaceutically acceptable salt thereof is a compound represented by general formula (II) or a pharmaceutically acceptable salt thereof:

[0152] in:

[0153] x is 0, 1, 2, or 3;

[0154] y is 0, 1, 2, or 3;

[0155] Ring A, R 1 、R a 、R 3 -R 9 , n1, n2 and n3 are as defined in the general formula (I).

[0156] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (I-1), general formula (I-2), general formula (II) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (II-1) or general formula (II-2) or a pharmaceutically acceptable salt thereof:

[0157] in:

[0158] ○ indicates that the ring where G1 and G2 are located is aromatic;

[0159] x is 0, 1, 2, or 3;

[0160] y is 0, 1, 2, or 3;

[0161] G1 is N or NR 5a ;

[0162] G2 is selected from O, S, N, NR 7a and CR 7b ;

[0163] R 7a is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group, and a heteroarylalkyl group;

[0164] R 7b is a hydrogen atom or R 7 ;

[0165] Ring A, R 1 、R a 、R 3 、R 5a 、R 6 -R 9 , n1, n2 and n3 are as defined in the general formula (I).

[0166] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (I-1), general formula (II) or general formula (II-1) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (II-1-1) or general formula (II-1-2) or a pharmaceutically acceptable salt thereof:

[0167] in:

[0168] x is 0, 1, 2, or 3;

[0169] y is 0, 1, 2, or 3;

[0170] Ring A, R 1 、R a 、R 3 、R 5a 、R 6 -R 9 , n1, n2 and n3 are as defined in the general formula (I).

[0171] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (I-2), general formula (II) or general formula (II-2) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (II-2-1) or general formula (II-2-2) or a pharmaceutically acceptable salt thereof:

[0172] in:

[0173] ○ indicates that the ring where G1 and G2 are located is aromatic;

[0174] x is 0, 1, 2, or 3;

[0175] y is 0, 1, 2, or 3;

[0176] G1 is N or NR 5a ;

[0177] G2 is selected from O, S, N, NR 7a and CR 7b ;

[0178] R 7a is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group, and a heteroarylalkyl group;

[0179] R 7b is a hydrogen atom or R 7 ;

[0180] Ring A, R 1 、R a 、R 3 、R 5a 、R 6 -R 9 , n1, n2 and n3 are as defined in the general formula (I).

[0181] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (M), the general formula (M-1) or the general formula (M-2) or a pharmaceutically acceptable salt thereof:

[0182] in:

[0183] Ring A, Ring B, R a 、R 3 、R 6 -R 9 , n2 and n3 are as defined in the general formula (I).

[0184] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (X), the general formula (X-1) or the general formula (X-2) or a pharmaceutically acceptable salt thereof:

[0185] in:

[0186] Ring C is a nitrogen-containing heterocyclic group;

[0187] q is 0, 1, 2, 3, 4, or 5;

[0188] R 7c is a hydrogen atom or R 7 ;

[0189] G 1 , G 2 , G 3 and G 4 Each independently is O or S;

[0190] R 25 Selected from R d , OR d and NR e R f ;

[0191] Ring B, R B 、R a 、R d 、R e 、R f 、R 3b 、R 6 -R 9 and n2 are as defined in the general formula (I).

[0192] In some embodiments of the present disclosure, the compound represented by the general formula (X), the general formula (X-1) or the general formula (X-2) or a pharmaceutically acceptable salt thereof, wherein G 1 , G 2 , G 3 and G 4 are all O; in some embodiments, G 1 S; G 2 , G 3 and G 4 is O; in some embodiments, G 2 S; G 1 , G 3 and G 4 is O; in some embodiments, G 3 S; G 1 , G 2 and G 4 is O; in some embodiments, G 4 S; G 1 , G 2 and G 3 It is O.

[0193] In some embodiments of the present disclosure, the compound represented by the general formula (X), the general formula (X-1) or the general formula (X-2) or a pharmaceutically acceptable salt thereof, wherein G 1 , G 2 , G 3 and G 4 At most one of them is S.

[0194] In some embodiments of the present disclosure, the compound represented by the general formula (I) or the general formula (M) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (III), the general formula (III-1) or the general formula (III-2) or a pharmaceutically acceptable salt thereof:

[0195] in:

[0196] Ring C is a nitrogen-containing heterocyclic group;

[0197] q is 0, 1, 2, 3, 4, or 5;

[0198] Ring A, Ring B, R B 、R a 、R 3b 、R 3c 、R 6 -R 9 , n2 and n3 are as defined in the general formula (I).

[0199] In some embodiments of the present disclosure, the compound represented by general formula (I) or a pharmaceutically acceptable salt thereof is a compound represented by general formula (IV), general formula (IV-1) or general formula (IV-2) or a pharmaceutically acceptable salt thereof:

[0200] in:

[0201] n3 is 0, 1, or 2;

[0202] R 7b is a hydrogen atom or R 7 ;

[0203] Ring B, R a 、R 3 、R 6 -R 9 and n2 are as defined in the general formula (I).

[0204] In some embodiments of the present disclosure, the compound represented by general formula (I) or a pharmaceutically acceptable salt thereof is a compound represented by general formula (V), general formula (V-1) or general formula (V-2) or a pharmaceutically acceptable salt thereof:

[0205] in:

[0206] n3 is 0, 1, 2, or 3;

[0207] R 7a is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group, and a heteroarylalkyl group;

[0208] Ring B, R a、R 3 、R 6 -R 9 and n2 are as defined in the general formula (I).

[0209] In some embodiments of the present disclosure, the compound represented by general formula (I) or a pharmaceutically acceptable salt thereof is a compound represented by general formula (VI), general formula (VI-1) or general formula (VI-2) or a pharmaceutically acceptable salt thereof:

[0210] in:

[0211] n3 is 0, 1, 2, or 3;

[0212] Ring B, R a 、R 3 、R 5a 、R 6 -R 9 and n2 are as defined in the general formula (I).

[0213] In some embodiments of the present disclosure, the compound represented by formula (I), formula (M), formula (X), formula (X-1), formula (X-2), formula (III), formula (III-1) or formula (III-2) or a pharmaceutically acceptable salt thereof is a compound represented by formula (VII), formula (VII-1) or formula (VII-2) or a pharmaceutically acceptable salt thereof:

[0214] in:

[0215] R 7c is a hydrogen atom or R 7 ;

[0216] R Q Selected from hydrogen atoms, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl and -C(O)C 1-6 alkyl;

[0217] R bb is a hydrogen atom or R B ;

[0218] R a , Ring B, R B 、R d 、R 3b 、R 6 -R 9 and n2 are as defined in the general formula (I).

[0219] In some embodiments of the present disclosure, the compound or its pharmaceutically acceptable salt is not

[0220] In some embodiments of the present disclosure, the compound or its pharmaceutically acceptable salt is not

[0221] In some embodiments of the present disclosure, in the compound represented by formula (I) or a pharmaceutically acceptable salt thereof, X is a bond.

[0222] In some embodiments of the present disclosure, the compound represented by general formula (I) or general formula (II) or a pharmaceutically acceptable salt thereof, wherein for Where: ○ indicates that the ring where G1 and G2 are located is aromatic; G1 is N or NR 5a ; G2 is selected from O, S, N, NR 7a and CR 7b ; R 7a is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group, and a heteroarylalkyl group; R 7b is a hydrogen atom or R 7 ; Ring A, R 3 、R 5a 、R 7 , n1 and n3 are as defined in the general formula (I).

[0223] In some embodiments of the present disclosure, the compound represented by general formula (I) or general formula (II) or a pharmaceutically acceptable salt thereof, wherein Selected from R 7a is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group, and a heteroarylalkyl group; R 7b is a hydrogen atom or R 7 ; n3 is 0, 1 or 2; Ring A, R 5a 、R 3 and R 7 As defined in formula (I); in some embodiments, Selected from R 7a is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group, and a heteroarylalkyl group; R 7b is a hydrogen atom or R 7 ; n3 is 0, 1 or 2; R5a 、R 3 and R 7 As defined in general formula (I).

[0224] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (I-1), general formula (I-2), general formula (II), general formula (II-1), general formula (II-1-1), general formula (II-1-2), general formula (II-2), general formula (II-2-1) or general formula (II-2-2) or a pharmaceutically acceptable salt thereof, wherein R 1 Selected from hydrogen atoms, C 1-6 alkyl and 3 to 6 membered cycloalkyl; in some embodiments, R 1 A hydrogen atom or C 1-6 alkyl; in some embodiments, R 1 is selected from a hydrogen atom, a methyl group, and a cyclopropyl group; in some embodiments, R 1 is a hydrogen atom or a methyl group; in some embodiments, R 1 A hydrogen atom.

[0225] In some embodiments of the present disclosure, the compound represented by the general formula (I), general formula (I-1) or general formula (I-2) or a pharmaceutically acceptable salt thereof, wherein R 2 -C(O)R a or-C(O)OR a ; R a As defined in formula (I); in some embodiments, R 2 -C(O)R a or -C(S)R a ; R a As defined in formula (I); in some embodiments, R 2 -C(O)R a ; R a As defined in formula (I); in some embodiments, R 2 Selected from R 2a is selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl; n is 0, 1 or 2; R A1 is a hydrogen atom or R A ; R A As defined in formula (I); in some embodiments, R 2 Selected from R 2a is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group, and a heteroarylalkyl group; RA1 is a hydrogen atom or R A ; R A2 is a hydrogen atom or R A ; R A As defined in formula (I); in some embodiments, R 2 Selected from R 2a Selected from hydrogen atoms, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl and 3 to 6 membered cycloalkyl; R A1 and R A2 are the same or different and are each independently selected from hydrogen atom, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 haloalkoxy, 3 to 6 membered cycloalkyl, and cyano; in some embodiments, R 2 Selected from In some embodiments, R 2 Selected from In some embodiments, R 2 Selected from

[0226] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1), or a pharmaceutically acceptable salt thereof, wherein R a Selected from C 1-6 alkyl, 3 to 8 membered cycloalkyl, 6 to 10 membered aryl, 5 to 10 membered heteroaryl, 6 to 10 membered arylC 1-6 Alkyl and 5- to 10-membered heteroaryl C 1-6 Alkyl; the C 1-6 alkyl, 3 to 8 membered cycloalkyl, 6 to 10 membered aryl, 5 to 10 membered heteroaryl, 6 to 10 membered arylC 1-6 Alkyl and 5- to 10-membered heteroaryl C 1-6The alkyl groups are each independently optionally substituted with one or more R A Replacement; R A As defined in formula (I); in some embodiments, R a is optionally replaced by one or more R A substituted 6 to 10 membered aryl or optionally substituted by one or more R A substituted 5- to 10-membered heteroaryl; R A As defined in formula (I); in some embodiments, R a is optionally replaced by one or more R A substituted phenyl or optionally substituted by one or more R A Substituted 5- or 6-membered heteroaryl; R A As defined in formula (I); in some embodiments, R a is optionally replaced by one or more R A Substituted 5- or 6-membered heteroaryl; R A As defined in formula (I); in some embodiments, R a is optionally replaced by one or more R A Substituted 5-membered heteroaryl; R A As defined in formula (I); in some embodiments, R a is selected from the group consisting of pyrazolyl, pyrrolyl, oxadiazolyl, oxazolyl, furanyl, triazolyl, imidazolyl, pyridinyl, pyridazinyl, pyrazinyl and phenyl; and R a Optionally one or more R A Replacement; R A As defined in formula (I); in some embodiments, R a is selected from pyrazolyl, pyrrolyl and oxadiazolyl; and R a Optionally one or more R A Replacement; R A As defined in formula (I); in some embodiments, R a Selected from R A1 is a hydrogen atom or R A ; n is 0, 1 or 2; R 2a is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group, and a heteroarylalkyl group; R A As defined in formula (I); in some embodiments, R a Selected from R 2a is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group, and a heteroarylalkyl group; R A1 is a hydrogen atom or RA ; R A2 is a hydrogen atom or R A ; R A As defined in formula (I); in some embodiments, R a Selected from R 2a Selected from hydrogen atoms, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl and 3 to 6 membered cycloalkyl; R A1 and R A2 are the same or different and are each independently selected from hydrogen atom, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 haloalkoxy, 3 to 6 membered cycloalkyl, and cyano; in some embodiments, R a for R 2a C 1-6 alkyl; in some embodiments, R a is optionally replaced by one or more R A Substituted 5- or 6-membered heteroaryl; R A are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 haloalkoxy, 3 to 6 membered cycloalkyl, and cyano; in some embodiments, R a Selected from In some embodiments, R a Selected from In some embodiments, R a Selected from In some embodiments, R a Selected from In some embodiments, R a for In some embodiments, R a for

[0227] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1), or a pharmaceutically acceptable salt thereof, wherein R 2a Selected from hydrogen atoms, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 alkyl, 3 to 6 membered cycloalkyl, 3 to 6 membered heterocyclic group, 3 to 6 membered cycloalkyl C 1-6 Alkyl and 3 to 6 membered heterocyclic C 1-6 alkyl; in some embodiments, R 2a Selected from hydrogen atoms, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 hydroxyalkyl and 3 to 6 membered cycloalkyl; in some embodiments, R 2a C 1-6 alkyl or 3 to 6 membered cycloalkyl; in some embodiments, R 2a C 1-6 alkyl; in some embodiments, R 2a Selected from methyl, ethyl and isopropyl.

[0228] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1) or a pharmaceutically acceptable salt thereof, wherein R A1 Selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C1-6 Haloalkoxy, cyano, hydroxy, C 1-6 Alkoxy C 1-6 alkyl, 3 to 6 membered cycloalkyl, 3 to 6 membered heterocyclic group, 3 to 6 membered cycloalkyl C 1-6 Alkyl and 3 to 6 membered heterocyclic C 1-6 alkyl; in some embodiments, R A1 Selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 haloalkoxy, 3 to 6 membered cycloalkyl, and cyano; in some embodiments, R A1 C 1-6 alkyl or 3 to 6 membered cycloalkyl; in some embodiments, R A1 C 1-6 alkyl; in some embodiments, R A1 is selected from methyl, ethyl and cyclopropyl; in some embodiments, R A1 is methyl or cyclopropyl; in some embodiments, R A1 It is a methyl group.

[0229] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1) or a pharmaceutically acceptable salt thereof, wherein R A2 Selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, cyano, hydroxy, C 1-6 Alkoxy C 1-6 alkyl, 3 to 6 membered cycloalkyl, 3 to 6 membered heterocyclic group, 3 to 6 membered cycloalkyl C 1-6 Alkyl and 3 to 6 membered heterocyclic C 1-6 alkyl; in some embodiments, R A2 Selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 haloalkoxy, 3 to 6 membered cycloalkyl, and cyano; in some embodiments, R A2 Selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 haloalkyl and cyano; in some embodiments, R A2 It is a cyano group.

[0230] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1), or a pharmaceutically acceptable salt thereof, wherein R A are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, cyano, hydroxy, C 1-6 Alkoxy C 1-6 alkyl, 3 to 6 membered cycloalkyl, 3 to 6 membered heterocyclic group, 3 to 6 membered cycloalkyl C 1-6 Alkyl and 3 to 6 membered heterocyclic C 1-6 alkyl; in some embodiments, R A are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 haloalkoxy, 3 to 6 membered cycloalkyl, and cyano; in some embodiments, R A The same or different, and each independently selected from C 1-6 alkyl, cyano, and 3- to 6-membered cycloalkyl; in some embodiments, R A The same or different, and each independently is C 1-6 alkyl or cyano; in some embodiments, R A are the same or different and are each independently selected from methyl, ethyl, isopropyl, cyano and cyclopropyl; in some embodiments, R AThe same or different, and each independently selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 alkyl, 3 to 6 membered cycloalkyl, 3 to 6 membered heterocyclic group, 3 to 6 membered cycloalkyl C 1-6 Alkyl and 3 to 6 membered heterocyclic C 1-6 alkyl; in some embodiments, R A The same or different, and each independently selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 hydroxyalkyl and 3 to 6 membered cycloalkyl; in some embodiments, R A C 1-6 alkyl or 3 to 6 membered cycloalkyl; in some embodiments, R A C 1-6 alkyl; in some embodiments, R A is selected from methyl, ethyl and isopropyl; in some embodiments, R A is methyl or isopropyl; in some embodiments, R A is methyl; in some embodiments, R A are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 haloalkyl and cyano; in some embodiments, R A It is a cyano group.

[0231] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (III), (III-1) or (III-2) or pharmaceutically acceptable salts thereof, wherein ring A is a 6- to 10-membered aryl group or a 5- to 10-membered heteroaryl group; ring A is a phenyl group or a 5- or 6-membered heteroaryl group; in some embodiments, ring A is selected from phenyl, pyridyl, pyrazolyl, pyrazinyl and pyridazinyl; in some embodiments, ring A is selected from phenyl, pyrazolyl, pyridyl and pyridazinyl; in some embodiments, ring A is selected from phenyl, pyrazolyl and pyridazinyl; in some embodiments, ring A is phenyl or pyrazolyl; in some embodiments, ring A is phenyl or pyridazinyl; in some embodiments, ring A is phenyl; in some embodiments, ring A is pyrazolyl.

[0232] In some embodiments of the present disclosure, the compound represented by formula (I), formula (I-1), formula (II), formula (II-1), formula (II-1-1) or formula (II-1-2) or a pharmaceutically acceptable salt thereof, wherein for Ring A, n3, R 3 and R 7 As defined in formula (I); in some embodiments, for n3 is 0, 1 or 2; R 3 and R 7 As defined in formula (I); in some embodiments, for R 7c is a hydrogen atom or R 7 ; R 3 and R 7 As defined in formula (I); in some embodiments, for R 7c is a hydrogen atom or R 7 ; R 3 and R 7 As defined in general formula (I).

[0233] In some embodiments of the present disclosure, the compound represented by the general formula (I-2), the general formula (II-2), the general formula (II-2-1) or the general formula (II-2-2) or a pharmaceutically acceptable salt thereof, wherein Selected from R 7a is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group, and a heteroarylalkyl group; R 7b is a hydrogen atom or R 7 ; n3 is 0, 1 or 2; R 5a 、R 3 and R 7 As defined in formula (I); in some embodiments, Selected from R 7c is a hydrogen atom or R 7 ; R 3 and R 7 As defined in formula (I); in some embodiments, Selected from R 7c is a hydrogen atom or R 7 ; R 3 and R7 As defined in general formula (I).

[0234] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (II), (II-1), (II-1-1), (II-1-2), (M), (M-1), (M-2), (III), (III-1) or (III-2) or a pharmaceutically acceptable salt thereof, wherein for n3 is 0, 1 or 2; R 7 As defined in formula (I); in some embodiments, for R 7c is a hydrogen atom or R 7 ; R 7 As defined in formula (I); in some embodiments, for R 7c is a hydrogen atom or R 7 ; R 7 As defined in formula (I); in some embodiments, for In some embodiments, for R 7c is a hydrogen atom or R 7 ; R 7 As defined in formula (I); in some embodiments, for * end is connected to NH.

[0235] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1) or (VII-2) or a pharmaceutically acceptable salt thereof, wherein R 3a and R 3b are the same or different and are each independently selected from hydrogen atom, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 alkyl and 3 to 6 membered cycloalkyl; in some embodiments, R 3aand R 3b are the same or different and are each independently selected from hydrogen atom, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl and C 1-6 Alkoxy C 1-6 alkyl; in some embodiments, R 3a and R 3b are the same or different and are each independently selected from hydrogen atom, C 1-6 alkyl and 3 to 6 membered cycloalkyl; in some embodiments, R 3a and R 3b are the same or different and are each independently selected from a hydrogen atom, a methyl group and a cyclopropyl group; in some embodiments, R 3a and R 3b The same or different, and each independently a hydrogen atom or a C 1-6 alkyl; in some embodiments, R 3a is a hydrogen atom; in some embodiments, R 3b C 1-6 alkyl; in some embodiments, R 3a and R 3b are the same or different and are each independently a hydrogen atom or a methyl group; in some embodiments, R 3a is a hydrogen atom; R 3b Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 alkyl and 3 to 6 membered cycloalkyl; in some embodiments, R 3a is a hydrogen atom; R 3b Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl and C 1-6 Alkoxy C 1-6 alkyl; in some embodiments, R 3a is a hydrogen atom; R 3b C 1-6 alkyl or 3 to 6 membered cycloalkyl; in some embodiments, R 3a is a hydrogen atom; R 3b is methyl or cyclopropyl; in some embodiments, R 3a is a hydrogen atom; R 3b C 1-6 alkyl; in some embodiments, R 3a is a hydrogen atom; R 3b is methyl; in some embodiments, R 3a is a hydrogen atom; R3b It is cyclopropyl.

[0236] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (G), (G-1), (G-2), (B), (B-1), (B-2), (B-3), (B-4), (C), (C-1), (C-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1) or (VII-2) or a pharmaceutically acceptable salt thereof, wherein R 3b Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 alkyl and 3 to 6 membered cycloalkyl; in some embodiments, R 3b Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl and C 1-6 Alkoxy C 1-6 alkyl; in some embodiments, R 3b C 1-6 alkyl or 3 to 6 membered cycloalkyl; in some embodiments, R 3b C 1-6 alkyl; in some embodiments, R 3b is methyl or cyclopropyl; in some embodiments, R 3b is methyl; in some embodiments, R 3b Selected from C 1-6 Alkyl, 3 to 6 membered cycloalkyl, 3 to 6 membered cycloalkylC 1-6 Alkyl and -CH2OR d ; R d Selected from C 1-6 Alkyl, C 1-6 haloalkyl and 3 to 6 membered cycloalkyl; in some embodiments, R 3b Selected from methyl, cyclopropyl, In some embodiments, R 3b For-(CR x R y ) s ORd ; R x 、R y , s and R d As defined in formula (I); in some embodiments, R 3b -CH2OR d ; R d Selected from C 1-6 Alkyl, C 1-6 haloalkyl and 3 to 6 membered cycloalkyl; in some embodiments, R 3b -CH2OR d ; R d is selected from methyl, difluoromethyl and cyclopropyl; in some embodiments, R 3b for

[0237] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1) or (VI-2) or a pharmaceutically acceptable salt thereof, wherein R 3c and R 3d The same or different, and each independently selected from C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 1-6 Haloalkyl, -C(O)R d 、-NR g C(O)R d 、-C(O)NR e R f , 3 to 8 membered heterocyclyl (in some embodiments, 5 or 6 membered heterocyclyl) and 5 to 10 membered heteroaryl (in some embodiments, 5 or 6 membered heteroaryl); said 3 to 8 membered heterocyclyl (in some embodiments, 5 or 6 membered heterocyclyl) and 5 to 10 membered heteroaryl (in some embodiments, 5 or 6 membered heteroaryl) are each independently optionally substituted by one or more R B Replacement; R B 、R d 、R e 、R f and R g As defined in formula (I);

[0238] In some embodiments, R 3c and R 3dare the same or different and are each independently selected from methyl, isopropyl, methoxymethyl,

[0239] In some embodiments, R 3c and R 3d are the same or different and are each independently selected from methyl, isopropyl, methoxymethyl,

[0240] In some embodiments, R 3c and R 3d are the same or different and are each independently selected from methyl, isopropyl, methoxymethyl,

[0241] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (E) or (E-1) or a pharmaceutically acceptable salt thereof, wherein R 3c Selected from C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 1-6 Haloalkyl and -NR g C(O)R d ; R d and R g As defined in formula (I); in some embodiments, R 3c Selected from C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl and C 1-6 haloalkyl; in some embodiments, R 3c Selected from C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl and C 1-6 haloalkyl; in some embodiments, R 3c C 1-6 Alkyl or C 1-6 haloalkyl; in some embodiments, R 3c C1-6 Alkyl or C 1-6 Alkoxy C 1-6 alkyl; in some embodiments, R 3c C 1-6 Alkoxy C 1-6 alkyl; in some embodiments, R 3c is methyl or methoxymethyl; in some embodiments, R 3c is methoxymethyl; in some embodiments, R 3c Selected from-NR g C(O)R d 、-NR g C(S)R d 、-NR g C(O)NR e R f and -NR g C(S)NR e R f ; R e 、R f 、R d and R g As defined in formula (I); in some embodiments, R 3c -NR g C(O)R d ; R d and R g As defined in formula (I); in some embodiments, R 3c -NR g C(O)R d ; R g is a hydrogen atom; R d Selected from C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 Alkoxy C 1-6 alkyl; in some embodiments, R 3c Selected from methyl, isopropyl, methoxymethyl, In some embodiments, R 3c Selected from methyl, isopropyl, methoxymethyl and In some embodiments, R 3c Selected from methyl, methoxymethyl, In some embodiments, R 3c Selected from In some embodiments, R 3c Selected from In some embodiments, R3c Selected from In some embodiments, R 3c for In some embodiments, R 3c for

[0242] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1) or (VI-2) or a pharmaceutically acceptable salt thereof, wherein R 3d Selected from -C(O)R d 、-NR g C(O)R d 、-C(O)NR e R f , 3 to 8 membered heterocyclyl (the 3 to 8 membered heterocyclyl is in some embodiments a 5 or 6 membered heterocyclyl) and 5 to 10 membered heteroaryl (the 5 to 10 membered heteroaryl is in some embodiments a 5 or 6 membered heteroaryl); the 3 to 8 membered heterocyclyl (the 3 to 8 membered heterocyclyl is in some embodiments a 5 or 6 membered heterocyclyl) and 5 to 10 membered heteroaryl (the 5 to 10 membered heteroaryl is in some embodiments a 5 or 6 membered heteroaryl) are each independently optionally substituted by one or more R B Replacement; R B 、R d 、R e 、R f and R g As defined in formula (I); in some embodiments, R 3d -C(O)NR e R f ; R e A hydrogen atom or C 1-6 Alkyl; R f C 1-6 Alkyl or C 1-6 haloalkyl; or, R e and R f Together with the nitrogen atom to which it is attached, it forms a 5- or 6-membered heterocyclic group, wherein the 5- or 6-membered heterocyclic group is optionally substituted by one or more R B Replacement; R B As defined in formula (I); in some embodiments, R 3d -C(O)NR e R f ; R e and Rf Together with the nitrogen atom to which it is attached, it forms a 5- or 6-membered heterocyclic group, wherein the 5- or 6-membered heterocyclic group is optionally substituted by one or more R B Replacement; R B As defined in formula (I); in some embodiments, R 3d -C(O)NR e R f ; R e A hydrogen atom or C 1-6 Alkyl; R f C 1-6 Alkyl or C 1-6 haloalkyl; in some embodiments, R 3d -C(O)NR e R f or -NR g C(O)R d ; R e A hydrogen atom or C 1-6 Alkyl; R f C 1-6 Alkyl or C 1-6 Haloalkyl; R d C 1-6 Alkyl or C 1-6 Haloalkyl; R g is a hydrogen atom; in some embodiments, R 3d Selected from In some embodiments, R 3d Selected from

[0243] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1) or (VI-2) or a pharmaceutically acceptable salt thereof, wherein R 3d -C(O)R d or -C(O)NR e R f ; R d 、R e and R f As defined in formula (I); in some embodiments, R 3d -C(O)R d or -C(S)R d ; Rd As defined in formula (I); in some embodiments, R 3d -C(O)R d ; R d As defined in formula (I); in some embodiments, R 3d for Ring C' is selected from cycloalkyl, heterocyclyl, aryl and heteroaryl; q is 0, 1, 2, 3, 4 or 5; R B As defined in formula (I); in some embodiments, R 3d for G 3 is O or S; Ring C is a nitrogen-containing heterocyclic group; q is 0, 1, 2, 3, 4 or 5; R B As defined in formula (I); in some embodiments, R 3d for Ring C is a nitrogen-containing heterocyclic group; q is 0, 1, 2, 3, 4 or 5; R B As defined in formula (I); in some embodiments, R 3d Selected from In some embodiments, R 3d Selected from In some embodiments, R 3d Selected from In some embodiments, R 3d for

[0244] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1) or (VI-2) or pharmaceutically acceptable salts thereof, wherein ring C' is a 3- to 8-membered heterocyclic group; in some embodiments, ring C' is a 5- or 6-membered heterocyclic group; in some embodiments, ring C' is a 6-membered heterocyclic group; in some embodiments, ring C' is a 6-membered nitrogen-containing heterocyclic group; in some embodiments, ring C' is a piperidinyl or piperazinyl; in some embodiments, ring C' is a piperazinyl.

[0245] In some embodiments of the present disclosure, the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1) or ( VI-2) or a pharmaceutically acceptable salt thereof, wherein ring C is a 3- to 8-membered nitrogen-containing heterocyclic group; in some embodiments, ring C is a 5- or 6-membered nitrogen-containing heterocyclic group; in some embodiments, ring C is a 6-membered nitrogen-containing heterocyclic group; in some embodiments, ring C is a piperidinyl or piperazinyl; in some embodiments, ring C is a piperazinyl; in some embodiments, ring C is selected from azetidinyl, piperazinyl, piperidinyl, morpholinyl, thiomorpholinyl, 1,1-dioxothiomorpholinyl, azaspiro[3,3]heptane and 4,7-diazaspiro[2.5]octane.

[0246] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1) or (VI-2) or pharmaceutically acceptable salts thereof, wherein q is 0, 1, 2 or 3; in some embodiments, q is 1 or 2; in some embodiments, q is 1; in some embodiments, q is 2.

[0247] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1) or (VI-2) or a pharmaceutically acceptable salt thereof, wherein R 3d is optionally replaced by one or more R B substituted 5- to 10-membered heteroaryl (the 5- to 10-membered heteroaryl, in some embodiments, is a 5- or 6-membered heteroaryl); R B As defined in formula (I); in some embodiments, R 3dis selected from tetrazolyl, pyridone, pyridine nitrogen oxide and pyridinyl; said tetrazolyl, pyridone, pyridine nitrogen oxide and pyridinyl are each independently optionally substituted by one or more R B Replacement; R B As defined in formula (I); in some embodiments, R 3d is tetrazolyl or pyridone; the tetrazolyl and pyridone groups are each independently optionally substituted by one or more R B Replacement; R B As defined in formula (I); in some embodiments, R 3d is optionally replaced by one or more R B substituted pyridinyl nitroxide or optionally substituted by one or more R B Substituted pyridinyl; R B As defined in formula (I); in some embodiments, R 3d is optionally replaced by one or more R B Substituted pyridinyl N-oxide; R B As defined in formula (I); in some embodiments, R 3d is optionally replaced by one or more R B Substituted pyridinyl; R B As defined in formula (I); in some embodiments, R 3d Selected from and j is 0, 1, 2 or 3; m is 0, 1, 2 or 3; R B0 and R B1 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group, and a heteroarylalkyl group; R B As defined in formula (I); in some embodiments, R 3d for j is 0, 1, 2 or 3; R B0 and R B1 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group, and a heteroarylalkyl group; R B As defined in formula (I); in some embodiments, R 3d for j is 0, 1, 2 or 3; R B1 is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group, and a heteroarylalkyl group; R BAs defined in formula (I); in some embodiments, R 3d for In some embodiments, R 3d for m is 0, 1, 2, or 3 (in some embodiments, 2); R B As defined in formula (I); in some embodiments, R 3d for m is 0, 1, 2, or 3 (in some embodiments, 2); R B As defined in formula (I); in some embodiments, R 3d Selected from In some embodiments, R 3d for In some embodiments, R 3d for

[0248] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1) or (VI-2) or a pharmaceutically acceptable salt thereof, wherein R 3d is optionally replaced by one or more R B Substituted 3 to 8 membered heterocyclyl (the 3 to 8 membered heterocyclyl is, in some embodiments, a 5- or 6-membered heterocyclyl, and in some embodiments, a 5-membered heterocyclyl); R B As defined in formula (I); in some embodiments, R 3d for R B2 is a hydrogen atom or R B ; R B As defined in formula (I); in some embodiments, R 3d for R B2 Selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 haloalkyl and 3 to 6 membered cycloalkyl; wherein the 3 to 6 membered cycloalkyl is optionally substituted with one or more cyano groups; in some embodiments, R 3d for R B2 Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 Haloalkyl (in some embodiments, C1-6 haloalkyl, in some embodiments trifluoromethyl); in some embodiments, R 3d Selected from In some embodiments, R 3d Selected from In some embodiments, R 3d Selected from In some embodiments, R 3d for

[0249] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1) or (VI-2) or pharmaceutically acceptable salts thereof, wherein n4 is 0 or 1; in some embodiments, n4 is 0; in some embodiments, n4 is 1.

[0250] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1) or (VI-2) or pharmaceutically acceptable salts thereof, wherein n5 is 0 or 1; in some embodiments, n5 is 0; in some embodiments, n5 is 1.

[0251] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1) or (VI-2) or pharmaceutically acceptable salts thereof, wherein n4 is 0 or 1; n5 is 0 or 1; in some embodiments, n4 is 0; n5 is 0; in some embodiments, n4 is 0; n5 is 1; in some embodiments, n4 is 1; n5 is 1.

[0252] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1), or a pharmaceutically acceptable salt thereof, wherein R d Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered heterocyclic group and 3 to 8 membered cycloalkyl C 1-6 Alkyl; the 3 to 8 membered heterocyclic group and the 3 to 8 membered cycloalkyl C 1-6 The alkyl groups are each independently optionally substituted with one or more R B Replacement; R B As defined in formula (I); in some embodiments, R d Selected from C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 Alkoxy C 1-6 alkyl; in some embodiments, R d Selected from C 1-6 Alkyl, C 1-6 haloalkyl and 3 to 6 membered cycloalkyl; in some embodiments, R d is selected from methyl, difluoromethyl and cyclopropyl; in some embodiments, R d C 1-6 Alkoxy C 1-6 alkyl; in some embodiments, R d Selected from ethyl, methoxymethyl, In some embodiments, R d Selected from methoxymethyl, In some embodiments, R d C 1-6 Alkyl or C 1-6 haloalkyl; in some embodiments, R d Ethyl or In some embodiments, R d Selected from ethyl, methoxymethyl, In some embodiments, Rd Selected from ethyl, methoxymethyl, In some embodiments, R d is selected from cycloalkyl, heterocyclic, aryl and heteroaryl; the cycloalkyl, heterocyclic, aryl and heteroaryl are each independently optionally replaced by one or more R B Substituted; in some embodiments, R d is optionally replaced by one or more R B substituted 3 to 8 membered heterocyclyl; in some embodiments, R d is optionally replaced by one or more R B substituted 3 to 8 membered nitrogen-containing heterocyclic group; in some embodiments, R d is optionally replaced by one or more R B substituted 5- or 6-membered heterocyclyl; in some embodiments, R d is optionally replaced by one or more R B substituted 5- or 6-membered nitrogen-containing heterocyclic group; in some embodiments, R d is optionally replaced by one or more R B substituted 6-membered heterocyclyl; in some embodiments, R d is optionally replaced by one or more R B substituted 6-membered nitrogen-containing heterocyclic group; in some embodiments, R d is optionally replaced by one or more R B substituted piperazinyl or optionally substituted with one or more R B substituted piperidinyl; in some embodiments, R d is optionally replaced by one or more R B substituted piperazinyl; in some embodiments, R d Selected from In some embodiments, R d Selected from In some embodiments, R d Selected from

[0253] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1), or a pharmaceutically acceptable salt thereof, wherein R e and R f are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 1-6 hydroxyalkyl and 3 to 6-membered cycloalkyl; or, R e and R f Together with the nitrogen atom to which it is attached, it forms a 5- or 6-membered heterocyclic group, wherein the 5- or 6-membered heterocyclic group is optionally substituted by one or more R B Replacement; R B As defined in formula (I); in some embodiments, R e and R f are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl, C 1-6 haloalkyl and 3 to 6 membered cycloalkyl; in some embodiments, R e and R f are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl and C 1-6 haloalkyl; in some embodiments, R e and R f are the same or different and are each independently selected from a hydrogen atom, a methyl group, and cyclopropyl; in some embodiments, R e and R f are the same or different and are each independently selected from hydrogen atoms, methyl groups and In some embodiments, R e A hydrogen atom or C 1-6 alkyl; in some embodiments, R f C 1-6 Alkyl or C 1-6 Halogenated alkyl.

[0254] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1), or a pharmaceutically acceptable salt thereof, wherein R g Selected from hydrogen atoms, C 1-6 alkyl and 3 to 6 membered cycloalkyl; in some embodiments, R g A hydrogen atom or C 1-6 alkyl; in some embodiments, R g is a hydrogen atom or a methyl group; in some embodiments, R g A hydrogen atom.

[0255] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1) or (VI-2) or a pharmaceutically acceptable salt thereof, wherein R 3 for n4 is 0 or 1; n5 is 0 or 1; R 3a is a hydrogen atom; R 3b Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl and 3 to 6 membered cycloalkyl; R 3c and R 3d The same or different, and each independently selected from C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 1-6 Haloalkyl, -C(O)R d 、-C(S)R d 、-NR g C(O)R d 、-NR g C(S)Rd 、-C(O)NR e R f 、-C(S)NR e R f 、-NR g C(O)NR e R f 、-NR g C(S)NR e R f , 5 or 6 membered heterocyclic group and 5 or 6 membered heteroaryl; the 5 or 6 membered heterocyclic group and 5 or 6 membered heteroaryl are each independently optionally substituted by one or more R B Replacement; R d Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered heterocyclic group and 3 to 8 membered cycloalkyl C 1-6 Alkyl; the 3 to 8 membered heterocyclic group and the 3 to 8 membered cycloalkyl C 1-6 The alkyl groups are each independently optionally substituted with one or more R B Replacement; R e and R f are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl, C 1-6 Haloalkyl and 3 to 6-membered cycloalkyl; R g is a hydrogen atom; R B are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 haloalkyl and oxo; in some embodiments, R 3 Selected from

[0256] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1) or (VI-2) or a pharmaceutically acceptable salt thereof, wherein R 3 for n4 is 0 or 1; n5 is 0 or 1; R 3a is a hydrogen atom; R 3b Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl and 3 to 6 membered cycloalkyl; R 3c and R 3d The same or different, and each independently selected from C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 1-6 Haloalkyl, -C(O)R d 、-NR g C(O)R d 、-C(O)NR e R f , 5 or 6 membered heterocyclic group and 5 or 6 membered heteroaryl; the 5 or 6 membered heterocyclic group and 5 or 6 membered heteroaryl are each independently optionally substituted by one or more R B Replacement; R d Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered heterocyclic group and 3 to 8 membered cycloalkyl C 1-6 Alkyl; the 3 to 8 membered heterocyclic group and the 3 to 8 membered cycloalkyl C 1-6 The alkyl groups are each independently optionally substituted with one or more R B Replacement; R e and R f are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl and C 1-6 Haloalkyl; R g is a hydrogen atom; R B are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 haloalkyl and oxo; in some embodiments, R 3 Selected from

[0257] In some embodiments, R 3 Selected from

[0258] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1) or (VI-2) or a pharmaceutically acceptable salt thereof, wherein R 3 for n4 is 0 or 1; n5 is 0 or 1; R 3a is a hydrogen atom; R 3b Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl and 3 to 6 membered cycloalkyl; R 3c and R 3d The same or different, and each independently selected from C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 1-6 Haloalkyl, -C(O)R d 、-NR g C(O)R d 、-C(O)NR e R f 、-NR g C(O)NR e R f , 5 or 6 membered heterocyclic group and 5 or 6 membered heteroaryl; the 5 or 6 membered heterocyclic group and 5 or 6 membered heteroaryl are each independently optionally substituted by one or more R B Replacement; R d Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered heterocyclic group and 3 to 8 membered cycloalkyl C 1-6 Alkyl; the 3 to 8 membered heterocyclic group and the 3 to 8 membered cycloalkyl C 1-6 The alkyl groups are each independently optionally substituted with one or more R B Replacement; R e and R f are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl, C 1-6 Haloalkyl and 3 to 6-membered cycloalkyl; R g is a hydrogen atom; R Bare the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 haloalkyl and oxo; in some embodiments, R 3 Selected from

[0259] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1) or (VI-2) or a pharmaceutically acceptable salt thereof, wherein R 3 for n4 is 0 or 1; n5 is 0 or 1; R 3a is a hydrogen atom; R 3b Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl and C 1-6 Alkoxy C 1-6 Alkyl; R 3c and R 3d The same or different, and each independently selected from C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 1-6 Haloalkyl, -C(O)R d 、-NR g C(O)R d 、-C(O)NR e R f , 5 or 6 membered heterocyclic group and 5 or 6 membered heteroaryl; the 5 or 6 membered heterocyclic group and 5 or 6 membered heteroaryl are each independently optionally substituted by one or more R B Replacement; R d Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered heterocyclic group and 3 to 8 membered cycloalkyl C 1-6 Alkyl; the 3 to 8 membered heterocyclic group and the 3 to 8 membered cycloalkyl C 1-6 The alkyl groups are each independently optionally substituted with one or more R B Replacement; R e and R fare the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl and C 1-6 Haloalkyl; R g is a hydrogen atom; R B are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 haloalkyl and oxo; in some embodiments, R 3 Selected from

[0260] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1) or (VI-2) or a pharmaceutically acceptable salt thereof, wherein R 3 for R 3b 、R 3c and R 3d As defined in formula (I); in some embodiments, R 3 for Ring C' is selected from cycloalkyl, heterocyclyl, aryl and heteroaryl; q is 0, 1, 2, 3, 4 or 5; R B 、R 3b and R 3c As defined in formula (I); in some embodiments, R 3 for G 3 and G 4 are each independently O or S; Ring C is a nitrogen-containing heterocyclic group; q is 0, 1, 2, 3, 4 or 5; R 25 Selected from R d , OR d and NR e R f ; R B 、R 3b 、R d 、R e and R f As defined in formula (I); in some embodiments, R 3 for Ring C is a nitrogen-containing heterocyclic group; q is 0, 1, 2, 3, 4 or 5; R B 、R 3b and R 3cAs defined in formula (I); in some embodiments, R 3 Selected from In some embodiments, R 3 Selected from In some embodiments, R 3 Selected from In some embodiments, R 3 Selected from In some embodiments, R 3 Selected from In some embodiments, R 3 for In some embodiments, R 3 for In some embodiments, R 3 for

[0261] In some embodiments of the present disclosure, for q is 0, 1, or 2; R B C 1-6 Alkyl; R Q Selected from hydrogen atoms, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl and -C(O)C 1-6 Alkyl; In some embodiments of the present disclosure, for R Q Selected from hydrogen atoms, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl and -C(O)C 1-6 Alkyl; R bb A hydrogen atom or C 1-6 Alkyl; In some embodiments of the present disclosure, Selected from In some embodiments, Selected from

[0262] In some embodiments of the present disclosure, Selected from In some embodiments of the present disclosure, Selected from

[0263] In some embodiments of the present disclosure, R Q A hydrogen atom or C 1-6 alkyl; in some embodiments, R Q C 1-6 alkyl; in some embodiments, R Q It is a methyl group.

[0264] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1) or (VI-2) or a pharmaceutically acceptable salt thereof, wherein R 3 for R 3c and R 3d As defined in formula (I); in some embodiments, R 3 for R 3c Selected from C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl and C 1-6 Haloalkyl; R 3d Selected from C(O)NR e R f NR g C(O)R d , optionally one or more R B substituted 5 or 6 membered heteroaryl and optionally substituted by one or more R B substituted 5- or 6-membered heterocyclic group; R B are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and oxo; R d 、R e 、R f and R g As defined in formula (I); in some embodiments, R 3 for R 3c Selected from C 1-6Alkyl, C 1-6 Alkoxy C 1-6 Alkyl and C 1-6 Haloalkyl; R 3d is optionally replaced by one or more R B substituted 5 or 6 membered heteroaryl or optionally substituted by one or more R B substituted 5- or 6-membered heterocyclic group; R B are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 haloalkyl and oxo; in some embodiments, R 3 for R 3c Selected from C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl and C 1-6 Haloalkyl; R 3d is optionally replaced by one or more R B Substituted 5- or 6-membered heteroaryl; R B are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 haloalkyl and oxo; in some embodiments, R 3 Selected from In some embodiments, R 3 Selected from In some embodiments, R 3 Selected from In some embodiments, R 3 for

[0265] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1) or (VI-2) or a pharmaceutically acceptable salt thereof, wherein R 3 is optionally replaced by one or more R B substituted 5- to 10-membered heteroaryl (the 5- to 10-membered heteroaryl is, in some embodiments, a 5- or 6-membered heteroaryl, and in some embodiments, a 6-membered heteroaryl); R BAs defined in formula (I); in some embodiments, R 3 is optionally replaced by one or more R B substituted pyridinyl nitroxide or optionally substituted by one or more R B Substituted pyridinyl; R B As defined in formula (I); in some embodiments, R 3 is optionally replaced by one or more R B substituted pyridinyl N-oxide; in some embodiments, R 3 is optionally replaced by one or more R B substituted pyridinyl; in some embodiments, R 3 for m is 0, 1, 2, or 3 (in some embodiments, 2); R B As defined in formula (I); in some embodiments, R 3 for m is 0, 1, 2, or 3 (in some embodiments, 2); R B As defined in formula (I); in some embodiments, R 3 for m is 0, 1, 2, or 3 (in some embodiments, 2); R B As defined in formula (I); in some embodiments, R 3 for In some embodiments, R 3 for

[0266] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1) or (VI-2) or a pharmaceutically acceptable salt thereof, wherein R 3 A hydrogen atom.

[0267] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1) or (VI-2) or a pharmaceutically acceptable salt thereof, wherein R B0 Selected from hydrogen atoms, C1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 hydroxyalkyl and 3 to 6 membered cycloalkyl; in some embodiments, R B0 Selected from hydrogen atoms, C 1-6 Alkyl and C 1-6 haloalkyl; in some embodiments, R B0 C 1-6 haloalkyl; in some embodiments, R B0 for

[0268] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (E) or (E-1) or a pharmaceutically acceptable salt thereof, wherein R B1 Selected from hydrogen atoms, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 hydroxyalkyl and 3 to 6 membered cycloalkyl; in some embodiments, R B1 Selected from hydrogen atoms, C 1-6 Alkyl and C 1-6 haloalkyl; in some embodiments, R B1 A hydrogen atom or C 1-6 alkyl; in some embodiments, R B1 A hydrogen atom.

[0269] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1) or (VI-2) or a pharmaceutically acceptable salt thereof, wherein R B2 Selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 haloalkyl and 3 to 6 membered cycloalkyl; wherein the 3 to 6 membered cycloalkyl is optionally substituted with one or more cyano groups; in some embodiments, R B2 Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6haloalkyl; in some embodiments, R B2 C 1-6 haloalkyl; in some embodiments, R B2 It is trifluoromethyl.

[0270] In some embodiments of the present disclosure, the compound represented by the general formula (E) or the general formula (E-1) or a pharmaceutically acceptable salt thereof, wherein R B3 is halogen; in some embodiments, R B3 is F or Cl; in some embodiments, R B3 For F.

[0271] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1) or (VI-2) or pharmaceutically acceptable salts thereof, wherein m is 0, 1 or 2; in some embodiments, m is 1 or 2; in some embodiments, m is 2; in some embodiments, m is 1.

[0272] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1) or (VI-2) or pharmaceutically acceptable salts thereof, wherein j is 0 or 1; in some embodiments, j is 1.

[0273] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1), or a pharmaceutically acceptable salt thereof, wherein R B are the same or different and are each independently selected from halogen, C 1-6Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 haloalkoxy, cyano, hydroxy, 3- to 6-membered cycloalkyl, and oxo; in some embodiments, R B are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 haloalkyl and oxo; in some embodiments, R B are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 haloalkyl; in some embodiments, R B C 1-6 alkyl; in some embodiments, R B is methyl; in some embodiments, R B Halogen or C 1-6 haloalkyl; in some embodiments, R B are the same or different and are each independently selected from F, methyl, trifluoromethyl, and oxo; in some embodiments, R B The same or different, and each independently selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl and 3 to 6 membered cycloalkyl; in some embodiments, R B The same or different, and each independently is C 1-6 Alkyl or C 1-6 haloalkyl; in some embodiments, R B C 1-6 haloalkyl; in some embodiments, R B for In some embodiments, R B Selected from halogen, C 1-6 Alkyl, C 1-6 haloalkyl and 3 to 6 membered cycloalkyl; wherein the 3 to 6 membered cycloalkyl is optionally substituted with one or more cyano groups; in some embodiments, R B It is trifluoromethyl.

[0274] In some embodiments of the present disclosure, the compound represented by the general formula (X), (X-1), (X-2), (III), (III-1), (III-2), (VII-1), (VII-1), (VII-2), (C), (C-1) or (C-2) or a pharmaceutically acceptable salt thereof, wherein R bb Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6haloalkyl; in some embodiments, R bb A hydrogen atom or C 1-6 alkyl; in some embodiments, R bb is a hydrogen atom or a methyl group; in some embodiments, R bb is a hydrogen atom; in some embodiments, R bb It is a methyl group.

[0275] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1) or (VI-2) or pharmaceutically acceptable salts thereof, wherein n1 is 0 or 1; in some embodiments, n1 is 1; in some embodiments, n1 is 0.

[0276] In some embodiments of the present disclosure, the compound represented by the general formula (I) or the general formula (II) or a pharmaceutically acceptable salt thereof, wherein R 4 =O; or, R 4 is connected to ring A to form a 5-membered heteroaryl group fused to ring A; the 5-membered heteroaryl group is optionally substituted by one or more R 7 Replacement; R 7 As defined in formula (I); in some embodiments, R 4 =O; or, R 4 Connected to ring A to form an imidazole group fused to ring A; the imidazole group is optionally replaced by an R 7 or multiple substitutions; R 7 As defined in formula (I); in some embodiments, R 4 =0; in some embodiments, R 4 It is connected to ring A to form an imidazole group fused to ring A.

[0277] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (VI), (VI-1) or (VI-2) or a pharmaceutically acceptable salt thereof, wherein R 5a Selected from hydrogen atoms, C 1-6 alkyl and 3 to 6 membered cycloalkyl; in some embodiments, R 5a A hydrogen atom or C 1-6 alkyl; in some embodiments, R 5ais a hydrogen atom or a methyl group; in some embodiments, R 5a A hydrogen atom.

[0278] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII-1), (VII-1), (VII-2), (E) or (E-1) or a pharmaceutically acceptable salt thereof, wherein each R 7 are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 haloalkoxy, 3- to 6-membered cycloalkyl, and cyano; in some embodiments, each R 7 are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 haloalkyl; in some embodiments, each R 7 The same or different, and each independently halogen or C 1-6 alkyl; in some embodiments, R 7 is halogen; in some embodiments, each R 7 are the same or different and are each independently F or methyl; in some embodiments, R 7 For F.

[0279] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-2), (II), (II-2), (II-2-1), (II-2-2), (V), (V-1) or (V-2) or a pharmaceutically acceptable salt thereof, wherein R 7a Selected from hydrogen atoms, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 hydroxyalkyl and 3 to 6 membered cycloalkyl; in some embodiments, R 7a A hydrogen atom or C 1-6 alkyl; in some embodiments, R 7a A hydrogen atom.

[0280] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-2), (II), (II-2), (II-2-1), (II-2-2), (IV), (IV-1) or (IV-2) or a pharmaceutically acceptable salt thereof, wherein R 7b Selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 hydroxyalkyl and 3 to 6 membered cycloalkyl; in some embodiments, R 7b Selected from hydrogen atoms, halogens and C 1-6 alkyl; in some embodiments, R 7b is a hydrogen atom or a halogen; in some embodiments, R 7b A hydrogen atom.

[0281] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII-1), (VII-1), (VII-2), (G), (G-1), (G-2), (E) or (E-1) or a pharmaceutically acceptable salt thereof, wherein R 7c Selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 haloalkoxy, 3 to 6 membered cycloalkyl, and cyano; in some embodiments, R 7c Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 haloalkyl; in some embodiments, R 7c Selected from hydrogen atoms, halogens and C 1-6 alkyl; in some embodiments, R 7c is a hydrogen atom or a halogen; in some embodiments, R 7c is halogen; in some embodiments, R 7c is F; in some embodiments, R 7c is a hydrogen atom; in some embodiments, R 7c is a hydrogen atom or F; in some embodiments, R 7c is methyl; in some embodiments, R7c is selected from the group consisting of a hydrogen atom, F and a methyl group.

[0282] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-2), (II), (II-2), (II-2-1) or (II-2-2) or a pharmaceutically acceptable salt thereof, wherein G1 is N or NR 5a ; R 5a A hydrogen atom or C 1-6 alkyl; in some embodiments, G1 is N or NH; in some embodiments, G1 is N.

[0283] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-2), (II), (II-2), (II-2-1) or (II-2-2) or a pharmaceutically acceptable salt thereof, wherein G2 is selected from N, NR 7a and CR 7b ; R 7a and R 7b As defined in formula (I-2); in some embodiments, G2 is selected from N, NH and CH.

[0284] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1) or (VI-2) or pharmaceutically acceptable salts thereof, wherein n3 is 0, 1 or 2; in some embodiments, n3 is 0 or 1; in some embodiments, n3 is 0; in some embodiments, n3 is 1.

[0285] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1) or (VI-2) or a pharmaceutically acceptable salt thereof, wherein each R 7 are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6Alkoxy, C 1-6 haloalkoxy, 3 to 6 membered cycloalkyl, and cyano; and / or n3 is 0, 1, or 2; in some embodiments, each R 7 The same or different, and each independently halogen or C 1-6 alkyl; and / or n3 is 0 or 1; in some embodiments, R 7 is halogen; and / or n3 is 0 or 1; in some embodiments, R 7 is halogen; and / or n3 is 1.

[0286] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (III), (III-1), (III-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII-1), (VII-1), (VII-2), (E) or (E-1) or its Pharmaceutically acceptable salts, wherein Ring B is a 4- to 10-membered cycloalkyl or a 4- to 10-membered heterocyclyl; in some embodiments, Ring B is a 4- to 10-membered cycloalkyl; in some embodiments, Ring B is a 4- to 8-membered cycloalkyl; in some embodiments, Ring B is a 6- to 7-membered cycloalkyl or a 6- to 7-membered heterocyclyl; in some embodiments, Ring B is a 5- to 7-membered cycloalkyl; in some embodiments, Ring B is a cyclohexyl or cycloheptyl; in some embodiments, Ring B is a cyclohexyl; in some embodiments, Ring B is a cycloheptyl; in some embodiments, Ring B is selected from In some embodiments, Ring B is selected from In some embodiments, Ring B is cyclohexyl; in some embodiments, Ring B is selected from In some embodiments, Ring B is selected from In some embodiments, Ring B is

[0287] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII-1), (VII-1), (VII-2), (E) or (E-1), or a pharmaceutically acceptable salt thereof, wherein for x is 0, 1, 2, or 3; y is 0, 1, 2, or 3; R 6 、R 8 、R 9 and n2 are as defined in formula (I); in some embodiments, for R 6 、R 8 、R 9 and n2 are as defined in formula (I); in some embodiments, R 6 and n2 are as defined in formula (I); in some embodiments, Selected from In some embodiments, Selected from In some embodiments, Selected from In some embodiments, Selected from In some embodiments, Selected from In some embodiments, Selected from In some embodiments, Selected from In some embodiments, Selected from In some embodiments, In some embodiments, Selected from In some embodiments, Selected from

[0288] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1), or a pharmaceutically acceptable salt thereof, wherein for R 6 、R 8 、R 9 and n2 are as defined in formula (I); in some embodiments, for R 6 and n2 are as defined in formula (I); in some embodiments, Selected from In some embodiments, Selected from In some embodiments, Selected from In some embodiments, Selected from In some embodiments, Selected from In some embodiments, for In some embodiments, Selected from

[0289] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1), or a pharmaceutically acceptable salt thereof, wherein R 8 and R 9 are the same or different and are each independently selected from hydrogen, halogen and C 1-6 Alkyl, or R 8 and R 9 and the carbon atoms to which they are attached together form a 3- to 6-membered cycloalkyl group; in some embodiments, R 8 and R 9 are the same or different and are each independently selected from hydrogen, halogen and C 1-6 Alkyl, or R 8 and R 9 and the carbon atom to which it is attached together form a cyclopropyl group; in some embodiments, R 8 and R 9 are the same or different and are each independently selected from hydrogen atom, halogen, C 1-6 alkyl and 3 to 6 membered cycloalkyl; in some embodiments, R 8 and R 9 are the same or different and are each independently a hydrogen atom or a halogen; in some embodiments, R 8 and R 9 are the same or different and are each independently halogen; in some embodiments, R 8 and R 9 are the same or different and are each independently selected from hydrogen, F and methyl; or R 8 and R 9 and the carbon atom to which it is attached together form a cyclopropyl group; in some embodiments, R 8 and R 9 is a hydrogen atom or F; in some embodiments, R 8 and R 9 are the same or different and are each independently halogen; in some embodiments, R 8 and R 9 For F.

[0290] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1) or pharmaceutically acceptable salts thereof, wherein x is 0, 1 or 2; in some embodiments, x is 1 or 2; in some embodiments, x is 1; in some embodiments, x is 2; in some embodiments, x is 3.

[0291] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1) or pharmaceutically acceptable salts thereof, wherein y is 0, 1 or 2; in some embodiments, y is 0 or 1; in some embodiments, y is 1; in some embodiments, y is 0.

[0292] In some embodiments of the present disclosure, the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), The compound represented by (VII-1), (VII-2), (E) or (E-1) or a pharmaceutically acceptable salt thereof, wherein x is 0, 1, 2 or 3; y is 0 or 1; in some embodiments, x is 0, 1 or 2; y is 0 or 1; in some embodiments, x is 1 or 2; y is 0 or 1; in some embodiments, x is 0 and y is 0; in some embodiments, x is 1 and y is 0; in some embodiments, x is 1 and y is 1; in some embodiments, x is 2 and y is 0; in some embodiments, x is 2 and y is 1; in some embodiments, x is 3 and y is 0.

[0293] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (M), (M-1), (M-2), (X), (X-1), (X-2), (II-1-2), (II-2), (II-2-1), (II-2-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1), or a pharmaceutically acceptable salt thereof, wherein each R 6 are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and =CR 15 R 16 ; R 15 and R 16 are the same or different and are each independently a hydrogen atom or a halogen; in some embodiments, each R 6 are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 haloalkyl; in some embodiments, each R 6 The same or different, and each independently is C 1-6 alkyl; in some embodiments, R 6 It is a methyl group.

[0294] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1) or pharmaceutically acceptable salts thereof, wherein n2 is 0 or 1; in some embodiments, n2 is 0; in some embodiments, n2 is 1.

[0295] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1), or a pharmaceutically acceptable salt thereof, wherein R 6 Selected from halogen, C 1-6 Alkyl and C 1-6 haloalkyl; and / or n2 is 0 or 1.

[0296] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1) or (VII-2) or a pharmaceutically acceptable salt thereof, wherein R 25 R d or NR e R f ; R d 、R e and R fAs defined in formula (I); in some embodiments, R 25 R d ; R d As defined in formula (I); in some embodiments, R 25 Selected from ethyl, methoxymethyl, In some embodiments, R 25 for In some embodiments, R 25 for

[0297] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1), or a pharmaceutically acceptable salt thereof, wherein R 10 A hydrogen atom or C 1-6 alkyl; in some embodiments, R 10 is a hydrogen atom; in some embodiments, R 10 C 1-6 alkyl.

[0298] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1), or a pharmaceutically acceptable salt thereof, wherein R 11 and R 12 are the same or different and are each independently selected from a hydrogen atom or C 1-6 alkyl; in some embodiments, R 11 and R 12 A hydrogen atom.

[0299] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1), or a pharmaceutically acceptable salt thereof, wherein R 13 A hydrogen atom or C 1-6 alkyl; in some embodiments, R 13 A hydrogen atom.

[0300] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1), or a pharmaceutically acceptable salt thereof, wherein R 14 Selected from hydrogen atoms, C 1-6 Alkyl, hydroxyl and C 1-6 Alkoxy; in some embodiments, R 14 A hydrogen atom or C 1-6 alkyl; in some embodiments, R 14 A hydrogen atom.

[0301] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1), or a pharmaceutically acceptable salt thereof, wherein R 15 and R16 are the same or different and are each independently selected from hydrogen atom, halogen, C 1-6 alkyl and 3 to 6 membered cycloalkyl; in some embodiments, R 15 and R 16 are the same or different and are each independently a hydrogen atom or a halogen; in some embodiments, R 15 and R 16 are the same or different and are each independently a hydrogen atom or F; in some embodiments, R 15 and R 16 For F.

[0302] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1), or a pharmaceutically acceptable salt thereof, wherein R 17a and R 17b The same or different, and each independently is C 1-6 alkyl; in some embodiments, R 17a and R 17b It is a methyl group.

[0303] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1), or a pharmaceutically acceptable salt thereof, wherein R 18 Selected from hydrogen atoms, C 1-6 Alkyl, hydroxyl and C 1-6 Alkoxy; in some embodiments, R 18 A hydrogen atom or C 1-6 alkyl; in some embodiments, R 18 A hydrogen atom.

[0304] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1), or a pharmaceutically acceptable salt thereof, wherein R 19 and R 20 are the same or different and are each independently selected from hydrogen atom, halogen, C 1-6 alkyl and 3 to 6 membered cycloalkyl; in some embodiments, R 19 and R 20 are the same or different and are each independently a hydrogen atom or a halogen; in some embodiments, R 19 and R 20 are the same or different and are each independently a hydrogen atom or F; in some embodiments, R 19 and R 20 For F.

[0305] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1), or a pharmaceutically acceptable salt thereof, wherein R 21 A hydrogen atom or C 1-6 alkyl; in some embodiments, R 21 is a hydrogen atom; in some embodiments, R 21 C 1-6 alkyl.

[0306] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1), or a pharmaceutically acceptable salt thereof, wherein R 22 and R 23 are the same or different and are each independently selected from a hydrogen atom or C 1-6 alkyl; in some embodiments, R 22 and R 23 A hydrogen atom.

[0307] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1), or a pharmaceutically acceptable salt thereof, wherein R 24 A hydrogen atom or C 1-6 alkyl; in some embodiments, R 24 A hydrogen atom.

[0308] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1), or a pharmaceutically acceptable salt thereof, wherein R 0 are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 haloalkoxy, 3- to 6-membered cycloalkyl, cyano, hydroxy, and oxo; in some embodiments, R 0 are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl.

[0309] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1), or a pharmaceutically acceptable salt thereof, wherein R t are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 haloalkoxy, 3- to 6-membered cycloalkyl, cyano, hydroxy, and oxo; in some embodiments, R t are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl.

[0310] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1), or a pharmaceutically acceptable salt thereof, wherein R x and R y are the same or different and are each independently selected from hydrogen, halogen and C 1-6 alkyl; in some embodiments, Rx and R y A hydrogen atom.

[0311] In some embodiments of the present disclosure, the compounds represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1) or pharmaceutically acceptable salts thereof, wherein s is 0 or 1; in some embodiments, s is 1; in some embodiments, s is 0; in some embodiments, s is 1 or 2.

[0312] In some embodiments of the present disclosure, the compound represented by the general formula (I), (I-1), (I-2), (II), (II-1), (II-1-1), (II-1-2), (II-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (E) or (E-1) or a pharmaceutically acceptable salt thereof, wherein v is 0; in some embodiments, v is 1; in some embodiments, v is 2.

[0313] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein X is a bond; Selected from R 5a A hydrogen atom or C 1-6 Alkyl; R 7a A hydrogen atom or C 1-6 Alkyl; R 7b Selected from hydrogen atoms, halogens and C 1-6 Alkyl; each R 7 are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 Haloalkyl; n3 is 0, 1 or 2; R 3 for n4 is 0 or 1; n5 is 0 or 1; R 3ais a hydrogen atom; R 3b Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl and C 1-6 Alkoxy C 1-6 Alkyl; R 3c and R 3d The same or different, and each independently selected from C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 1-6 Haloalkyl, -C(O)R d 、-NR g C(O)R d 、-C(O)NR e R f , 5 or 6 membered heterocyclic group and 5 or 6 membered heteroaryl; the 5 or 6 membered heterocyclic group and 5 or 6 membered heteroaryl are each independently optionally substituted by one or more R B Replacement; R d Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered heterocyclic group and 3 to 8 membered cycloalkyl C 1-6 Alkyl; the 3 to 8 membered heterocyclic group and the 3 to 8 membered cycloalkyl C 1-6 The alkyl groups are each independently optionally substituted with one or more R B Replacement; R e and R f are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl and C 1-6 Haloalkyl; R g is a hydrogen atom; R B are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 haloalkyl and oxo; Ring B is a 4- to 10-membered cycloalkyl; R 1 is a hydrogen atom; R 2 -C(O)R a ; R a is optionally replaced by one or more R A Substituted 5- or 6-membered heteroaryl; R A are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 haloalkoxy, 3- to 6-membered cycloalkyl, and cyano; n2 is 0; R8 and R 9 are the same or different and are each independently a hydrogen atom or a halogen.

[0314] In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein X is a bond; Selected from R 5a A hydrogen atom or C 1-6 Alkyl; R 7a A hydrogen atom or C 1-6 Alkyl; R 7b Selected from hydrogen atoms, halogens and C 1-6 Alkyl; each R 7 are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 Haloalkyl; n3 is 0, 1 or 2; R 3 for n4 is 0 or 1; n5 is 0 or 1; R 3a is a hydrogen atom; R 3b Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl and C 1-6 Alkoxy C 1-6 Alkyl; R 3c and R 3d The same or different, and each independently selected from C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 1-6 Haloalkyl, -C(O)R d 、-NR g C(O)R d 、-C(O)NR e R f , 5 or 6 membered heterocyclic group and 5 or 6 membered heteroaryl; the 5 or 6 membered heterocyclic group and 5 or 6 membered heteroaryl are each independently optionally substituted by one or more R B Replacement; R d Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered heterocyclic group and 3 to 8 membered cycloalkyl C 1-6 Alkyl; the 3 to 8 membered heterocyclic group and the 3 to 8 membered cycloalkyl C 1-6 The alkyl groups are each independently optionally substituted with one or more R B Replacement; R e and Rf are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl and C 1-6 Haloalkyl; R g is a hydrogen atom; R B are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 haloalkyl and oxo; Ring B is a 5- to 7-membered cycloalkyl; R 1 is a hydrogen atom; R 2 -C(O)R a ; R a is optionally replaced by one or more R A Substituted 5- or 6-membered heteroaryl; R A are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 haloalkoxy, 3- to 6-membered cycloalkyl, and cyano; n2 is 0; R 8 and R 9 are the same or different and are each independently a hydrogen atom or a halogen.

[0315] In some embodiments of the present disclosure, the compound represented by the general formula (I-1) or a pharmaceutically acceptable salt thereof, wherein Ring A is phenyl or a 5- or 6-membered heteroaryl; Ring B is a 5- to 7-membered cycloalkyl; R 1 is a hydrogen atom; R 2 -C(O)R a ; R a is optionally replaced by one or more R A Substituted 5- or 6-membered heteroaryl; R A are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, 3- to 6-membered cycloalkyl, and cyano; R 5a A hydrogen atom or C 1-6 Alkyl; n2 is 0; each R 7 are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 Haloalkyl; n3 is 0, 1 or 2; R 8 and R 9 are the same or different and are each independently a hydrogen atom or a halogen; R 3 for n4 is 0 or 1; n5 is 0 or 1; R3a is a hydrogen atom; R 3b Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl and C 1-6 Alkoxy C 1-6 Alkyl; R 3c and R 3d The same or different, and each independently selected from C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 1-6 Haloalkyl, -C(O)R d 、-NR g C(O)R d 、-C(O)NR e R f , 5 or 6 membered heterocyclic group and 5 or 6 membered heteroaryl; the 5 or 6 membered heterocyclic group and 5 or 6 membered heteroaryl are each independently optionally substituted by one or more R B Replacement; R d Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered heterocyclic group and 3 to 8 membered cycloalkyl C 1-6 Alkyl; the 3 to 8 membered heterocyclic group and the 3 to 8 membered cycloalkyl C 1-6 The alkyl groups are each independently optionally substituted with one or more R B Replacement; R e and R f are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl and C 1-6 Haloalkyl; R g is a hydrogen atom; R B are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and oxo; n1 is 1.

[0316] In some embodiments of the present disclosure, the compound represented by the general formula (I-1) or a pharmaceutically acceptable salt thereof, wherein R 1 is a hydrogen atom; R 2 Selected from R 2a Selected from hydrogen atoms, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 hydroxyalkyl and 3 to 6 membered cycloalkyl; n is 0, 1 or 2; each R A are the same or different and are each independently selected from halogen, C1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 haloalkoxy, 3- to 6-membered cycloalkyl, and cyano; Ring B is cyclohexyl; R 5a is a hydrogen atom; n2 is 0; R 8 and R 9 are the same or different and are each independently a hydrogen atom or a halogen; for Each R 7 are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 Haloalkyl; n3 is 0, 1 or 2; R 3 for n4 is 0 or 1; n5 is 0 or 1; R 3a is a hydrogen atom; R 3b Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl and C 1-6 Alkoxy C 1-6 Alkyl; R 3c and R 3d The same or different, and each independently selected from C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 1-6 Haloalkyl, -C(O)R d 、-NR g C(O)R d 、-C(O)NR e R f , 5 or 6 membered heterocyclic group and 5 or 6 membered heteroaryl; the 5 or 6 membered heterocyclic group and 5 or 6 membered heteroaryl are each independently optionally substituted by one or more R B Replacement; R d Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered heterocyclic group and 3 to 8 membered cycloalkyl C 1-6 Alkyl; the 3 to 8 membered heterocyclic group and the 3 to 8 membered cycloalkyl C 1-6 The alkyl groups are each independently optionally substituted with one or more R B Replacement; R e and R f are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl and C 1-6Haloalkyl; R g is a hydrogen atom; R B are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and oxo.

[0317] In some embodiments of the present disclosure, the compound represented by the general formula (I-2) or a pharmaceutically acceptable salt thereof, wherein R 1 is a hydrogen atom; R 2 Selected from R 2a Selected from hydrogen atoms, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 hydroxyalkyl and 3 to 6 membered cycloalkyl; n is 0, 1 or 2; each R A are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 haloalkoxy, 3- to 6-membered cycloalkyl, and cyano; Ring B is a 5- to 7-membered cycloalkyl; n2 is 0; R 8 and R 9 are the same or different and are each independently a hydrogen atom or a halogen; Selected from and R 5a A hydrogen atom or C 1-6 Alkyl; R 7a A hydrogen atom or C 1-6 Alkyl; R 7b Selected from hydrogen atoms, halogens and C 1-6 Alkyl; each R 7 are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 Haloalkyl; n3 is 0, 1 or 2; R 3 for n4 is 0 or 1; n5 is 0 or 1; R 3a is a hydrogen atom; R 3b Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl and C 1-6 Alkoxy C 1-6 Alkyl; R 3c and R 3d The same or different, and each independently selected from C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C1-6 Alkyl, C 1-6 Haloalkyl, -C(O)R d 、-NR g C(O)R d 、-C(O)NR e R f , 5 or 6 membered heterocyclic group and 5 or 6 membered heteroaryl; the 5 or 6 membered heterocyclic group and 5 or 6 membered heteroaryl are each independently optionally substituted by one or more R B Replacement; R d Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered heterocyclic group and 3 to 8 membered cycloalkyl C 1-6 Alkyl; the 3 to 8 membered heterocyclic group and the 3 to 8 membered cycloalkyl C 1-6 The alkyl groups are each independently optionally substituted with one or more R B Replacement; R e and R f are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl and C 1-6 Haloalkyl; R g is a hydrogen atom; R B are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and oxo.

[0318] In some embodiments of the present disclosure, the compound represented by the general formula (II) or a pharmaceutically acceptable salt thereof, wherein R 1 is a hydrogen atom; R a Selected from R 2a Selected from hydrogen atoms, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 hydroxyalkyl and 3 to 6 membered cycloalkyl; n is 0, 1 or 2; each R A are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 haloalkoxy, 3- to 6-membered cycloalkyl, and cyano; n2 is 0; R 8 and R 9 are the same or different and are each independently a hydrogen atom or a halogen; x is 0, 1 or 2; y is 0, 1 or 2; Selected from R5a A hydrogen atom or C 1-6 Alkyl; R 7a A hydrogen atom or C 1-6 Alkyl; R 7b Selected from hydrogen atoms, halogens and C 1-6 Alkyl; each R 7 are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 Haloalkyl; n3 is 0, 1 or 2; R 3 for n4 is 0 or 1; n5 is 0 or 1; R 3a is a hydrogen atom; R 3b Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl and C 1-6 Alkoxy C 1-6 Alkyl; R 3c and R 3d The same or different, and each independently selected from C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 1-6 Haloalkyl, -C(O)R d 、-NR g C(O)R d 、-C(O)NR e R f , 5 or 6 membered heterocyclic group and 5 or 6 membered heteroaryl; the 5 or 6 membered heterocyclic group and 5 or 6 membered heteroaryl are each independently optionally substituted by one or more R B Replacement; R d Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered heterocyclic group and 3 to 8 membered cycloalkyl C 1-6 Alkyl; the 3 to 8 membered heterocyclic group and the 3 to 8 membered cycloalkyl C 1-6 The alkyl groups are each independently optionally substituted with one or more R B Replacement; R e and R f are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl and C 1-6 Haloalkyl; R g is a hydrogen atom; R B are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and oxo.

[0319] In some embodiments of the present disclosure, the compound represented by the general formula (II-1), the general formula (II-1-1) or the general formula (II-1-2) or a pharmaceutically acceptable salt thereof, wherein R 1 is a hydrogen atom; R a is optionally replaced by one or more R A Substituted 5- or 6-membered heteroaryl; R A are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, 3- to 6-membered cycloalkyl, and cyano; R 5a A hydrogen atom or C 1-6 Alkyl; Ring A is phenyl or 5- or 6-membered heteroaryl; each R 7 are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 Haloalkyl; n3 is 0, 1 or 2; n2 is 0; R 8 and R 9 are the same or different and are each independently a hydrogen atom or a halogen; x is 0, 1 or 2; y is 0, 1 or 2; n1 is 1; R 3 for n4 is 0 or 1; n5 is 0 or 1; R 3a is a hydrogen atom; R 3b Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl and C 1-6 Alkoxy C 1-6 Alkyl; R 3c and R 3d The same or different, and each independently selected from C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 1-6 Haloalkyl, -C(O)R d 、-NR g C(O)R d 、-C(O)NR e R f , 5 or 6 membered heterocyclic group and 5 or 6 membered heteroaryl; the 5 or 6 membered heterocyclic group and 5 or 6 membered heteroaryl are each independently optionally substituted by one or more R B Replacement; R d Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered heterocyclic group and 3 to 8 membered cycloalkyl C 1-6 Alkyl, the 3 to 8 membered heterocyclic group and the 3 to 8 membered cycloalkyl C 1-6 The alkyl groups are each independently optionally substituted with one or more R B Replacement; R e and R f are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl and C 1-6 Haloalkyl; R g is a hydrogen atom; R B are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and oxo.

[0320] In some embodiments of the present disclosure, the compound represented by the general formula (II-2), the general formula (II-2-1) or the general formula (II-2-2) or a pharmaceutically acceptable salt thereof, wherein R 1 is a hydrogen atom; R a is optionally replaced by one or more R A Substituted 5- or 6-membered heteroaryl; R A are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 haloalkoxy, 3- to 6-membered cycloalkyl, and cyano; Selected from R 5a A hydrogen atom or C 1-6 Alkyl; R 7a A hydrogen atom or C 1-6 Alkyl; R 7b Selected from hydrogen atoms, halogens and C 1-6 Alkyl; each R 7 are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 Haloalkyl; n3 is 0, 1 or 2; n2 is 0; R 8 and R 9 are the same or different and are each independently a hydrogen atom or a halogen; x is 0, 1 or 2; y is 0, 1 or 2; R 3 for n4 is 0 or 1; n5 is 0 or 1; R 3a is a hydrogen atom; R 3b Selected from C 1-6 Alkyl, C 1-6Halogenated alkyl, C 1-6 Hydroxyalkyl and C 1-6 Alkoxy C 1-6 Alkyl; R 3c and R 3d The same or different, and each independently selected from C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 1-6 Haloalkyl, -C(O)R d 、-NR g C(O)R d 、-C(O)NR e R f , 5 or 6 membered heterocyclic group and 5 or 6 membered heteroaryl; the 5 or 6 membered heterocyclic group and 5 or 6 membered heteroaryl are each independently optionally substituted by one or more R B Replacement; R d Selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered heterocyclic group and 3 to 8 membered cycloalkyl C 1-6 Alkyl, the 3 to 8 membered heterocyclic group and the 3 to 8 membered cycloalkyl C 1-6 The alkyl groups are each independently optionally substituted with one or more R B Replacement; R e and R f are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl and C 1-6 Haloalkyl; R g is a hydrogen atom; R B are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and oxo.

[0321] In some embodiments of the present disclosure, the compound represented by the general formula (M), (M-1) or (M-2) or a pharmaceutically acceptable salt thereof, wherein: R a is optionally replaced by one or more R A Substituted 5-membered heteroaryl; R A are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 haloalkoxy, 3- to 6-membered cycloalkyl, and cyano; n2 is 0; ring B is a 4- to 10-membered cycloalkyl; R 8 and R 9are the same or different and are each independently a hydrogen atom or a halogen; Ring A is a phenyl group; R 7 Halogen or C 1-6 Alkyl; n3 is 0 or 1; R 3 for R B are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 Haloalkyl; m is 0, 1 or 2.

[0322] In some embodiments of the present disclosure, the compound represented by the general formula (M), (M-1) or (M-2) or a pharmaceutically acceptable salt thereof, wherein: R a is optionally replaced by one or more R A Substituted 5-membered heteroaryl; R A are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 haloalkoxy, 3- to 6-membered cycloalkyl, and cyano; n2 is 0; ring B is a 4- to 10-membered cycloalkyl; R 8 and R 9 are the same or different and are each independently a hydrogen atom or a halogen; Ring A is a 5-membered heteroaryl group; R 7 Halogen or C 1-6 Alkyl; n3 is 0 or 1; R 3 for R 3c Selected from C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl and C 1-6 Haloalkyl; R 3d is optionally replaced by one or more R B substituted 5 or 6 membered heteroaryl or optionally substituted by one or more R B substituted 5- or 6-membered heterocyclic group; R B are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and oxo.

[0323] In some embodiments of the present disclosure, the compound represented by the general formula (M), (M-1) or (M-2) or a pharmaceutically acceptable salt thereof, wherein: R a Selected from n2 is 0; Ring B is cyclohexyl; R 8 and R 9 are the same or different and are each independently a hydrogen atom or a halogen; for R 7c is halogen; R 3 for R 3c Selected from C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl and C 1-6 Haloalkyl; R 3d for R B Selected from halogen, C 1-6 Alkyl and C 1-6 Haloalkyl; j is 0 or 1; R B1 A hydrogen atom or C 1-6 alkyl.

[0324] In some embodiments of the present disclosure, the compound represented by the general formula (X), the general formula (X-1) or the general formula (X-2) or a pharmaceutically acceptable salt thereof, wherein: R a Selected from and Ring B is a 4- to 10-membered cycloalkyl group or a 4- to 10-membered heterocyclic group; R 8 and R 9 are the same or different and are each independently selected from hydrogen, halogen and C 1-6 Alkyl; or, R 8 and R 9 and its connected carbon atoms together form a 3- to 6-membered cycloalkyl group; R 6 Selected from halogen, C 1-6 Alkyl and C 1-6 Haloalkyl; n2 is 0 or 1; R 7c Selected from hydrogen atoms, halogens and C 1-6 Alkyl; R 3b C 1-6 Alkyl or 3 to 6 membered cycloalkyl; G 1 , G 2 , G 3 and G 4 Each independently represents O or S; Ring C represents a 6-membered nitrogen-containing heterocyclic group; R B are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 haloalkyl; q is 0, 1, 2 or 3; R 25 Selected from R d , OR d and NR e R f ; R d Selected from C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 Alkoxy C 1-6 Alkyl; Re and R f are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl, C 1-6 haloalkyl and 3- to 6-membered cycloalkyl.

[0325] In some embodiments of the present disclosure, the compound represented by the general formula (X), the general formula (X-1) or the general formula (X-2) or a pharmaceutically acceptable salt thereof, wherein: R a for Selected from G 1 , G 2 , G 3 and G 4 are each independently O or S; R 7c is halogen; R 3b C 1-6 alkyl; Selected from R 25 Selected from ethyl, methoxymethyl,

[0326] In some embodiments of the present disclosure, the compound represented by the general formula (X), the general formula (X-1) or the general formula (X-2) or a pharmaceutically acceptable salt thereof, wherein Ring B is a 4- to 10-membered cycloalkyl group or a 4- to 10-membered heterocyclic group; R 8 and R 9 are the same or different and are each independently selected from hydrogen, halogen and C 1-6 Alkyl; or, R 8 and R 9 and its connected carbon atoms together form a 3- to 6-membered cycloalkyl group; R 6 Selected from halogen, C 1-6 Alkyl and C 1-6 Haloalkyl; n2 is 0 or 1; R 7c Selected from hydrogen atoms, halogens and C 1-6 Alkyl; R 3b C 1-6 Alkyl or 3 to 6 membered cycloalkyl; G 1 , G 2 , G 3 and G 4 Each independently represents O or S; Ring C represents a 6-membered nitrogen-containing heterocyclic group; R B are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 haloalkyl; q is 0, 1, 2 or 3; R 25 Selected from R d , ORd and NR e R f ; R d Selected from C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 Alkoxy C 1-6 Alkyl; R e and R f are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl, C 1-6 haloalkyl and 3- to 6-membered cycloalkyl.

[0327] In some embodiments of the present disclosure, the compound represented by the general formula (III), the general formula (III-1) or the general formula (III-2) or a pharmaceutically acceptable salt thereof, wherein: R a is optionally replaced by one or more R A Substituted 5-membered heteroaryl; R A are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, 3- to 6-membered cycloalkyl, and cyano; R 3b C 1-6 Alkyl; R 3c for Ring C is a 6-membered nitrogen-containing heterocyclic group; R B are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 haloalkyl; q is 0, 1, 2 or 3; ring A is phenyl or a 5- or 6-membered heteroaryl; R 7 Halogen or C 1-6 alkyl; n3 is 0 or 1; n2 is 0; Ring B is a 4- to 10-membered cycloalkyl; R 8 and R 9 are the same or different and are each independently a hydrogen atom or a halogen.

[0328] In some embodiments of the present disclosure, the compound represented by the general formula (III), the general formula (III-1) or the general formula (III-2) or a pharmaceutically acceptable salt thereof, wherein: R a is optionally replaced by one or more R A Substituted 5-membered heteroaryl; R A are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6haloalkoxy, 3- to 6-membered cycloalkyl, and cyano; n2 is 0; ring B is a 4- to 10-membered cycloalkyl; R 8 and R 9 are the same or different and are each independently a hydrogen atom or a halogen; Ring A is a phenyl group; R 7 Halogen or C 1-6 Alkyl; n3 is 0 or 1; R 3b C 1-6 Alkyl or 3 to 6-membered cycloalkyl; R 3c -NR g C(O)R d ; R g is a hydrogen atom; R d Selected from C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 Alkoxy C 1-6 Alkyl; Ring C is a 6-membered nitrogen-containing heterocyclic group; R B are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 haloalkyl; q is 0, 1, 2 or 3.

[0329] In some embodiments of the present disclosure, the compound represented by the general formula (III), the general formula (III-1) or the general formula (III-2) or a pharmaceutically acceptable salt thereof, wherein: R a Selected from R 3b C 1-6 Alkyl or 3 to 6-membered cycloalkyl; R 3c for for R 7c is halogen; Ring C is a 6-membered nitrogen-containing heterocyclic group; R B are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 haloalkyl; q is 0, 1, 2 or 3; n2 is 0; ring B is a 4- to 10-membered cycloalkyl; R 8 and R 9 are the same or different and are each independently a hydrogen atom or a halogen.

[0330] In some embodiments of the present disclosure, the compound represented by the general formula (III), the general formula (III-1) or the general formula (III-2) or a pharmaceutically acceptable salt thereof, wherein: R a Selected from R 3b C 1-6 Alkyl or 3 to 6-membered cycloalkyl; R 3c Selected from for R 7c is a halogen; for R Q C 1-6 Alkyl; R bb A hydrogen atom or C 1-6 alkyl; n2 is 0; Ring B is a 4- to 10-membered cycloalkyl; R 8 and R 9 are the same or different and are each independently selected from hydrogen, halogen and C 1-6 Alkyl; or, R 8 and R 9 and the carbon atoms to which it is attached together form a 3- to 6-membered cycloalkyl group.

[0331] In some embodiments of the present disclosure, the compound represented by the general formula (III), the general formula (III-1) or the general formula (III-2) or a pharmaceutically acceptable salt thereof, wherein: R a Selected from R 3b C 1-6 Alkyl or 3 to 6-membered cycloalkyl; R 3c Selected from for R 7c is a halogen; for R Q C 1-6 Alkyl; R bb A hydrogen atom or C 1-6 alkyl; n2 is 0; Ring B is a 4- to 10-membered cycloalkyl; R 8 and R 9 are the same or different and are each independently selected from hydrogen, halogen and C 1-6 Alkyl; or, R 8 and R 9 and the carbon atoms to which it is attached together form a 3- to 6-membered cycloalkyl group.

[0332] In some embodiments of the present disclosure, the compound represented by the general formula (VII), the general formula (VII-1) or the general formula (VII-2) or a pharmaceutically acceptable salt thereof, wherein R a is optionally replaced by one or more R A Substituted 5-membered heteroaryl; R A are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6Alkoxy, C 1-6 haloalkoxy, 3- to 6-membered cycloalkyl, and cyano; Ring B is a 4- to 10-membered cycloalkyl; R 8 and R 9 are the same or different and are each independently selected from hydrogen, halogen and C 1-6 Alkyl; or, R 8 and R 9 and its connected carbon atoms together form a 3- to 6-membered cycloalkyl group; n2 is 0; R 7c is halogen; R 3b C 1-6 Alkyl or 3 to 6-membered cycloalkyl; R d Selected from C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 Alkoxy C 1-6 Alkyl; R Q C 1-6 Alkyl; R bb A hydrogen atom or C 1-6 alkyl.

[0333] In some embodiments of the present disclosure, the compound represented by the general formula (VII), the general formula (VII-1) or the general formula (VII-2) or a pharmaceutically acceptable salt thereof, wherein: R a Selected from Selected from R 7c is halogen; R 3b C 1-6 Alkyl or 3 to 6-membered cycloalkyl; R d Selected from C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 Alkoxy C 1-6 Alkyl; R Q C 1-6 Alkyl; R bb A hydrogen atom or C 1-6 alkyl.

[0334] In some embodiments of the present disclosure, the compound represented by the general formula (IV), the general formula (IV-1) or the general formula (IV-2) or a pharmaceutically acceptable salt thereof, wherein: R a is optionally replaced by one or more R A Substituted 5-membered heteroaryl; R A are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C1-6 Alkoxy, C 1-6 haloalkoxy, 3- to 6-membered cycloalkyl, and cyano; n2 is 0; ring B is a 4- to 10-membered cycloalkyl; R 8 and R 9 are the same or different and are each independently a hydrogen atom or a halogen; R 7b is a hydrogen atom or a halogen; R 7 Halogen or C 1-6 Alkyl; n3 is 0 or 1; R 3 for R 3c C 1-6 Alkyl or C 1-6 Haloalkyl; R 3d -C(O)NR e R f ; R e A hydrogen atom or C 1-6 Alkyl; R f C 1-6 Alkyl or C 1-6 Halogenated alkyl.

[0335] In some embodiments of the present disclosure, the compound represented by the general formula (V), the general formula (V-1) or the general formula (V-2) or a pharmaceutically acceptable salt thereof, wherein: R a is optionally replaced by one or more R A Substituted 5-membered heteroaryl; R A are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 haloalkoxy, 3- to 6-membered cycloalkyl, and cyano; n2 is 0; ring B is a 4- to 10-membered cycloalkyl; R 8 and R 9 are the same or different and are each independently a hydrogen atom or a halogen; R 7a is a hydrogen atom; R 7 Halogen or C 1-6 Alkyl; n3 is 0 or 1; R 3 for or R 3c C 1-6 Alkyl or C 1-6 Haloalkyl; R 3d -C(O)NR e R f or -NR g C(O)R d ; R e A hydrogen atom or C 1-6 Alkyl; Rf C 1-6 Alkyl or C 1-6 Haloalkyl; R d C 1-6 Alkyl or C 1-6 Haloalkyl; R g is a hydrogen atom; R B are the same or different and are each independently selected from halogen, C 1-6 Alkyl and C 1-6 Haloalkyl; m is 0, 1 or 2.

[0336] Table A Typical compounds of the present disclosure include, but are not limited to:

[0337] Another aspect of the present disclosure relates to a compound represented by formula (IA) or a salt thereof,

[0338] in:

[0339] X, Ring A, Ring B, R 1 -R 7 , n1, n2 and n3 are as defined in the general formula (I).

[0340] Another aspect of the present disclosure relates to a compound represented by general formula (I-1A) or a salt thereof,

[0341] in:

[0342] Ring A, Ring B, R 1 -R 3 、R 5a 、R 6 、R 7 , n1, n2 and n3 are as defined in the general formula (I-1).

[0343] Another aspect of the present disclosure relates to a compound represented by general formula (I-2A) or a salt thereof,

[0344] in:

[0345] ○ indicates that the ring where G1 and G2 are located is aromatic;

[0346] Ring A, Ring B, R 1 -R 3 , G1, G2, R 6 、R 7 , n1, n2 and n3 are as defined in the general formula (I-2).

[0347] Another aspect of the present disclosure relates to a compound represented by general formula (IIA) or a salt thereof,

[0348] in:

[0349] Ring A, x, y, R 1 、R a 、R 3 -R 7 , n1, n2 and n3 are as defined in the general formula (II).

[0350] Another aspect of the present disclosure relates to compounds represented by general formula (II-1A), general formula (II-1-1A), general formula (II-1-2A) or salts thereof,

[0351] in:

[0352] Ring A, x, y, R 1 、R a 、R3 、R 5a 、R 6 、R 7 , n1, n2 and n3 are as defined in general formula (II-1), general formula (II-1-1) or general formula (II-1-2).

[0353] Another aspect of the present disclosure relates to a compound represented by general formula (II-2A), general formula (II-2-1A), or general formula (II-2-2A), or a salt thereof,

[0354] in:

[0355] ○ indicates that the ring where G1 and G2 are located is aromatic;

[0356] Ring A, x, y, R 1 、R a 、R 3 , G1, G2, R 6 、R 7 , n1, n2 and n3 are as defined in general formula (II-2), general formula (II-2-1) or general formula (II-2-2).

[0357] Another aspect of the present disclosure relates to a compound represented by formula (MA), (M-1A) or (M-2A) or a salt thereof,

[0358] in:

[0359] Ring A, Ring B, R a 、R 3 、R 6 、R 7 , n2 and n3 are as defined in the general formula (M), (M-1) or (M-2).

[0360] Another aspect of the present disclosure relates to a compound represented by formula (XA), (X-1A) or (X-2A) or a salt thereof,

[0361] in:

[0362] Ring B, Ring C, Ring G 1 , G 2 , G 3 , G 4 、R a 、R B ,q,R 3b 、R 6 、n2、R 7c and R 25 As defined in general formula (X), (X-1) or (X-2).

[0363] Another aspect of the present disclosure relates to a compound represented by formula (IIIA), formula (III-1A), or formula (III-2A), or a salt thereof,

[0364] in:

[0365] Ring A, Ring B, Ring C, R B 、R a 、R 3b 、R 3c 、R 6 、R 7 , q, n2 and n3 are as defined in the general formula (III), the general formula (III-1) or the general formula (III-2).

[0366] Another aspect of the present disclosure relates to a compound represented by formula (IVA), formula (IV-1A) or formula (IV-2A) or a salt thereof,

[0367] in:

[0368] R a , Ring B, R 6 、R 3 、R 7 、R 7b , n2 and n3 are as defined in general formula (IV), general formula (IV-1) or general formula (IV-2).

[0369] Another aspect of the present disclosure relates to a compound represented by Formula (VA), Formula (V-1A) or Formula (V-2A) or a salt thereof,

[0370] in:

[0371] R a , Ring B, R 6 、R 7 、R 7a , n2 and n3 are as defined in general formula (V), general formula (V-1) or general formula (V-2).

[0372] Another aspect of the present disclosure relates to a compound represented by formula (VIIA), formula (VII-1A) or formula (VII-2A) or a salt thereof,

[0373] in:

[0374] R a , Ring B, R 6 、n2、R 7c 、R 3b 、R d 、R bb and R QAs defined in general formula (VII), general formula (VII-1) or general formula (VII-2).

[0375] Another aspect of the present disclosure relates to a compound represented by general formula (IIa) or a salt thereof,

[0376] in:

[0377] Ring A, x, y, R 1 、R 3 、R 4 -R 9 , n1, n2 and n3 are as defined in the general formula (II).

[0378] Another aspect of the present disclosure relates to a compound represented by formula (II-1a), formula (II-1-1a) or formula (II-1-2a) or a salt thereof,

[0379] in:

[0380] Ring A, x, y, R 1 、R 3 、R 5a 、R 6 -R 9 , n1, n2 and n3 are as defined in general formula (II-1), general formula (II-1-1) or general formula (II-1-2).

[0381] Another aspect of the present disclosure relates to a compound represented by formula (II-2a), formula (II-2-1a) or formula (II-2-2a) or a salt thereof,

[0382] in:

[0383] ○ indicates that the ring where G1 and G2 are located is aromatic;

[0384] Ring A, x, y, R 1 、R 3 , G1, G2, R 6 -R 9 , n1, n2 and n3 are as defined in general formula (II-2), general formula (II-2-1) or general formula (II-2-2).

[0385] Another aspect of the present disclosure relates to a compound represented by formula (Ma), (M-1a) or (M-2a) or a salt thereof,

[0386] in:

[0387] Ring A, Ring B, R 3 、R 6 、R7 、R 8 、R 9 , n2 and n3 are as defined in the general formula (M), (M-1) or (M-2).

[0388] Another aspect of the present disclosure relates to a compound represented by general formula (Xa), (X-1a) or (X-2a) or a salt thereof,

[0389] in:

[0390] Ring B, Ring C, Ring G 2 , G 3 , G 4 、R B ,q,R 3b 、R 6 、n2、R 7c 、R 8 、R 9 and R 25 As defined in general formula (X), (X-1) or (X-2).

[0391] Another aspect of the present disclosure relates to a compound represented by formula (IIIa), formula (III-1a) or formula (III-2a) or a salt thereof,

[0392] in:

[0393] Ring A, Ring B, Ring C, R B ,q,R 3b 、R 3c 、R 6 -R 9 , n2 and n3 are as defined in general formula (III), general formula (III-1) or general formula (III-2).

[0394] Another aspect of the present disclosure relates to compounds represented by general formula (Ba), (B-1a), (B-2a), (B-3a) and (B-4a) or salts thereof,

[0395] in:

[0396] R 7d 、R 7e 、R 7f and R 3b As defined in formula (B), (B-1), (B-2), (B-3) and (B-4). Another aspect of the present disclosure relates to compounds represented by formula (Ca), (C-1a) and (C-2a) or salts thereof,

[0397] in:

[0398] R 7d 、R 7e 、R 7f 、R 3b 、R 3e and R bb As defined in general formula (C), (C-1) or (C-2).

[0399] Another aspect of the present disclosure relates to a compound represented by formula (EA) or (E-1A) or a salt thereof,

[0400] in:

[0401] Ring B, R 6 、n2、R 8 、R 9 、R 3c 、R 7c 、R B1 and R B3 As defined in general formula (E) or general formula (E-1).

[0402] Another aspect of the present disclosure relates to a compound represented by formula (IVa), (IV-1a) or (IV-2a) or a salt thereof,

[0403] in:

[0404] Ring B, R 3 、R 6 -R 9 、R 7b , n2 and n3 are as defined in general formula (IV), general formula (IV-1) or general formula (IV-2).

[0405] Another aspect of the present disclosure relates to a compound represented by formula (Va), (V-1a) or (V-2a) or a salt thereof,

[0406] in:

[0407] Ring B, R 3 、R 6 -R 9 、R 7a , n2 and n3 are as defined in general formula (V), general formula (V-1) or general formula (V-2).

[0408] Another aspect of the present disclosure relates to a compound represented by formula (VIIa), (VII-1a) or (VII-2a) or a salt thereof,

[0409] in:

[0410] Ring B, R6 、n2、R 8 、R 9 、R 7c 、R 3b 、R d 、R bb and R Q As defined in general formula (VII), general formula (VII-1) or general formula (VII-2).

[0411] In some embodiments of the present disclosure, the compound represented by the general formula (IA) or a salt thereof, wherein X is a bond; Ring B is a cycloalkyl group; R 2 -C(O)R a ; R a As defined in general formula (I); and the compound represented by general formula (IA) or a salt thereof, which is not

[0412] In some embodiments of the present disclosure, the compound represented by the general formula (I-1A) or a salt thereof, wherein ring B is a cycloalkyl group; R 2 -C(O)R a ; R a As defined in general formula (I); and the compound represented by general formula (I-1A) or a salt thereof, which is not

[0413] In some embodiments of the present disclosure, the compound represented by the general formula (I-2A) or a salt thereof, wherein ring B is a cycloalkyl group; R 2 -C(O)R a ; R a As defined in general formula (I).

[0414] In some embodiments of the present disclosure, the compound represented by the general formula (IIA) or the general formula (II-1A) or its salt is not

[0415] In some embodiments of the present disclosure, the compound represented by the general formula (II-1-1A) or its salt is not

[0416] Table B Typical intermediate compounds disclosed herein include, but are not limited to:

[0417] Scheme 1: Another aspect of the present disclosure relates to a method for preparing the compound represented by the above general formula (I) or a pharmaceutically acceptable salt thereof, the method comprising:

[0418] The compound represented by general formula (IA) or a salt thereof reacts with the compound represented by general formula (IB) or a salt thereof to obtain the compound represented by general formula (I) or a pharmaceutically acceptable salt thereof;

[0419] in:

[0420] The general formula (IB) is R is selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;

[0421] X, Ring A, Ring B, R 1 -R 9 , n1, n2 and n3 are as defined in the general formula (I).

[0422] Scheme 2: Another aspect of the present disclosure relates to a method for preparing the compound represented by the above general formula (I-1) or a pharmaceutically acceptable salt thereof, the method comprising:

[0423] The compound represented by the general formula (I-1A) or a salt thereof reacts with the compound represented by the general formula (IB) or a salt thereof to obtain the compound represented by the general formula (I-1) or a pharmaceutically acceptable salt thereof;

[0424] in:

[0425] The general formula (IB) is R is selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;

[0426] Ring A, Ring B, R 1 -R 3 、R 5a 、R 6 -R 9, n1, n2 and n3 are as defined in the general formula (I-1).

[0427] Scheme 3: Another aspect of the present disclosure relates to a method for preparing the compound represented by the above general formula (I-2) or a pharmaceutically acceptable salt thereof, the method comprising:

[0428] The compound represented by general formula (I-2A) or a salt thereof reacts with the compound represented by general formula (IB) or a salt thereof to obtain the compound represented by general formula (I-2) or a pharmaceutically acceptable salt thereof;

[0429] in:

[0430] The general formula (IB) is R is selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;

[0431] ○ indicates that the ring where G1 and G2 are located is aromatic;

[0432] Ring A, Ring B, R 1 -R 3 , G1, G2, R 6 -R 9 , n1, n2 and n3 are as defined in the general formula (I-2).

[0433] Scheme 4: Another aspect of the present disclosure relates to a method for preparing the compound represented by the above general formula (II) or a pharmaceutically acceptable salt thereof, the method comprising:

[0434] The compound represented by general formula (IIA) or a salt thereof reacts with the compound represented by general formula (IB) or a salt thereof to obtain the compound represented by general formula (II) or a pharmaceutically acceptable salt thereof;

[0435] in:

[0436] The general formula (IB) is R is selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;

[0437] Ring A, x, y, R 1 、R a 、R 3 -R 9 , n1, n2 and n3 are as defined in the general formula (II).

[0438] Scheme 5: Another aspect of the present disclosure relates to a method for preparing a compound represented by the above-mentioned general formula (II-1), general formula (II-1-1) or general formula (II-1-2) or a pharmaceutically acceptable salt thereof, the method comprising:

[0439] The compound represented by the general formula (II-1A) or a salt thereof reacts with the compound represented by the general formula (IB) or a salt thereof to obtain the compound represented by the general formula (II-1) or a pharmaceutically acceptable salt thereof;

[0440] The compound represented by the general formula (II-1-1A) or a salt thereof reacts with the compound represented by the general formula (IB) or a salt thereof to obtain the compound represented by the general formula (II-1-1) or a pharmaceutically acceptable salt thereof;

[0441] The compound represented by the general formula (II-1-2A) or a salt thereof reacts with the compound represented by the general formula (IB) or a salt thereof to obtain the compound represented by the general formula (II-1-2) or a pharmaceutically acceptable salt thereof;

[0442] in:

[0443] The general formula (IB) is R is selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;

[0444] Ring A, x, y, R 1 、R a 、R 3 、R 5a 、R 6 -R 9 , n1, n2 and n3 are as defined in general formula (II-1), general formula (II-1-1) or general formula (II-1-2).

[0445] Scheme 6: Another aspect of the present disclosure relates to a method for preparing a compound represented by the above-mentioned general formula (II-2), general formula (II-2-1) or general formula (II-2-2) or a pharmaceutically acceptable salt thereof, the method comprising:

[0446] The compound represented by general formula (II-2A) or a salt thereof reacts with the compound represented by general formula (IB) or a salt thereof to obtain the compound represented by general formula (II-2) or a pharmaceutically acceptable salt thereof;

[0447] The compound represented by the general formula (II-2-1A) or a salt thereof reacts with the compound represented by the general formula (IB) or a salt thereof to obtain the compound represented by the general formula (II-2-1) or a pharmaceutically acceptable salt thereof;

[0448] The compound represented by the general formula (II-2-2A) or a salt thereof reacts with the compound represented by the general formula (IB) or a salt thereof to obtain the compound represented by the general formula (II-2-2) or a pharmaceutically acceptable salt thereof;

[0449] in:

[0450] The general formula (IB) is R is selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;

[0451] ○ indicates that the ring where G1 and G2 are located is aromatic;

[0452] Ring A, x, y, R 1 、R a 、R 3 , G1, G2, R 6 -R 9 , n1, n2 and n3 are as defined in general formula (II-2), general formula (II-2-1) or general formula (II-2-2).

[0453] Scheme 7: Another aspect of the present disclosure relates to a method for preparing a compound represented by the above-mentioned general formula (M), (M-1) or (M-2) or a pharmaceutically acceptable salt thereof, the method comprising:

[0454] The compound represented by the general formula (MA) or a salt thereof reacts with the compound represented by the general formula (IB) or a salt thereof to obtain the compound represented by the general formula (M) or a pharmaceutically acceptable salt thereof; or

[0455] The compound represented by the general formula (M-1A) or a salt thereof reacts with the compound represented by the general formula (IB) or a salt thereof to obtain the compound represented by the general formula (M-1) or a pharmaceutically acceptable salt thereof; or

[0456] The compound represented by the general formula (M-2A) or a salt thereof reacts with the compound represented by the general formula (IB) or a salt thereof to obtain the compound represented by the general formula (M-2) or a pharmaceutically acceptable salt thereof;

[0457] in:

[0458] The general formula (IB) is R is selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;

[0459] in:

[0460] Ring A, Ring B, R a 、R3 、R 6 -R 9 , n2 and n3 are as defined in the general formula (M), (M-1) or (M-2).

[0461] Scheme 8: Another aspect of the present disclosure relates to a method for preparing a compound represented by the above-mentioned general formula (X), general formula (X-1) or general formula (X-2) or a pharmaceutically acceptable salt thereof, the method comprising:

[0462] The compound represented by the general formula (XA) or a salt thereof reacts with the compound represented by the general formula (IB) or a salt thereof to obtain the compound represented by the general formula (X) or a pharmaceutically acceptable salt thereof; or

[0463] The compound represented by the general formula (X-1A) or a salt thereof reacts with the compound represented by the general formula (IB) or a salt thereof to obtain the compound represented by the general formula (X-1) or a pharmaceutically acceptable salt thereof; or

[0464] The compound represented by the general formula (X-2A) or a salt thereof reacts with the compound represented by the general formula (IB) or a salt thereof to obtain the compound represented by the general formula (X-2) or a pharmaceutically acceptable salt thereof;

[0465] in:

[0466] The general formula (IB) is R is selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;

[0467] in:

[0468] Ring B, Ring C, Ring G 1 , G 2 , G 3 , G 4 、R a 、R B ,q,R 3b 、R 6 、n2、R 7c 、R 8 、R 9 and R 25 As defined in general formula (X), (X-1) or (X-2).

[0469] Scheme 9: Another aspect of the present disclosure relates to a method for preparing a compound represented by the above-mentioned general formula (III), general formula (III-1) or general formula (III-2) or a pharmaceutically acceptable salt thereof, the method comprising:

[0470] The compound represented by general formula (IIIA) or a salt thereof reacts with the compound represented by general formula (IB) or a salt thereof to obtain the compound represented by general formula (III) or a pharmaceutically acceptable salt thereof;

[0471] or

[0472] The compound represented by the general formula (III-1A) or a salt thereof reacts with the compound represented by the general formula (IB) or a salt thereof to obtain the compound represented by the general formula (III-1) or a pharmaceutically acceptable salt thereof;

[0473] or

[0474] The compound represented by the general formula (III-2A) or a salt thereof reacts with the compound represented by the general formula (IB) or a salt thereof to obtain the compound represented by the general formula (III-2) or a pharmaceutically acceptable salt thereof;

[0475] in:

[0476] The general formula (IB) is R is selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;

[0477] Ring A, Ring B, Ring C, R B 、R a 、R 3b 、R 3c 、R 6 -R 9 , q, n2 and n3 are as defined in the general formula (III), the general formula (III-1) or the general formula (III-2).

[0478] Scheme 10: Another aspect of the present disclosure relates to a method for preparing the compound represented by the above-mentioned general formula (IV), (IV-1) or (IV-2) or a pharmaceutically acceptable salt thereof, the method comprising:

[0479] The compound represented by general formula (IVA) or a salt thereof reacts with the compound represented by general formula (IB) or a salt thereof to obtain the compound represented by general formula (IV) or a pharmaceutically acceptable salt thereof; or

[0480] The compound represented by the general formula (IV-1A) or a salt thereof reacts with the compound represented by the general formula (IB) or a salt thereof to obtain the compound represented by the general formula (IV-1) or a pharmaceutically acceptable salt thereof; or

[0481] The compound represented by the general formula (IV-2A) or a salt thereof reacts with the compound represented by the general formula (IB) or a salt thereof to obtain the compound represented by the general formula (IV-2) or a pharmaceutically acceptable salt thereof;

[0482] in:

[0483] The general formula (IB) is R is selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;

[0484] in:

[0485] Ring B, R a 、R 7b 、R 3 、R 6 -R 9 , n2 and n3 are as defined in formula (IV), (IV-1) or (IV-2).

[0486] Scheme 11: Another aspect of the present disclosure relates to a method for preparing a compound represented by the above-mentioned general formula (V), (V-1) or (V-2) or a pharmaceutically acceptable salt thereof, the method comprising:

[0487] The compound represented by general formula (VA) or its salt reacts with the compound represented by general formula (IB) or its salt to obtain the compound represented by general formula (V) or its pharmaceutically acceptable salt; or

[0488] The compound represented by the general formula (V-1A) or a salt thereof reacts with the compound represented by the general formula (IB) or a salt thereof to obtain the compound represented by the general formula (V-1) or a pharmaceutically acceptable salt thereof; or

[0489] The compound represented by the general formula (V-2A) or a salt thereof reacts with the compound represented by the general formula (IB) or a salt thereof to obtain the compound represented by the general formula (V-2) or a pharmaceutically acceptable salt thereof;

[0490] in:

[0491] The general formula (IB) is R is selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;

[0492] in:

[0493] Ring B, R a 、R 7a 、R 3 、R 6 -R 9 , n2 and n3 are as defined in formula (V), (V-1) or (V-2).

[0494] Scheme 12: Another aspect of the present disclosure relates to a method for preparing the compounds represented by the above-mentioned general formula (VII), general formula (VII-1) and general formula (VII-2) or pharmaceutically acceptable salts thereof, the method comprising:

[0495] The compound represented by general formula (VIIA) or a salt thereof reacts with the compound represented by general formula (IB) or a salt thereof to obtain the compound represented by general formula (VII) or a pharmaceutically acceptable salt thereof;

[0496] The compound represented by the general formula (VII-1A) or a salt thereof reacts with the compound represented by the general formula (IB) or a salt thereof to obtain the compound represented by the general formula (VII-1) or a pharmaceutically acceptable salt thereof;

[0497] The compound represented by the general formula (VII-2A) or a salt thereof reacts with the compound represented by the general formula (IB) or a salt thereof to obtain the compound represented by the general formula (VII-2) or a pharmaceutically acceptable salt thereof;

[0498] in:

[0499] The general formula (IB) is R is selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;

[0500] R a , Ring B, R 8 、R 9 、R 6 、n2、R 7c 、R 3b 、R d 、R bb and R Q As defined in general formula (VII), general formula (VII-1) or general formula (VII-2).

[0501] Scheme 13: Another aspect of the present disclosure relates to a method for preparing the compound represented by the above general formula (I) or a pharmaceutically acceptable salt thereof, the method comprising:

[0502] When n1 is 1 and R 3 is optionally replaced by one or more R B When the pyridyl group is substituted, the compound represented by the general formula (I) undergoes oxidation reaction to obtain n1 is 1, and R 3 is optionally replaced by one or more R B The compound represented by the general formula (I) of substituted pyridine nitrogen oxide; wherein: R B , Ring A, Ring B, R 1 、R 2 、R 4 -R 9 , n2 and n3 are as defined in the general formula (I).

[0503] Scheme 14: Another aspect of the present disclosure relates to a method for preparing the compound represented by the above general formula (I-1) or a pharmaceutically acceptable salt thereof, the method comprising:

[0504] When n1 is 1 and R 3 is optionally replaced by one or more R B When the pyridyl group is substituted, the compound represented by the general formula (I-1) undergoes oxidation reaction to obtain n1 is 1, and R 3 is optionally replaced by one or more R B A compound represented by the general formula (I-1) of a substituted pyridine nitrogen oxide; wherein: R B , Ring A, Ring B, R 1 、R 2 、R 5a 、R 6 -R 9 , n2 and n3 are as defined in the general formula (I-1).

[0505] Scheme 15: Another aspect of the present disclosure relates to a method for preparing the compound represented by the above-mentioned general formula (I-2) or a pharmaceutically acceptable salt thereof, the method comprising:

[0506] When n1 is 1 and R 3 is optionally replaced by one or more R B When the pyridyl group is substituted, the compound represented by the general formula (I-2) undergoes oxidation reaction to obtain n1 is 1, and R 3 is optionally replaced by one or more R B A compound represented by the general formula (I-2) of a substituted pyridine nitrogen oxide; wherein: ○ indicates that the ring where G1 and G2 are located is aromatic; R B , Ring A, Ring B, R1, R2, G1, G2, R 6 -R 9 , n2 and n3 are as defined in the general formula (I-2).

[0507] Scheme 16: Another aspect of the present disclosure relates to a method for preparing the compound represented by the above general formula (II) or a pharmaceutically acceptable salt thereof, the method comprising:

[0508] When n1 is 1 and R 3 is optionally replaced by one or more R B When the pyridyl group is substituted, the compound represented by the general formula (II) undergoes oxidation reaction to obtain n1 is 1, and R 3 is optionally replaced by one or more R B A compound represented by the general formula (II) of a substituted pyridine nitrogen oxide; wherein: R B , Ring A, x, y, R 1 、R a 、R 4 -R9 , n2 and n3 are as defined in the general formula (II).

[0509] Scheme 17: Another aspect of the present disclosure relates to a method for preparing a compound represented by the above-mentioned general formula (II-1), general formula (II-1-1) or general formula (II-1-2) or a pharmaceutically acceptable salt thereof, the method comprising:

[0510] When n1 is 1 and R 3 is optionally replaced by one or more R B When substituted pyridine is used, the compound represented by the general formula (II-1) undergoes oxidation reaction to obtain n1 is 1, and R 3 is optionally replaced by one or more R B A compound represented by the general formula (II-1) of a substituted pyridine nitrogen oxide; or

[0511] When n1 is 1 and R 3 is optionally replaced by one or more R B When the pyridyl group is substituted, the compound represented by the general formula (II-1-1) undergoes oxidation reaction to obtain n1 is 1, and R 3 is optionally replaced by one or more R B A compound represented by the general formula (II-1-1) of a substituted pyridine nitrogen oxide; or

[0512] When n1 is 1 and R 3 is optionally replaced by one or more R B When the pyridyl group is substituted, the compound represented by the general formula (II-1-2) undergoes oxidation reaction to obtain n1 is 1, and R 3 is optionally replaced by one or more R B A compound represented by the general formula (II-1-2) of a substituted pyridine nitrogen oxide;

[0513] Where: R B , Ring A, x, y, R 1 、R a 、R 5a 、R 6 -R 9 , n2 and n3 are as defined in general formula (II-1), general formula (II-1-1) or general formula (II-1-2).

[0514] Scheme 18: Another aspect of the present disclosure relates to a method for preparing a compound represented by the above-mentioned general formula (II-2), general formula (II-2-1) or general formula (II-2-2) or a pharmaceutically acceptable salt thereof, the method comprising:

[0515] When n1 is 1 and R 3 is optionally replaced by one or more R BWhen the pyridyl group is substituted, the compound represented by the general formula (II-2) undergoes oxidation reaction to obtain n1 is 1, and R 3 is optionally replaced by one or more R B A compound represented by the general formula (II-2) of a substituted pyridine nitrogen oxide; or

[0516] When n1 is 1 and R 3 is optionally replaced by one or more R B When the pyridyl group is substituted, the compound represented by the general formula (II-2-1) undergoes oxidation reaction to obtain n1 is 1, and R 3 is optionally replaced by one or more R B A compound represented by the general formula (II-2-1) of a substituted pyridine nitrogen oxide; or

[0517] When n1 is 1 and R 3 is optionally replaced by one or more R B When the pyridyl group is substituted, the compound represented by the general formula (II-2-2) undergoes oxidation reaction to obtain n1 is 1, and R 3 is optionally replaced by one or more R B A compound represented by the general formula (II-2-2) of a substituted pyridine nitrogen oxide;

[0518] Wherein: ○ indicates that the ring where G1 and G2 are located is aromatic; R B , Ring A, x, y, R 1 、R a , G1, G2, R 6 -R 9 , n2 and n3 are as defined in general formula (II-2), general formula (II-2-1) or general formula (II-2-2).

[0519] Scheme 19: Another aspect of the present disclosure relates to a method for preparing the compound represented by the above general formula (II) or a pharmaceutically acceptable salt thereof, the method comprising:

[0520] The compound represented by general formula (IIa) or its salt and R w C(O)R a The compound or its salt undergoes a condensation reaction to obtain the compound represented by general formula (II) or a pharmaceutically acceptable salt thereof;

[0521] in:

[0522] R w is OH or halogen; in some embodiments, is OH;

[0523] Ring A, x, y, R 1 、R a 、R 3-R 9 , n1, n2 and n3 are as defined in the general formula (II).

[0524] Scheme 20: Another aspect of the present disclosure relates to a method for preparing the compound represented by the above-mentioned general formula (II-1), general formula (II-1-1), general formula (II-1-2) or a pharmaceutically acceptable salt thereof, the method comprising:

[0525] The compound represented by the general formula (II-1a) or its salt and R w C(O)R a The compound or its salt undergoes a condensation reaction to obtain a compound represented by general formula (II-1) or a pharmaceutically acceptable salt thereof;

[0526] or

[0527] The compound represented by the general formula (II-1-1a) or its salt and R w C(O)R a The compound or its salt undergoes a condensation reaction to obtain the compound represented by general formula (II-1-1) or a pharmaceutically acceptable salt thereof;

[0528] or

[0529] The compound represented by the general formula (II-1-2a) or its salt and R w C(O)R a The compound or its salt undergoes a condensation reaction to obtain the compound represented by general formula (II-1-2) or a pharmaceutically acceptable salt thereof;

[0530] in:

[0531] R w is OH or halogen; in some embodiments, is OH;

[0532] Ring A, x, y, R 1 、R a 、R 3 、R 5a 、R 6 -R 9 , n1, n2 and n3 are as defined in general formula (II-1), general formula (II-1-1) or general formula (II-1-2).

[0533] Scheme 21: Another aspect of the present disclosure relates to a method for preparing the compound represented by the above-mentioned general formula (II-2), general formula (II-2-1), general formula (II-2-2) or a pharmaceutically acceptable salt thereof, the method comprising:

[0534] The compound represented by general formula (II-2a) or its salt and R wC(O)R a The compound or its salt undergoes a condensation reaction to obtain a compound represented by general formula (II-2) or a pharmaceutically acceptable salt thereof;

[0535] or

[0536] The compound represented by the general formula (II-2-1a) or its salt and R w C(O)R a The compound or its salt undergoes a condensation reaction to obtain the compound represented by general formula (II-2-1) or a pharmaceutically acceptable salt thereof;

[0537] or

[0538] The compound represented by the general formula (II-2-2a) or its salt and R w C(O)R a The compound or its salt undergoes a condensation reaction to obtain a compound represented by general formula (II-2-2) or a pharmaceutically acceptable salt thereof;

[0539] in:

[0540] R w is OH or halogen; in some embodiments, is OH;

[0541] ○ indicates that the ring where G1 and G2 are located is aromatic;

[0542] Ring A, x, y, R 1 、R a 、R 3 , G1, G2, R 6 -R 9 , n1, n2 and n3 are as defined in general formula (II-2), general formula (II-2-1) or general formula (II-2-2).

[0543] Scheme 22: Another aspect of the present disclosure relates to a method for preparing a compound represented by the above-mentioned general formula (M), general formula (M-1) or general formula (M-2) or a pharmaceutically acceptable salt thereof, the method comprising:

[0544] The compound represented by the general formula (Ma) or its salt and R w C(O)R a The compound or its salt undergoes condensation reaction to obtain the compound represented by general formula (M) or its pharmaceutically acceptable salt; or

[0545] The compound represented by the general formula (M-1a) or its salt and R w C(O)R a The compound or its salt undergoes condensation reaction to obtain the compound represented by general formula (M-1) or its pharmaceutically acceptable salt; or

[0546] The compound represented by the general formula (M-2a) or its salt and R w C(O)R a The compound or its salt undergoes a condensation reaction to obtain a compound represented by general formula (M-2) or a pharmaceutically acceptable salt thereof;

[0547] in:

[0548] R w is OH or halogen; in some embodiments, is OH;

[0549] Ring A, Ring B, R a 、R 3 、R 6 -R 9 , n2 and n3 are as defined in the general formula (M), (M-1) or (M-2).

[0550] Scheme 23: Another aspect of the present disclosure relates to a method for preparing a compound represented by the above-mentioned general formula (X), general formula (X-1) or general formula (X-2) or a pharmaceutically acceptable salt thereof, the method comprising:

[0551] The compound represented by the general formula (Xa) or a salt thereof and R w C(G 1 )R a The compound or its salt undergoes a condensation reaction to obtain a compound represented by general formula (X) or a pharmaceutically acceptable salt thereof;

[0552] or

[0553] The compound represented by the general formula (X-1a) or its salt and R w C(G 1 )R a The compound or its salt undergoes a condensation reaction to obtain a compound represented by the general formula (X-1) or a pharmaceutically acceptable salt thereof;

[0554] or

[0555] The compound represented by the general formula (X-2a) or its salt and R w C(G 1 )R a The compound or its salt undergoes a condensation reaction to obtain a compound represented by the general formula (X-2) or a pharmaceutically acceptable salt thereof;

[0556] in:

[0557] R w is OH or halogen; in some embodiments, is OH;

[0558] Ring B, Ring C, Ring G 1 , G 2 , G 3, G 4 、R a 、R B ,q,R 3b 、R 6 、n2、R 7c 、R 8 、R 9 and R 25 As defined in general formula (X), (X-1) or (X-2).

[0559] Scheme 24: Another aspect of the present disclosure relates to a method for preparing a compound represented by the above-mentioned general formula (III), general formula (III-1) or general formula (III-2) or a pharmaceutically acceptable salt thereof, the method comprising:

[0560] The compound represented by general formula (IIIa) or its salt and R w C(O)R a The compound or its salt undergoes a condensation reaction to obtain the compound represented by general formula (III) or a pharmaceutically acceptable salt thereof;

[0561] or

[0562] The compound represented by general formula (III-1a) or its salt and R w C(O)R a The compound or its salt undergoes a condensation reaction to obtain a compound represented by general formula (III-1) or a pharmaceutically acceptable salt thereof;

[0563] or

[0564] The compound represented by general formula (III-2a) or its salt and R w C(O)R a The compound or its salt undergoes a condensation reaction to obtain a compound represented by general formula (III-2) or a pharmaceutically acceptable salt thereof;

[0565] in:

[0566] R w is OH or halogen; in some embodiments, is OH;

[0567] Ring A, Ring B, Ring C, R B 、R a 、R 3b 、R 3c 、R 6 -R 9 , q, n2 and n3 are as defined in the general formula (III), the general formula (III-1) or the general formula (III-2).

[0568] Scheme 25: Another aspect of the present disclosure relates to a method for preparing a compound represented by the above-mentioned general formula (IV), general formula (IV-1) or general formula (IV-2) or a pharmaceutically acceptable salt thereof, the method comprising:

[0569] The compound represented by general formula (IVa) or its salt and R w C(O)R a The compound or its salt undergoes condensation reaction to obtain the compound represented by general formula (IV) or its pharmaceutically acceptable salt; or

[0570] The compound represented by the general formula (IV-1a) or its salt and R w C(O)R a The compound or its salt undergoes condensation reaction to obtain the compound represented by general formula (IV-1) or its pharmaceutically acceptable salt; or

[0571] The compound represented by the general formula (IV-2a) or its salt and R w C(O)R a The compound or its salt undergoes a condensation reaction to obtain a compound represented by general formula (IV-2) or a pharmaceutically acceptable salt thereof;

[0572] in:

[0573] R w is OH or halogen; in some embodiments, is OH;

[0574] Ring B, R a 、R 7b 、R 3 、R 6 -R 9 , n2 and n3 are as defined in formula (IV), (IV-1) or (IV-2).

[0575] Scheme 26: Another aspect of the present disclosure relates to a method for preparing a compound represented by the above-mentioned general formula (V), general formula (V-1) or general formula (V-2) or a pharmaceutically acceptable salt thereof, the method comprising:

[0576] The compound represented by general formula (Va) or its salt and R w C(O)R a The compound or its salt undergoes condensation reaction to obtain the compound represented by general formula (V) or its pharmaceutically acceptable salt; or

[0577] The compound represented by the general formula (V-1a) or its salt and R w C(O)R a The compound or its salt undergoes condensation reaction to obtain the compound represented by general formula (V-1) or its pharmaceutically acceptable salt; or

[0578] The compound represented by the general formula (V-2a) or its salt and R w C(O)R a The compound or its salt undergoes a condensation reaction to obtain a compound represented by general formula (V-2) or a pharmaceutically acceptable salt thereof;

[0579] in:

[0580] R w is OH or halogen; in some embodiments, is OH;

[0581] Ring B, R a 、R 7a 、R 3 、R 6 -R 9 , n2 and n3 are as defined in formula (V), (V-1) or (V-2).

[0582] Scheme 27: Another aspect of the present disclosure relates to a method for preparing the compounds represented by the above-mentioned general formula (VII), general formula (VII-1) and general formula (VII-2) or pharmaceutically acceptable salts thereof, the method comprising:

[0583] The compound represented by general formula (VIIa) or its salt and R w C(O)R a The compound or its salt undergoes a condensation reaction to obtain a compound represented by general formula (VII) or a pharmaceutically acceptable salt thereof;

[0584] The compound represented by the general formula (VII-1a) or a salt thereof and R w C(O)R a The compound or its salt undergoes a condensation reaction to obtain a compound represented by general formula (VII-1) or a pharmaceutically acceptable salt thereof;

[0585] The compound represented by the general formula (VII-2a) or its salt and R w C(O)R a The compound or its salt undergoes a condensation reaction to obtain a compound represented by general formula (VII-2) or a pharmaceutically acceptable salt thereof;

[0586] in:

[0587] R w is OH or halogen; in some embodiments, is OH;

[0588] R a , Ring B, R 6 、n2、R 8 、R 9 、R 7c 、R 3b 、Rd 、R bb and R Q As defined in general formula (VII), general formula (VII-1) or general formula (VII-2).

[0589] Scheme 28: Another aspect of the present disclosure relates to a method for preparing a compound represented by the above-mentioned general formula (B), general formula (B-1), general formula (B-2), general formula (B-3) or general formula (B-4) or a pharmaceutically acceptable salt thereof, the method comprising:

[0590] The compound represented by general formula (Ba) or its salt undergoes a condensation reaction with the compound represented by general formula (Bb) or its salt to obtain the compound represented by general formula (B) or its pharmaceutically acceptable salt;

[0591] The compound represented by the general formula (B-1a) or its salt undergoes a condensation reaction with the compound represented by the general formula (Bb) or its salt to obtain the compound represented by the general formula (B-1) or its pharmaceutically acceptable salt;

[0592] The compound represented by the general formula (B-2a) or its salt undergoes a condensation reaction with the compound represented by the general formula (Bb) or its salt to obtain the compound represented by the general formula (B-2) or its pharmaceutically acceptable salt;

[0593] The compound represented by the general formula (B-3a) or its salt undergoes a condensation reaction with the compound represented by the general formula (Bb) or its salt to obtain the compound represented by the general formula (B-3) or its pharmaceutically acceptable salt;

[0594] The compound represented by the general formula (B-4a) or its salt undergoes a condensation reaction with the compound represented by the general formula (Bb) or its salt to obtain the compound represented by the general formula (B-4) or its pharmaceutically acceptable salt;

[0595] in:

[0596] R w is OH or halogen; in some embodiments, is OH;

[0597] R 2c 、R 2d 、R 2e 、R 2f 、R 2g 、R 3b 、R 7d 、R 7e and R 7f As defined in general formula (B), general formula (B-1), general formula (B-2), general formula (B-3) or general formula (B-4).

[0598] Scheme 29: Another aspect of the present disclosure relates to a method for preparing a compound represented by the above-mentioned general formula (C), general formula (C-1) or general formula (C-2) or a pharmaceutically acceptable salt thereof, the method comprising:

[0599] The compound represented by general formula (Ca) or its salt undergoes a condensation reaction with the compound represented by general formula (Bb) or its salt to obtain the compound represented by general formula (C) or its pharmaceutically acceptable salt;

[0600] The compound represented by the general formula (C-1a) or its salt undergoes a condensation reaction with the compound represented by the general formula (Bb) or its salt to obtain the compound represented by the general formula (C-1) or its pharmaceutically acceptable salt;

[0601] The compound represented by the general formula (C-2a) or its salt undergoes a condensation reaction with the compound represented by the general formula (Bb) or its salt to obtain the compound represented by the general formula (C-2) or its pharmaceutically acceptable salt;

[0602] in:

[0603] R w is OH or halogen; in some embodiments, is OH;

[0604] R 2c 、R 2d 、R 2e 、R 2f 、R 2g 、R 3b 、R 3e 、R bb 、R 7d 、R 7e and R 7f As defined in general formula (C), general formula (C-1) or general formula (C-2).

[0605] Scheme 30: Another aspect of the present disclosure relates to a method for preparing a compound represented by the above-mentioned general formula (E) or general formula (E-1) or a pharmaceutically acceptable salt thereof, the method comprising:

[0606] in:

[0607] The compound represented by the general formula (EA) or its salt and R w C(O)R a The compound or its salt undergoes a condensation reaction to obtain a compound represented by general formula (E) or a pharmaceutically acceptable salt thereof;

[0608] The compound represented by the general formula (E-1A) or a salt thereof and R w C(O)R a The compound or its salt undergoes a condensation reaction to obtain a compound represented by general formula (E-1) or a pharmaceutically acceptable salt thereof;

[0609] in:

[0610] R w is OH or halogen; in some embodiments, is OH;

[0611] R a , Ring B, R 6 、n2、R 8 、R 9 、R 3c 、R 7c 、R B1 and R B3 As defined in general formula (E) or general formula (E-1).

[0612] In some embodiments of the present disclosure, the reactions described in Schemes 1 to 12 are carried out under alkaline conditions.

[0613] In some embodiments of the present disclosure, R is pyridyl; in some embodiments, R is

[0614] In some embodiments of the present disclosure, the compound represented by general formula (IB) is 2-((difluoromethyl)sulfonyl)pyridine (in this case R 8 and R 9 is F).

[0615] In some embodiments of the present disclosure, the compound represented by the general formula (IB) can be replaced by (fluoromethyl)triphenylphosphonium tetrafluoroborate, (fluoromethyl)triphenylphosphonium tetrafluoroborate, (triphenylphosphonium)difluoroacetic acid inner salt, phosphonate carbon anion, phosphorus ylide, sulfur ylide, etc., and the target product is obtained by reaction.

[0616] In some embodiments of the present disclosure, R w For OH.

[0617] In some embodiments of the present disclosure, when R w When R is OH, the condensation reaction is carried out under alkaline conditions and in the presence of a condensing agent; w When is halogen, the condensation reaction is carried out under alkaline conditions.

[0618] In some embodiments of the present disclosure, the condensation reaction is carried out under alkaline conditions and optionally in the presence of a condensing agent; in some embodiments, the condensation reaction is carried out under alkaline conditions and in the presence of a condensing agent; in some embodiments, the condensation reaction is carried out in the presence of N,N-diisopropylethylamine and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU).

[0619] In some embodiments of the present disclosure, the reagents providing alkaline conditions include organic bases and inorganic bases, the organic bases including but not limited to triethylamine, N,N-diisopropylethylamine, N,N-diisopropylethylenediamine, phenyllithium, n-butyllithium, lithium diisopropylamide, potassium acetate, sodium tert-butoxide, potassium tert-butoxide, tetrabutylammonium fluoride, tetrabutylammonium fluoride in tetrahydrofuran or 1,8-diazabicycloundec-7-ene, the inorganic bases including but not limited to sodium hydride, potassium phosphate, sodium carbonate, sodium acetate, potassium acetate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, cesium fluoride and potassium hydroxide; in some embodiments, the reagent providing alkaline conditions is N,N-diisopropylethylamine; in some embodiments, the reagent providing alkaline conditions is potassium tert-butoxide.

[0620] In some embodiments of the present disclosure, the condensing agent includes but is not limited to 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N,N'-dicyclohexylcarbodiimide, N,N'-diisopropylcarbodiimide, O-benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroborate, 1-hydroxybenzotriazole, 1-hydroxy-7-azobenzotriazole, O-benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate, O-(7-azabenzotriazole-1 -yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), 2-(7-benzotriazole oxide)-N,N,N',N'-tetramethyluronium hexafluorophosphate, benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate or benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate; in some embodiments, the condensing agent is O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU).

[0621] In some embodiments of the present disclosure, the oxidation reaction is carried out under the action of an oxidant.

[0622] In some embodiments of the present disclosure, the oxidant includes but is not limited to meta-chloroperbenzoic acid, hydrogen peroxide, peracetic acid, magnesium monoperoxyphthalate (MMPP), potassium peroxymonosulfonate (OXONE), and in some embodiments is meta-chloroperbenzoic acid; in some embodiments, the oxidant is meta-chloroperbenzoic acid.

[0623] In some embodiments of the present disclosure, the above reaction is carried out in a solvent, and the solvent used includes but is not limited to: pyridine, ethylene glycol dimethyl ether, acetic acid, methanol, ethanol, acetonitrile, n-butanol, toluene, tetrahydrofuran, dichloromethane, petroleum ether, ethyl acetate, n-hexane, dimethyl sulfoxide, 1,4-dioxane, water, N,N-dimethylformamide, N,N-dimethylacetamide, 1,2-dibromoethane and mixtures thereof.

[0624] Another aspect of the present disclosure relates to a pharmaceutical composition comprising the general formula (I), (I-1), (I-2), (II), (II-1), (II-2), (II-1-1), (II-1-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV- 2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (G), (G-1), (G-2), (B), (B-1), (B-2), (B-3), (B-4), (C), (C-1), (C-2), a compound of formula (E) or (E-1) or shown in Table A, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.

[0625] The present disclosure further relates to the general formula (I), (I-1), (I-2), (II), (II-1), (II-2), (II-1-1), (II-1-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (V-2), I-2), (VII), (VII-1), (VII-2), (G), (G-1), (G-2), (B), (B-1), (B-2), (B-3), (B-4), (C), (C-1), (C-2), (E) or (E-1) or a compound shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, in the preparation of a medicament for treating and / or preventing a disease or condition mediated by IL-17; in some embodiments, wherein the IL-17 is IL-17A.

[0626] The present disclosure further relates to compounds of formula (I), (I-1), (I-2), (II), (II-1), (II-2), (II-1-1), (II-1-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (G), (G-1), (G-2), (B), (B-1), (B-2), (B-3), (B-4), (C), (C-1), (C-2), (E), or (E-1) or compounds shown in Table A, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising the same, for use in the preparation of pharmaceutical compositions for treating and / or preventing cancer, inflammation, or autoimmune diseases. Use in medicine; In some embodiments, the inflammatory or autoimmune disease is selected from arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa, rheumatoid arthritis, juvenile atopic arthritis, spondyloarthritis (e.g., axial spondyloarthritis), uveitis (e.g., non-infectious uveitis), bone erosion, intraperitoneal abscesses and adhesions, inflammatory bowel disease (IBD), Crohn's disease, allograft rejection (e.g., kidney), psoriasis, angiogenesis, arteriosclerosis Atherosclerosis, asthma (e.g., bronchial asthma), multiple sclerosis (MS), systemic lupus erythematosus, lupus nephritis, Behcet's syndrome (Behcet's disease), ulcerative colitis, Behcet's disease, Wegener's granulomatosis, sarcoidosis, systemic sclerosis, insulin-dependent diabetes mellitus, septic shock syndrome, Alzheimer's disease, inflammatory eye disease, palmoplantar pustulosis (PPP), atopic dermatitis, chronic obstructive pulmonary disease (COPD) and Helicobacter pylori-associated gastritis, in some embodiments selected from psoriasis, rheumatoid arthritis, spondyloarthritis and multiple sclerosis, in some embodiments psoriasis.

[0627] The present disclosure further relates to a method of inhibiting IL-17, comprising administering to a patient in need thereof a compound of the formula (I), (I-1), (I-2), (II), (II-1), (II-2), (II-1-1), (II-1-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), ( V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (G), (G-1), (G-2), (B), (B-1), (B-2), (B-3), (B-4), (C), (C-1), (C-2), (E) or (E-1), or a compound shown in Table A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same; in some embodiments, the IL-17 is IL-17A.

[0628] The present disclosure further relates to a method for treating and / or preventing a disease or condition mediated by IL-17, comprising administering to a patient in need thereof a compound of formula (I), (I-1), (I-2), (II), (II-1), (II-2), (II-1-1), (II-1-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), ( IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (G), (G-1), (G-2), (B), (B-1), (B-2), (B-3), (B-4), (C), (C-1), (C-2), (E) or (E-1), or a compound shown in Table A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same; in some embodiments, the IL-17 is IL-17A.

[0629] The present disclosure further relates to a method for treating and / or preventing cancer, inflammation or autoimmune diseases, comprising administering to a patient in need thereof a compound of formula (I), (I-1), (I-2), (II), (II-1), (II-2), (II-1-1), (II-1-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (G), (G-1), (G-2), (B), (B-1), (B-2), (B-3), (B-4), (C), (C-1), (C-2), (E) or (E-1) or a pharmaceutically acceptable salt thereof, or a combination thereof Pharmaceutical composition; In some embodiments, the inflammatory or autoimmune disease is selected from arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa, rheumatoid arthritis, juvenile atopic arthritis, spondyloarthritis (e.g., axial spondyloarthritis), uveitis (e.g., non-infectious uveitis), bone erosion, intraperitoneal abscesses and adhesions, inflammatory bowel disease (IBD), Crohn's disease, allograft rejection (e.g., kidney), psoriasis, angiogenesis, arteriosclerosis Atherosclerosis, asthma (e.g., bronchial asthma), multiple sclerosis (MS), systemic lupus erythematosus, lupus nephritis, Behcet's syndrome (Behcet's disease), ulcerative colitis, Behcet's disease, Wegener's granulomatosis, sarcoidosis, systemic sclerosis, insulin-dependent diabetes mellitus, septic shock syndrome, Alzheimer's disease, inflammatory eye disease, palmoplantar pustulosis (PPP), atopic dermatitis, chronic obstructive pulmonary disease (COPD) and Helicobacter pylori-associated gastritis, in some embodiments selected from psoriasis, rheumatoid arthritis, spondyloarthritis and multiple sclerosis, in some embodiments psoriasis.

[0630] The present disclosure further relates to a compound of formula (I), (I-1), (I-2), (II), (II-1), (II-2), (II-1-1), (II-1-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (G), (G-1), (G-2), (B), (B-1), (B-2), (B-3), (B-4), (C), (C-1), (C-2), (E) or (E-1) or a compound shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, for use as a medicament.

[0631] The present disclosure further relates to a general formula (I), (I-1), (I-2), (II), (II-1), (II-2), (II-1-1), (II-1-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), ( VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (G), (G-1), (G-2), (B), (B-1), (B-2), (B-3), (B-4), (C), (C-1), (C-2), (E) or (E-1), or a compound shown in Table A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, for use as an IL-17 inhibitor; in some embodiments, the IL-17 is IL-17A.

[0632] The present disclosure further relates to a general formula (I), (I-1), (I-2), (II), (II-1), (II-2), (II-1-1), (II-1-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (G), (G-1), (G-2), (B), (B-1), (B-2), (B-3), (B-4), (C), (C-1), (C-2), (E) or (E-1) or a compound shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, for inhibiting IL-17; in some embodiments, the IL-17 is IL-17A.

[0633] The present disclosure further relates to a general formula (I), (I-1), (I-2), (II), (II-1), (II-2), (II-1-1), (II-1-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1 , (VI-2), (VII), (VII-1), (VII-2), (G), (G-1), (G-2), (B), (B-1), (B-2), (B-3), (B-4), (C), (C-1), (C-2), (E) or (E-1) or a compound shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, for use in a drug for treating and / or preventing a disease or condition mediated by IL-17; in some embodiments, the IL-17 is IL-17A.

[0634] The present disclosure further relates to a compound of formula (I), (I-1), (I-2), (II), (II-1), (II-2), (II-1-1), (II-1-2), (II-2-1), (II-2-2), (M), (M-1), (M-2), (X), (X-1), (X-2), (III), (III-1), (III-2), (IV), (IV-1), (IV-2), (V), (V-1), (V-2), (VI), (VI-1), (VI-2), (VII), (VII-1), (VII-2), (G), (G-1), (G-2), (B), (B-1), (B-2), (B-3), (B-4), (C), (C-1), (C-2), (E) or (E-1) or a compound shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, for use in treating and / or preventing cancer, inflammation or Autoimmune disease; In some embodiments, the inflammatory or autoimmune disease is selected from arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa, rheumatoid arthritis, juvenile atopic arthritis, spondyloarthritis (e.g., axial spondyloarthritis), uveitis (e.g., non-infectious uveitis), bone erosions, intraperitoneal abscesses and adhesions, inflammatory bowel disease (IBD), Crohn's disease, allograft rejection (e.g., kidney), psoriasis, angiogenesis, atherosclerosis, asthma (e.g., bronchial asthma), multiple sclerosis (MS), systemic lupus erythematosus, lupus nephritis, Behçet's disease, ulcerative colitis, Behçet's disease, Wegener's granulomatosis, sarcoidosis, systemic sclerosis, insulin-dependent diabetes mellitus, septic shock syndrome, Alzheimer's disease, inflammatory eye disease, palmoplantar pustulosis (PPP), atopic dermatitis, chronic obstructive pulmonary disease (COPD), and Helicobacter pylori. pylori-associated gastritis, in some embodiments selected from the group consisting of psoriasis, rheumatoid arthritis, spondyloarthritis, and multiple sclerosis, in some embodiments psoriasis.

[0635] The IL-17 mediated diseases or conditions of the present disclosure are, in some embodiments, selected from cancer, inflammation, or autoimmune diseases; in some embodiments, inflammation or autoimmune diseases; in some embodiments, inflammation; in some embodiments, the inflammation or autoimmune diseases are selected from arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa, rheumatoid arthritis, juvenile atopic arthritis, spondyloarthritis (e.g., axial spondyloarthritis), uveitis (e.g., non-infectious uveitis), bone erosions, intraperitoneal abscesses and adhesions, inflammatory Intestinal disease (IBD), Crohn's disease, allogeneic transplant rejection (e.g., kidney), psoriasis, angiogenesis, atherosclerosis, asthma (e.g., bronchial asthma), multiple sclerosis (MS), systemic lupus erythematosus, lupus nephritis, Behcet's disease, ulcerative colitis, Behcet's disease, Wegener's granulomatosis, sarcoidosis, systemic sclerosis, insulin-dependent diabetes mellitus, septic shock syndrome, Alzheimer's disease, inflammatory eye disease, palmoplantar pustulosis (PPP), atopic dermatitis, chronic obstructive pulmonary disease (COPD) and Helicobacter pylori-associated gastritis, in some embodiments selected from psoriasis, rheumatoid arthritis, spondyloarthritis and multiple sclerosis, in some embodiments psoriasis.

[0636] The psoriasis described herein is, in some embodiments, selected from plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, and palmoplantar psoriasis.

[0637] The spondyloarthritis described herein is, in some embodiments, axial spondyloarthritis.

[0638] The uveitis described in the present disclosure is, in some embodiments, non-infectious uveitis.

[0639] The asthma described in the present disclosure is, in some embodiments, bronchial asthma.

[0640] The IL-17 described in the present disclosure is, in some embodiments, IL-17A or IL-17F, and in some embodiments, IL-17A.

[0641] In some embodiments, the cancer described herein is selected from the group consisting of:

[0642] Heart: sarcomas (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma, and teratoma;

[0643] Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, enchondromatous hamartoma, mesothelioma;

[0644] Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumor, viperoma), small intestine (adenocarcinoma, lymphoma, carcinoid tumor, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large intestine (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma);

[0645] Genitourinary tract: Kidney (adenocarcinoma, Wilms tumor, lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratoma, choriocarcinoma, sarcoma, stromal cell carcinoma, fibroma, fibroadenoma, adenomatous tumor, lipoma);

[0646] Liver: liver cancer (hepatocellular carcinoma), bile duct cancer, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma;

[0647] Biliary tract: gallbladder cancer, ampullary cancer, bile duct cancer;

[0648] Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell chordoma, osteochronfroma (osteocartilaginous exostosis), benign enchondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumor;

[0649] Nervous system: skull (osteomas, hemangiomas, granulomas, xanthomas, osteitis deformans), meninges (meningiomas, meningiosarcoma, gliomatosis), brain (astrocytomas, medulloblastomas, gliomas, ependymomas, germ cell tumors, glioblastoma multiforme, oligodendrogliomas, schwannomas, retinoblastomas, congenital tumors), spinal neurofibromas, meningiomas, gliomas, sarcomas);

[0650] Gynecological: Uterus (endometrial cancer), cervix (cervical cancer, pre-tumor cervical dysplasia), ovary (ovarian cancer (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumor, Sertoli-Leydig cell tumor, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonic rhabdomyosarcoma), fallopian tube (carcinoma);

[0651] Hematological: Blood (myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma);

[0652] Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, hydatidiform mole, lipoma, hemangioma, dermatofibroma, keloid, psoriasis;

[0653] Adrenal glands: neuroblastoma.

[0654] As a general guide, the active compounds of the present disclosure are, in some embodiments, presented in unit dosage form, or in a form that a patient can self-administer as a single dose. A unit dosage form of a compound or composition of the present disclosure can be a tablet, capsule, cachet, bottled solution, powder, granule, lozenge, suppository, reconstituted powder, or liquid formulation. Suitable unit dosage forms can range from 0.1 to 1000 mg.

[0655] The pharmaceutical composition of the present disclosure may contain one or more excipients in addition to the active compound, selected from the following ingredients: fillers (diluents), binders, wetting agents, disintegrants or excipients, etc. Depending on the administration method, the composition may contain 0.1 to 99% by weight of the active compound.

[0656] In some embodiments, the unit dose of the pharmaceutical composition is 0.001 mg-1000 mg.

[0657] In certain embodiments, the pharmaceutical composition contains 0.01-99.99% of the aforementioned compound or its pharmaceutically acceptable salt or its isotopic substitution, based on the total weight of the composition. In certain embodiments, the pharmaceutical composition contains 0.1-99.9% of the aforementioned compound or its pharmaceutically acceptable salt or its isotopic substitution. In certain embodiments, the pharmaceutical composition contains 0.5%-99.5% of the aforementioned compound or its pharmaceutically acceptable salt or its isotopic substitution. In certain embodiments, the pharmaceutical composition contains 1%-99% of the aforementioned compound or its pharmaceutically acceptable salt or its isotopic substitution. In certain embodiments, the pharmaceutical composition contains 2%-98% of the aforementioned compound or its pharmaceutically acceptable salt or its isotopic substitution.

[0658] In certain embodiments, the pharmaceutical composition comprises 0.01% to 99.99% of a pharmaceutically acceptable excipient, based on the total weight of the composition. In certain embodiments, the pharmaceutical composition comprises 0.1% to 99.9% of a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical composition comprises 0.5% to 99.5% of a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical composition comprises 1% to 99% of a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical composition comprises 2% to 98% of a pharmaceutically acceptable excipient.

[0659] The pharmaceutically acceptable salts of the compounds described in the present disclosure may be selected from inorganic salts or organic salts.

[0660] Tablets contain the active ingredient in admixture with nontoxic, pharmaceutically acceptable excipients suitable for tablet preparation. These excipients may include inert excipients, granulating agents, disintegrants, binders, and lubricants. Tablets may be uncoated or coated using known techniques that mask the taste of the drug or delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained-release effect over a longer period of time.

[0661] Oral formulations may also be provided in soft gelatin capsules wherein the active ingredient is mixed with an inert solid diluent or with a water-soluble carrier or oil-soluble vehicle.

[0662] Aqueous suspensions contain the active substance in admixture with excipients suitable for the preparation of aqueous suspensions. Such excipients are suspending agents, dispersing agents, or wetting agents. Aqueous suspensions may also contain one or more preservatives, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents.

[0663] Oil suspensions can be prepared by suspending the active ingredient in a vegetable oil or mineral oil. The oil suspension may contain a thickener. The above-mentioned sweeteners and flavoring agents may be added to provide a palatable preparation. These compositions may be preserved by adding antioxidants.

[0664] The pharmaceutical compositions of the present disclosure may also be in the form of oil-in-water emulsions. The oil phase may be a vegetable oil, a mineral oil, or a mixture thereof. Suitable emulsifiers may be naturally occurring phospholipids, and the emulsion may also contain sweeteners, flavorings, preservatives, and antioxidants. Such formulations may also contain demulcents, preservatives, colorants, and antioxidants.

[0665] The pharmaceutical compositions disclosed herein may be in the form of sterile injectable aqueous solutions. Acceptable vehicles or solvents that may be used include water, Ringer's solution, and isotonic sodium chloride solution. Sterile injectable formulations may be sterile injectable oil-in-water microemulsions in which the active ingredient is dissolved in an oil phase. The injectable solution or microemulsion may be administered into the patient's bloodstream via local, bolus injection. Alternatively, the solutions and microemulsions may be administered in a manner that maintains a constant circulating concentration of the disclosed compound. To maintain this constant concentration, a continuous intravenous drug delivery device may be used. An example of such a device is the Deltec CADD-PLUS™ 5400 intravenous pump.

[0666] Pharmaceutical compositions of the present disclosure may be in the form of sterile water for injection or oil suspensions for intramuscular and subcutaneous administration. The suspensions may be prepared using suitable dispersants or wetting agents and suspending agents as described above according to known techniques. Sterile injectable formulations may also be sterile injectable solutions or suspensions prepared in parenteral, nontoxic diluents or solvents. In addition, sterile fixed oils may be conveniently used as solvents or suspension media. For this purpose, any blended fixed oil may be used. In addition, fatty acids may also be used to prepare injections.

[0667] The disclosed compounds can be administered in the form of suppositories for rectal administration. These pharmaceutical compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid in the rectum and will therefore melt in the rectum to release the drug.

[0668] The compounds of the present disclosure can be administered by preparing water-suspended dispersible powders and granules by adding water. These pharmaceutical compositions can be prepared by mixing the active ingredient with a dispersing or wetting agent, a suspending agent, or one or more preservatives.

[0669] As is well known to those skilled in the art, the dosage of a drug depends on a variety of factors, including but not limited to the following: the activity of the specific compound used, the severity of the disease, the age of the patient, the weight of the patient, the health status of the patient, the behavior of the patient, the diet of the patient, the time of administration, the mode of administration, the rate of excretion, the combination of drugs, etc.; in addition, the optimal treatment method such as the mode of treatment, the daily dose of the compound or the type of pharmaceutically acceptable salt can be verified according to traditional treatment regimens.

[0670] Terminology

[0671] Unless otherwise stated, the terms used in the specification and claims have the following meanings.

[0672] The term "alkyl" refers to a saturated straight-chain or branched aliphatic hydrocarbon group having 1 to 20 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) carbon atoms (i.e., C 1-20 The alkyl group, in some embodiments, has an alkyl group of 1 to 12 carbon atoms (i.e., C 1-12 alkyl), in some embodiments an alkyl group having 1 to 6 carbon atoms (i.e., C 1-6 Non-limiting examples include: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2 ,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched-chain isomers thereof. The alkyl group may be substituted or unsubstituted. When substituted, it may be substituted at any available point of attachment, and the substituents are, in some embodiments, selected from one or more of a deuterium atom, a halogen, an alkoxy group, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclyloxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group.

[0673] The term "alkylene" refers to a divalent alkyl group, wherein alkyl is as defined above, having from 1 to 20 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) carbon atoms (i.e., C 1-20The alkylene group, in some embodiments, has an alkylene group of 1 to 12 carbon atoms (i.e., C 1-12 alkylene), in some embodiments an alkylene group having 1 to 6 carbon atoms (i.e., C 1-6 Alkylene). Non-limiting examples include: -CH2-, -CH(CH3)-, -C(CH3)2-, -CH2CH2-, -CH(CH2CH3)-, -CH2CH(CH3)-, -CH2C(CH3)2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, etc. Alkylene can be substituted or unsubstituted. When substituted, it can be substituted at any available point of attachment. In some embodiments, the substituent is selected from one or more of a deuterium atom, a halogen, an alkoxy group, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclyloxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group.

[0674] The term "alkenyl" refers to an alkyl group containing at least one carbon-carbon double bond in the molecule, wherein alkyl is as defined above and has 2 to 12 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12) carbon atoms (i.e., C 2-12 The alkenyl group, in some embodiments, has 2 to 6 carbon atoms (i.e., C 2-6 Alkenyl). Non-limiting examples include: ethenyl, propenyl, isopropenyl, butenyl, etc. Alkenyl can be substituted or unsubstituted. When substituted, it can be substituted at any available point of attachment. The substituents are, in some embodiments, selected from one or more of a deuterium atom, an alkoxy group, a halogen, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclyloxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group.

[0675] The term "alkynyl" refers to an alkyl group containing at least one carbon-carbon triple bond in the molecule, wherein alkyl is as defined above and has 2 to 12 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12) carbon atoms (i.e., C 2-12 The alkynyl group, in some embodiments, has 2 to 6 carbon atoms (i.e., C 2-6 Alkynyl). Non-limiting examples include: ethynyl, propynyl, butynyl, pentynyl, hexynyl, etc. Alkynyl can be substituted or unsubstituted. When substituted, it can be substituted at any available point of attachment. The substituents are, in some embodiments, selected from one or more of a deuterium atom, an alkoxy group, a halogen, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclyloxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group.

[0676] The term "alkoxy" refers to -O-(alkyl), wherein alkyl is as defined above. Non-limiting examples include methoxy, ethoxy, propoxy, and butoxy. Alkoxy groups may be substituted or unsubstituted. When substituted, they may be substituted at any available point of attachment, with the substituents being selected, in some embodiments, from one or more of a deuterium atom, a halogen, an alkoxy group, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclyloxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group.

[0677] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic all-carbon ring (i.e., monocyclic cycloalkyl) or polycyclic ring system (i.e., polycyclic cycloalkyl) having 3 to 20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (i.e., 3- to 20-membered cycloalkyl). The cycloalkyl group has, in some embodiments, 3 to 12 ring atoms (i.e., 3 to 12-membered cycloalkyl) and 3 to 10 ring atoms (i.e., 3 to 10-membered cycloalkyl), in some embodiments 3 to 8 ring atoms (i.e., 3 to 8-membered cycloalkyl), in some embodiments 4 to 7 ring atoms (i.e., 4 to 7-membered cycloalkyl), in some embodiments 5 or 6 ring atoms (i.e., 5 or 6-membered cycloalkyl), in some embodiments 3 to 6 ring atoms (i.e., 3 to 6-membered cycloalkyl); in some embodiments, "cycloalkyl" refers to cycloalkyl with 4 to 10 ring atoms (i.e., 4 to 10-membered cycloalkyl); in some embodiments, "cycloalkyl" refers to cycloalkyl with 5 to 7 ring atoms (i.e., 5 to 7-membered cycloalkyl).

[0678] Non-limiting examples of the monocyclic cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl and cyclooctyl.

[0679] The polycyclic cycloalkyl group includes: spirocycloalkyl group, fused cycloalkyl group and bridged cycloalkyl group.

[0680] The term "spiroalkyl" refers to a polycyclic ring system having a common carbon atom (called a spiro atom) between the rings, which may contain one or more double bonds within the ring, or one or more heteroatoms selected from nitrogen, oxygen and sulfur within the ring (the nitrogen may be optionally oxidized, i.e., to form nitrogen oxides; the sulfur may be optionally oxoed, i.e., to form sulfoxides or sulfones, but excluding -OO-, -OS- or -SS-), provided that it contains at least one all-carbon ring and the point of attachment is on the all-carbon ring, and has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (i.e., a 5- to 20-membered spiroalkyl). The spiroalkyl group has, in some embodiments, 6 to 14 ring atoms (i.e., a 6- to 14-membered spiroalkyl group), and in some embodiments, 7 to 10 ring atoms (i.e., a 7- to 10-membered spiroalkyl group). The spirocycloalkyl includes monospirocycloalkyl and polyspirocycloalkyl (such as bispirocycloalkyl, etc.), in some embodiments monospirocycloalkyl or bispirocycloalkyl, in some embodiments 3 yuan / 4 yuan, 3 yuan / 5 yuan, 3 yuan / 6 yuan, 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 3 yuan, 5 yuan / 4 yuan, 5 yuan / 5 yuan, 5 yuan / 6 yuan, 5 yuan / 7 yuan, 6 yuan / 3 yuan, 6 yuan / 4 yuan, 6 yuan / 5 yuan, 6 yuan / 6 yuan, 6 yuan / 7 yuan, 7 yuan / 5 yuan or 7 yuan / 6 yuan monospirocycloalkyl. Non-limiting examples include:

[0681] Its connection point can be at any position;

[0682] wait.

[0683] The term "fused cycloalkyl" refers to a polycyclic ring system that shares two adjacent carbon atoms between the rings, which is a monocyclic cycloalkyl fused to one or more monocyclic cycloalkyls, or a monocyclic cycloalkyl fused to one or more heterocyclyls, aryls, or heteroaryls, wherein the point of attachment is on the monocyclic cycloalkyl, which may contain one or more double bonds within the ring, and has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., a 5- to 20-membered fused cycloalkyl). The fused cycloalkyl, in some embodiments, has 6 to 14 ring atoms (i.e., a 6- to 14-membered fused cycloalkyl), and in some embodiments, has 7 to 10 ring atoms (i.e., a 7- to 10-membered fused cycloalkyl). The fused cycloalkyl includes bicyclic fused cycloalkyl and polycyclic fused cycloalkyl (such as tricyclic fused cycloalkyl, tetracyclic fused cycloalkyl, etc.), in some embodiments bicyclic fused cycloalkyl or tricyclic fused cycloalkyl, in some embodiments 3 yuan / 4 yuan, 3 yuan / 5 yuan, 3 yuan / 6 yuan, 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 3 yuan, 5 yuan / 4 yuan, 5 yuan / 5 yuan, 5 yuan / 6 yuan, 5 yuan / 7 yuan, 6 yuan / 3 yuan, 6 yuan / 4 yuan, 6 yuan / 5 yuan, 6 yuan / 6 yuan, 6 yuan / 7 yuan, 7 yuan / 5 yuan or 7 yuan / 6 yuan bicyclic fused cycloalkyl. Non-limiting examples include:

[0684] Its connection point can be at any position;

[0685] wait.

[0686] The term "bridged cycloalkyl" refers to a full carbon polycyclic ring system that shares two carbon atoms that are not directly connected between the rings, which may contain one or more double bonds within the ring and has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) carbon atoms (i.e., 5 to 20-membered bridged cycloalkyl). The bridged cycloalkyl, in some embodiments, has a bridged cycloalkyl of 6 to 14 carbon atoms (i.e., 6 to 14-membered bridged cycloalkyl), and in some embodiments, has a bridged cycloalkyl of 7 to 10 carbon atoms (i.e., 7 to 10-membered bridged cycloalkyl). The bridged cycloalkyl includes bicyclic bridged cycloalkyl and polycyclic bridged cycloalkyl (e.g., tricyclic bridged cycloalkyl, tetracyclic bridged cycloalkyl, etc.), and in some embodiments, is a bicyclic bridged cycloalkyl or a tricyclic bridged cycloalkyl. Non-limiting examples include:

[0687] Its connection point can be at any position.

[0688] The cycloalkyl group may be substituted or unsubstituted. When substituted, it may be substituted at any available point of attachment, and the substituents are, in some embodiments, selected from one or more of a deuterium atom, a halogen, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclyloxy group, a hydroxyl group, a hydroxyalkyl group, an oxo group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group.

[0689] The term "heterocyclyl" refers to a saturated or partially unsaturated monocyclic heterocycle (i.e., a monocyclic heterocyclyl) or a polycyclic heterocyclic ring system (i.e., a polycyclic heterocyclyl) containing at least one (e.g., 1, 2, 3, or 4) heteroatoms selected from nitrogen, oxygen, and sulfur (the nitrogen may be optionally oxidized, i.e., to form nitrogen oxides; the sulfur may be optionally oxoed, i.e., to form sulfoxides or sulfones, but excluding -OO-, -OS-, or -SS-) in the ring, and having 3 to 20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., a 3- to 20-membered heterocyclyl). The heterocyclyl group, in some embodiments, has 3 to 12 ring atoms (i.e., 3 to 12-membered heterocyclyl); further in some embodiments, has 3 to 10 ring atoms (i.e., 3 to 10-membered heterocyclyl) and has 3 to 8 ring atoms (i.e., 3 to 8-membered heterocyclyl); in some embodiments, has 5 to 7 ring atoms (i.e., 5 to 7-membered heterocyclyl); in some embodiments, has 3 to 6 ring atoms (i.e., 3 to 6-membered heterocyclyl); in some embodiments, has 5 or 6 ring atoms (i.e., 5 or 6-membered heterocyclyl); in some embodiments, has 6 ring atoms (i.e., 6-membered heterocyclyl); in some embodiments, has 5 ring atoms (i.e., 5-membered heterocyclyl).

[0690] Non-limiting examples of the monocyclic heterocyclic group include pyrrolidinyl, tetrahydropyranyl, 1,2,3,6-tetrahydropyridinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl and homopiperazinyl.

[0691] The polycyclic heterocyclic group includes a spiro heterocyclic group, a fused heterocyclic group and a bridged heterocyclic group.

[0692] The term "spiroheterocyclyl" refers to a polycyclic heterocyclic ring system in which the rings share one atom (called a spiro atom), which may contain one or more double bonds in the ring and at least one (e.g., 1, 2, 3 or 4) heteroatom selected from nitrogen, oxygen and sulfur (the nitrogen may be optionally oxidized, i.e., to form a nitrogen oxide; the sulfur may be optionally oxidized, i.e., to form a sulfoxide or sulfone, but excluding -OO-, -OS- or -SS-), provided that it contains at least one monocyclic heterocyclic group and the point of attachment is on the monocyclic heterocyclic group, which has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (i.e., a 5- to 20-membered spiroheterocyclyl). The spiro heterocyclic radical has the spiro heterocyclic radical (i.e. 6 to 14 yuan spiro heterocyclic radical) of 6 to 14 ring atoms in some embodiments, and has the spiro heterocyclic radical (i.e. 7 to 10 yuan spiro heterocyclic radical) of 7 to 10 ring atoms in some embodiments. The spiro heterocyclic radical includes monospiro heterocyclic radical and polyspiro heterocyclic radical (such as dispiro heterocyclic radical etc.), in some embodiments monospiro heterocyclic radical or dispiro heterocyclic radical, in some embodiments 3 yuan / 4 yuan, 3 yuan / 5 yuan, 3 yuan / 6 yuan, 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 3 yuan, 5 yuan / 4 yuan, 5 yuan / 5 yuan, 5 yuan / 6 yuan, 5 yuan / 7 yuan, 6 yuan / 3 yuan, 6 yuan / 4 yuan, 6 yuan / 5 yuan, 6 yuan / 6 yuan, 6 yuan / 7 yuan, 7 yuan / 5 yuan or 7 yuan / 6 yuan monospiro heterocyclic radical. Non-limiting examples include:

[0693] wait.

[0694] The term "fused heterocyclyl" refers to a polycyclic heterocyclic ring system that shares two adjacent atoms between the rings, which may contain one or more double bonds within the ring and at least one (e.g., 1, 2, 3, or 4) heteroatom selected from nitrogen, oxygen, and sulfur (the nitrogen may be optionally oxidized, i.e., to form a nitrogen oxide; the sulfur may be optionally oxidized, i.e., to form a sulfoxide or sulfone, but excluding -OO-, -OS-, or -SS-), which is a monocyclic heterocyclyl fused to one or more monocyclic heterocyclyls, or a monocyclic heterocyclyl fused to one or more cycloalkyl, aryl, or heteroaryl groups, wherein the point of attachment is on the monocyclic heterocyclyl, and has 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., a 5- to 20-membered fused heterocyclyl). The fused heterocyclic radical has, in some embodiments, a fused heterocyclic radical of 6 to 14 ring atoms (i.e., a 6 to 14-membered fused heterocyclic radical), and in some embodiments, a fused heterocyclic radical of 7 to 10 ring atoms (i.e., a 7 to 10-membered fused heterocyclic radical). The fused heterocyclic radical includes bicyclic and polycyclic fused heterocyclic radicals (e.g., tricyclic fused heterocyclic radicals, tetracyclic fused heterocyclic radicals, etc.), in some embodiments, a bicyclic fused heterocyclic radical or a tricyclic fused heterocyclic radical, and in some embodiments, a 3-yuan / 4-yuan, 3-yuan / 5-yuan, 3-yuan / 6-yuan, 4-yuan / 4-yuan, 4-yuan / 5-yuan, 4-yuan / 6-yuan, 5-yuan / 3-yuan, 5-yuan / 4-yuan, 5-yuan / 5-yuan, 5-yuan / 6-yuan, 5-yuan / 7-yuan, 6-yuan / 3-yuan, 6-yuan / 4-yuan, 6-yuan / 5-yuan, 6-yuan / 6-yuan, 6-yuan / 7-yuan, 7-yuan / 5-yuan or 7-yuan / 6-yuan bicyclic fused heterocyclic radical. Non-limiting examples include:

[0695] wait.

[0696] The term "bridged heterocyclyl" refers to a polycyclic heterocyclic ring system that shares two atoms that are not directly connected between the rings, which may contain one or more double bonds within the ring and at least one (e.g., 1, 2, 3, or 4) heteroatom selected from nitrogen, oxygen, and sulfur (the nitrogen may be optionally oxidized, i.e., to form nitrogen oxides; the sulfur may be optionally oxoed, i.e., to form sulfoxides or sulfones, but excluding -OO-, -OS-, or -SS-), having 5 to 20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., a 5- to 20-membered bridged heterocyclyl). In some embodiments, the bridged heterocyclyl has 6 to 14 ring atoms (i.e., a 6- to 14-membered bridged heterocyclyl), and in some embodiments, has 7 to 10 ring atoms (i.e., a 7- to 10-membered bridged heterocyclyl). According to the number of constituent rings, it can be divided into bicyclic bridged heterocyclic groups and polycyclic bridged heterocyclic groups (such as tricyclic bridged heterocyclic groups, tetracyclic bridged heterocyclic groups, etc.), and in some embodiments, it is a bicyclic bridged heterocyclic group or a tricyclic bridged heterocyclic group. Non-limiting examples include:

[0697] wait.

[0698] The heterocyclyl group may be substituted or unsubstituted. When substituted, it may be substituted at any available point of attachment, and the substituents are, in some embodiments, selected from one or more of a deuterium atom, a halogen, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclyloxy group, a hydroxyl group, a hydroxyalkyl group, an oxo group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group.

[0699] The term "aryl" refers to a monocyclic all-carbon aromatic ring (i.e., a monocyclic aromatic group) or a polycyclic aromatic ring system (i.e., a polycyclic aromatic group) having a conjugated π electron system, which has 6 to 14 (e.g., 6, 7, 8, 9, 10, 11, 12, 13, or 14) ring atoms (i.e., a 6- to 14-membered aromatic group). The aryl group, in some embodiments, is an aromatic group having 6 to 10 ring atoms (i.e., a 6- to 10-membered aromatic group). The monocyclic aromatic group is, for example, a phenyl group. Non-limiting examples of the polycyclic aromatic group include: naphthyl, anthracenyl, phenanthrenyl, etc. The polycyclic aromatic group also includes a phenyl group fused to one or more heterocyclic groups or cycloalkyl groups, or a naphthyl group fused to one or more heterocyclic groups or cycloalkyl groups, wherein the connection point is on the phenyl group or naphthyl group, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic aromatic ring system, non-limiting examples include:

[0700] wait.

[0701] The aryl group may be substituted or unsubstituted. When substituted, it may be substituted at any available point of attachment, and the substituents are, in some embodiments, selected from one or more of a deuterium atom, a halogen, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclyloxy group, a hydroxyl group, a hydroxyalkyl group, an oxo group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group.

[0702] The term "heteroaryl" refers to a monocyclic heteroaromatic ring (i.e., a monocyclic heteroaryl) or a polycyclic heteroaromatic ring system (i.e., a polycyclic heteroaryl) having a conjugated π electron system, which contains at least one (e.g., 1, 2, 3 or 4) heteroatom selected from nitrogen, oxygen and sulfur (the nitrogen may be optionally oxidized, i.e., to form a nitrogen oxide; the sulfur may be optionally oxidized, i.e., to form a sulfoxide or sulfone, but excluding -OO-, -OS- or -SS-), and has 5 to 14 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14) ring atoms (i.e., a 5- to 14-membered heteroaryl). The heteroaryl group has, in some embodiments, from 5 to 10 ring atoms (i.e., a 5- to 10-membered heteroaryl group), in some embodiments, 5 or 6 ring atoms (i.e., a 5- or 6-membered heteroaryl group); in some embodiments, 5 ring atoms (i.e., a 5-membered heteroaryl group); and in some embodiments, 6 ring atoms (i.e., a 6-membered heteroaryl group).

[0703] The monocyclic heteroaryl groups include, but are not limited to, furyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furazanyl, pyrrolyl, N-alkylpyrrolyl, pyridyl, pyrimidinyl, pyridonyl, N-alkylpyridone (e.g. etc.), pyrazinyl, pyridazinyl, pyridine nitrogen oxide, etc.

[0704] The polycyclic heteroaryl groups include, but are not limited to, indolyl, indazolyl, quinolyl, isoquinolyl, quinoxalinyl, phthalazinyl, benzimidazolyl, benzothiophenyl, quinazolinyl, benzothiazolyl, carbazolyl, and the like. The polycyclic heteroaryl groups also include monocyclic heteroaryl groups fused to one or more aromatic groups, wherein the point of attachment is on the aromatic ring, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic heteroaromatic ring system. The polycyclic heteroaryl groups also include monocyclic heteroaryl groups fused to one or more cycloalkyl or heterocyclic groups, wherein the point of attachment is on the monocyclic heteroaromatic ring, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic heteroaromatic ring system. Non-limiting examples include:

[0705] wait.

[0706] The heteroaryl group may be substituted or unsubstituted. When substituted, it may be substituted at any available point of attachment, and the substituents are, in some embodiments, selected from one or more of a deuterium atom, a halogen, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a cycloalkyloxy group, a heterocyclyloxy group, a hydroxyl group, a hydroxyalkyl group, a cyano group, an amino group, a nitro group, a cycloalkyl group, a heterocyclyl group, an aryl group, and a heteroaryl group.

[0707] The term "amino protecting group" refers to a group that is easily removed and introduced onto an amino group in order to keep the amino group unchanged while reacting other parts of the molecule. Non-limiting examples include: (trimethylsilyl)ethoxymethyl, tetrahydropyranyl, tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz), methyloxycarbonyl (Fmoc), allyloxycarbonyl (Alloc), trimethylsilylethoxycarbonyl (Teoc), methoxycarbonyl, ethoxycarbonyl, phthaloyl (Pht), p-toluenesulfonyl (Tos), tert-butylsulfinyl, trifluoroacetyl (Tfa), trichloroacetyl, trityl (Trt), 2,4-dimethoxybenzyl (DMB), p-methoxybenzyl (PMB), acetyl, benzyl, allyl, p-methoxybenzyl, and the like.

[0708] The term "hydroxy protecting group" refers to a group that is introduced on a hydroxy group and is easily removed, and is used to block or protect the hydroxy group while reacting on other functional groups of the compound. Non-limiting examples include: trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), tert-butyldimethylsilyl (TBS), tert-butyldimethylsilyl (TBDMS), tert-butyldiphenylsilyl (TBDPS), methyl, tert-butyl, allyl, benzyl, methoxymethyl (MOM), ethoxyethyl, 2-tetrahydropyranyl (THP), formyl, acetyl, benzoyl, p-nitrobenzoyl, etc.

[0709] The term "cycloalkylalkyl" refers to an alkyl group substituted with one or more cycloalkyl groups, wherein cycloalkyl and alkyl are as defined above.

[0710] The term "heterocyclylalkyl" refers to an alkyl group substituted by one or more heterocyclyl groups, wherein heterocyclyl and alkyl are as defined above.

[0711] The term "arylalkyl" refers to an alkyl group substituted with one or more aryl groups, wherein aryl and alkyl are as defined above.

[0712] The term "heteroarylalkyl" refers to an alkyl group substituted with one or more heteroaryl groups, wherein heteroaryl and alkyl are as defined above.

[0713] The term "alkoxyalkyl" refers to an alkyl group substituted by one or more alkoxy groups, wherein alkoxy and alkyl are as defined above.

[0714] The term "cycloalkyloxy" refers to a cycloalkyl-O- group in which cycloalkyl is as defined above.

[0715] The term "heterocyclyloxy" refers to a heterocyclyl-O- group in which heterocyclyl is as defined above.

[0716] The term "aryloxy" refers to an aryl-O- group in which the aryl group is as defined above.

[0717] The term "heteroaryloxy" refers to a heteroaryl-O- group in which heteroaryl is as defined above.

[0718] The term "alkylthio" refers to an alkyl-S- group in which alkyl is as defined above.

[0719] The term "haloalkyl" refers to an alkyl group substituted with one or more halogens, wherein alkyl is as defined above.

[0720] The term "deuterated alkoxy" refers to an alkoxy group substituted with one or more deuterium atoms, wherein alkoxy is as defined above.

[0721] The term "haloalkoxy" refers to an alkoxy group substituted with one or more halogens, wherein alkoxy is as defined above.

[0722] The term "deuterated alkyl" refers to an alkyl group substituted with one or more deuterium atoms, wherein alkyl is as defined above.

[0723] The term "hydroxyalkyl" refers to an alkyl group substituted with one or more hydroxy groups, wherein alkyl is as defined above.

[0724] The term "hydroxyalkoxy" refers to an alkoxy group substituted with one or more hydroxy groups, wherein alkoxy is as defined above.

[0725] The term "methylidene" refers to =CH2.

[0726] The term "halogen" refers to fluorine, chlorine, bromine or iodine.

[0727] The term "hydroxy" refers to -OH.

[0728] The term "mercapto" refers to -SH.

[0729] The term "amino" refers to -NH2.

[0730] The term "cyano" refers to -CN.

[0731] The term "nitro" refers to -NO2.

[0732] The term "oxo" or "oxo" refers to "=0".

[0733] The term "carbonyl" refers to C=O.

[0734] The term "acetyl" refers to -C(O)CH3.

[0735] The term "amido" refers to -C(O)NH2.

[0736] The term "carboxy" refers to -C(O)OH.

[0737] The term "carboxylate" refers to -C(O)O(alkyl), -C(O)O(cycloalkyl), (alkyl)C(O)O-, or (cycloalkyl)C(O)O-, where alkyl and cycloalkyl are as defined above.

[0738] The term "aminoalkyl" refers to an alkyl group substituted with one or more amino groups, wherein amino and alkyl are as defined above.

[0739] "Substituted or unsubstituted" refers to both the situation that the group is substituted and the situation that it is not substituted; when substituted, it can be substituted at any available point of attachment, and the substituent is selected from one or more of deuterium atom, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl in some embodiments.

[0740] The disclosed compounds may exist in specific stereoisomeric forms. The term "stereoisomer" refers to isomers having identical structures but different arrangements of atoms in space. It includes cis and trans (or Z and E) isomers, (-)- and (+)-isomers, (R)- and (S)-enantiomers, diastereomers, (D)- and (L)-isomers, tautomers, atropisomers, conformers and mixtures thereof (such as racemates, mixtures of diastereomers). The substituents in the disclosed compounds may have additional asymmetric atoms. All of these stereoisomers and their mixtures are included within the scope of the present disclosure. Optically active (-)- and (+)-isomers, (R)- and (S)-enantiomers and (D)- and (L)-isomers can be prepared by chiral synthesis, chiral reagents or other conventional techniques. An isomer of a compound disclosed herein can be prepared by asymmetric synthesis or chiral auxiliary, or, when the molecule contains a basic functional group (e.g., amino) or an acidic functional group (e.g., carboxyl), by forming a diastereomeric salt with an appropriate optically active acid or base, followed by diastereomeric resolution by conventional methods known in the art to obtain the pure isomer. Furthermore, separation of enantiomers and diastereomers is typically accomplished by chromatography.

[0741] In the chemical structures of the compounds disclosed herein, the bond Indicates that the configuration is not specified, that is, if chiral isomers exist in the chemical structure, the bond Can be or or include both and Two configurations. In the chemical structure of the compound disclosed in the present invention, the bond The configuration is not specified, that is, it can be Z or E, or both. For all carbon-carbon double bonds, even if only one configuration is named, both Z and E are included; The configuration is not specified, that is, it can be Z configuration or E configuration, or contain both configurations.

[0742] In the chemical structures of the compounds disclosed herein, "rac" is short for racemate (also known as raceme), which refers to an equimolar mixture of a pair of enantiomers. For example, when the compound has only one chiral center, "rac" refers to an equimolar mixture of the (R) configuration and the (S) configuration; when the compound has two chiral centers, "rac" refers to an equimolar mixture of the (R,R) configuration and the (S,S) configuration; or an equimolar mixture of the (R,S) configuration and the (S,R) configuration. Specifically, "rac-(1R,2R)" means that the compound is a racemate, which is an equimolar mixture of the (1R,2R) configuration and the (1S,2S) configuration.

[0743] The compounds of the present disclosure may exist in different tautomeric forms, and all such forms are included within the scope of the present disclosure. The term "tautomer" or "tautomeric form" refers to a structural isomer that exists in equilibrium and is readily converted from one isomeric form to another. This includes all possible tautomers, i.e., existing as a single isomer or as a mixture of any proportions of the tautomers. Non-limiting examples include: keto-enol, imine-enamine, lactam-lactim, etc. An example of an enamine-imine equilibrium is shown below:

[0744] For example, when referring to pyrazolyl, it is understood to include either of the following two structures or a mixture of two tautomers:

[0745] For another example, the disclosed compound 4 should be understood to include any one of the following two structures or a mixture of two tautomers:

[0746] All tautomeric forms are within the scope of the present disclosure, and the naming of compounds does not exclude any tautomer.

[0747] The compounds of the present disclosure include all suitable isotopic derivatives of the compounds thereof. The term "isotopic derivative" refers to a compound in which at least one atom is replaced by an atom having the same atomic number but a different atomic mass. Examples of isotopes that can be introduced into the compounds of the present disclosure include stable and radioactive isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine, and iodine, for example, 2 H (deuterium, D), 3 H (tritium, T),11 C. 13 C. 14 C. 15 N. 17 O. 18 O. 32 P. 33 P. 33 S. 34 S. 35 S. 36 S. 18 F. 36 Cl, 82 Br, 123 I. 124 I. 125 I. 129 I and 131 I, etc., in some embodiments, deuterium.

[0748] Compared to non-deuterated drugs, deuterated drugs have advantages such as reduced toxic side effects, increased drug stability, enhanced efficacy, and prolonged biological half-life. All isotopic variations of the compounds disclosed herein, whether radioactive or not, are encompassed by the present disclosure. Each available hydrogen atom attached to a carbon atom can be independently replaced with a deuterium atom, where the deuterium replacement can be partial or complete. Partial deuterium replacement refers to the replacement of at least one hydrogen atom with at least one deuterium atom.

[0749] Compounds of the present disclosure, when a position is specifically designated as "deuterium" or "D," are understood to have an abundance of deuterium at that position that is at least 1000 times greater than the natural abundance of deuterium (which is 0.015%) (i.e., at least 15% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 1000 times greater than the natural abundance of deuterium (i.e., at least 15% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 2000 times greater than the natural abundance of deuterium (i.e., at least 30% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 3000 times greater than the natural abundance of deuterium (i.e., at least 45% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 3340 times greater than the natural abundance of deuterium (i.e., at least 50.1% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 3500 times greater than the natural abundance of deuterium (i.e., at least 52.5% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 4000 times greater than the natural abundance of deuterium (i.e., at least 60% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 4500 times greater than the natural abundance of deuterium (i.e., at least 67.5% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 5000 times greater than the natural abundance of deuterium (i.e., at least 75% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 5500 times greater than the natural abundance of deuterium (i.e., at least 82.5% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 6000 times greater than the natural abundance of deuterium (i.e., at least 90% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 6333.3 times greater than the natural abundance of deuterium (i.e., at least 95% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 6466.7 times greater than the natural abundance of deuterium (i.e., at least 97% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 6600 times greater than the natural abundance of deuterium (i.e., at least 99% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 6633.3 times greater than the natural abundance of deuterium (ie, at least 99.5% deuterium incorporation).

[0750] "Optional" or "optionally" means that the event or circumstances described subsequently may but need not occur, and includes both situations in which the event or circumstances occur and do not occur. For example, "alkyl optionally (optionally) substituted with halogen or cyano" includes both situations in which the alkyl is substituted with halogen or cyano and situations in which the alkyl is not substituted with halogen and cyano.

[0751] "Substitution" or "substituted" means that one or more hydrogen atoms, in some embodiments 1 to 6, and in some embodiments 1 to 3 hydrogen atoms, in a group are independently replaced by a corresponding number of substituents. One skilled in the art will be able to determine (by experiment or theory) whether substitution is possible or not without undue effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when combined with a carbon atom with an unsaturated bond (such as an alkene).

[0752] A "pharmaceutical composition" refers to a mixture containing one or more compounds described herein, or pharmaceutically acceptable salts thereof, and other chemical components, as well as other components such as pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitating absorption of the active ingredients and thereby exerting their biological activity.

[0753] "Pharmaceutically acceptable salts" refer to salts of the compounds of the present disclosure, which may be selected from inorganic or organic salts. Such salts are safe and effective for use in mammals and possess the desired biological activity. They can be prepared during the final isolation and purification of the compound, or separately by reacting a suitable group with a suitable base or acid. Bases commonly used to form pharmaceutically acceptable salts include inorganic bases, such as sodium hydroxide and potassium hydroxide, and organic bases, such as ammonia. Acids commonly used to form pharmaceutically acceptable salts include inorganic acids and organic acids.

[0754] The term "pharmaceutically acceptable" as used herein refers to compounds, materials, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with patient tissues without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio, and effective for the intended use.

[0755] As used herein, the singular form "a," "an," and "the" include plural references and vice versa unless the context clearly dictates otherwise.

[0756] When the term "about" is applied to a parameter such as pH, concentration, temperature, etc., it indicates that the parameter can vary by ±10%, and in some embodiments, within ±5%. As will be understood by those skilled in the art, when a parameter is not critical, a number is generally given for illustrative purposes only and is not limiting. BRIEF DESCRIPTION OF THE DRAWINGS

[0757] Figure 1 shows the clinical scores of the limbs of CIA model rats.

[0758] Figure 2 shows the hind limb volume of CIA model rats.

[0759] FIG3 shows foot swelling in CIA model rats.

[0760] FIG4 shows the body weight changes of CIA model rats. DETAILED DESCRIPTION

[0761] The present disclosure is further described below with reference to the following embodiments, but these embodiments are not intended to limit the scope of the present disclosure.

[0762] Example

[0763] The structures of the compounds were determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). -6 The unit of ppm is given. NMR measurements were performed using a Bruker AVANCE-400 NMR spectrometer or a Bruker AVANCE NEO 500M NMR spectrometer. The solvents used were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), or deuterated methanol (CD3OD), and tetramethylsilane (TMS) was used as the internal standard.

[0764] MS was measured using an Agilent 1200 / 1290DAD-6110 / 6120 Quadrupole MS liquid spectrometer / mass spectrometer (manufacturer: Agilent, MS model: 6110 / 6120 Quadrupole MS), a Waters ACQuity UPLC-QD / SQD (manufacturer: Waters, MS model: Waters ACQuity Qda Detector / Waters SQ Detector), and a THERMO Ultimate 3000-Q Exactive (manufacturer: THERMO, MS model: THERMO Q Exactive).

[0765] High performance liquid chromatography (HPLC) analysis was performed using Agilent HPLC 1200DAD, Agilent HPLC 1200VWD and Waters HPLC e2695-2489 high performance liquid chromatographs.

[0766] Chiral HPLC analysis was performed using an Agilent 1260DAD high performance liquid chromatograph.

[0767] High performance liquid chromatography (HPLC) was performed using Waters 2545-2767, Waters 2767-SQ Detecor2, Shimadzu LC-20AP, and Gilson GX-281 preparative chromatographs.

[0768] Chiral preparations were performed using a Shimadzu LC-20AP preparative chromatograph.

[0769] The CombiFlash rapid preparation instrument used was Combiflash Rf200 (TELEDYNE ISCO).

[0770] The thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate. The specification of the silica gel plate used in thin layer chromatography (TLC) is 0.15mm~0.2mm, and the specification used for thin layer chromatography separation and purification products is 0.4mm~0.5mm.

[0771] Silica gel column chromatography generally uses Yantai Huanghai 200-300 mesh silica gel as the carrier.

[0772] Average kinase inhibition rate and IC 50 The values ​​were determined using a NovoStar microplate reader (BMG, Germany).

[0773] The known starting materials of the present invention can be synthesized by methods known in the art, or can be purchased from companies such as ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Accela ChemBio Inc, and Darui Chemicals.

[0774] Unless otherwise specified in the examples, all reactions can be carried out under an argon atmosphere or a nitrogen atmosphere.

[0775] Argon atmosphere or nitrogen atmosphere means that the reaction bottle is connected to an argon or nitrogen balloon with a capacity of about 1 L.

[0776] Hydrogen atmosphere means that the reaction bottle is connected to a hydrogen balloon with a capacity of about 1L.

[0777] The pressurized hydrogenation reaction uses a Parr 3916EKX hydrogenator and a Qinglan QL-500 hydrogen generator or an HC2-SS hydrogenator.

[0778] The hydrogenation reaction is usually carried out by evacuating the chamber and filling it with hydrogen, and the operation is repeated three times.

[0779] A CEM Discover-S 908860 microwave reactor was used for the microwave reaction.

[0780] Unless otherwise specified in the examples, the solution refers to an aqueous solution.

[0781] Unless otherwise specified in the examples, the reaction temperature is room temperature.

[0782] The reaction progress in the examples was monitored by thin layer chromatography (TLC). The developing solvent used in the reaction, the eluent system for column chromatography used to purify the compound, and the developing solvent system for thin layer chromatography included: A: dichloromethane / methanol system, B: n-hexane / ethyl acetate system, and C: petroleum ether / ethyl acetate system. The volume ratio of the solvent was adjusted according to the polarity of the compound, and a small amount of alkaline or acidic reagents such as triethylamine and acetic acid could also be added for adjustment.

[0783] Example 1

[0784] 3-(4-(2-(4-(difluoromethylene)cyclohexyl)-2-(1-methyl-1H-pyrazole-5-carboxamido)acetamido)phenyl)-2,4-dimethylpyridine 1-oxide 1

[0785] first step

[0786] Methyl 2-(((Benzyloxy)carbonyl)amino)-2-(1,4-dioxaspiro[4.5]decan-8-ylidene)acetate 1b

[0787] (±)-Benzyloxycarbonyl-α-phosphonoglycine trimethyl ester (21.2 g, 64.00 mmol, Shanghai Shaoyuan) was dissolved in dichloromethane (100 mL), and bicyclo[5.4.0]-1,8-diaza-7-nonene (DBU) (9.70 g, 63.72 mmol) was added dropwise at room temperature. The mixture was reacted at room temperature for 30 minutes. A dichloromethane solution (20 mL) of 1,4-dioxaspiro[4.5]decan-8-one 1a (10 g, 64.03 mmol, Shanghai Shaoyuan) was added, and the mixture was stirred at room temperature under a nitrogen atmosphere for 16 hours. Water was added to the reaction solution, and the mixture was extracted with dichloromethane (60 mL×3). The organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system B to obtain the title compound 1b (10.5 g, yield: 45.4%).

[0788] MS m / z(ESI):362.3[M+1].

[0789] Step 2

[0790] Methyl 2-amino-2-(1,4-dioxaspiro[4.5]dec-8-yl)acetate 1c

[0791] Compound 1b (10.5 g, 29.05 mmol) was dissolved in methanol (40 mL), and 10% palladium on carbon (containing 55% water) (927 mg, 8.71 mmol) was added. The reaction was stirred at room temperature under a hydrogen atmosphere for 16 hours. The reaction solution was filtered through celite, and the organic phase was concentrated under reduced pressure to give the crude title compound 1c (6 g, yield: 90.1%), which was used directly in the next reaction without purification.

[0792] MS m / z(ESI):230.4[M+1].

[0793] Step 3

[0794] Methyl 2-(((Benzyloxy)carbonyl)amino)-2-(1,4-dioxaspiro[4.5]dec-8-yl)acetate 1d

[0795] Compound 1c (6 g, 26.17 mmol) was dissolved in tetrahydrofuran (60 mL) and saturated sodium bicarbonate solution (60 mL). Benzyl chloroformate (6 g, 35.17 mmol, Shanghai Shaoyuan) was added dropwise under ice-cooling. The reaction was stirred at room temperature for 16 hours. The reaction solution was extracted with ethyl acetate (60 mL × 3). The organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent System B to give the title compound 1d (6.5 g, yield: 68.3%).

[0796] MS m / z(ESI):364.1[M+1].

[0797] Step 4

[0798] 2-(((Benzyloxy)carbonyl)amino)-2-(1,4-dioxaspiro[4.5]dec-8-yl)acetic acid 1e

[0799] Compound 1d (485 mg, 1.33 mmol) was dissolved in tetrahydrofuran (6 mL) and water (6 mL), and lithium hydroxide monohydrate (112 mg, 2.67 mmol) was added. The mixture was stirred at room temperature for 16 hours. 1N hydrochloric acid was added to adjust the pH to about 5. The reaction solution was extracted with ethyl acetate (20 mL × 3). The organic phases were combined and concentrated under reduced pressure to give the crude title compound 1e (390 mg, yield: 83.6%), which was used directly in the next reaction without purification.

[0800] MS m / z(ESI):350.3[M+1].

[0801] Step 5: Benzyl (2-((4-(2,4-dimethylpyridin-3-yl)phenyl)amino)-2-oxo-1-(1,4-dioxaspiro[4.5]dec-8-yl)ethyl)carbamate 1g

[0802] 4-(2,4-Dimethylpyridin-3-yl)aniline 1f (240 mg, 1.21 mmol, prepared by the method disclosed in Intermediate 1-18 on page 65 of the specification of patent application "WO2022091056") and compound 1e (423 mg, 1.21 mmol) were dissolved in pyridine (9 mL), and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (696 mg, 3.63 mmol, Shanghai Shaoyuan) was added. The reaction was stirred at room temperature for 16 hours, and the reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system A to obtain the title compound 1g (500 mg, yield: 78.0%).

[0803] MS m / z(ESI):530.5[M+1].

[0804] Step 6

[0805] 2-Amino-N-(4-(2,4-dimethylpyridin-3-yl)phenyl)-2-(1,4-dioxaspiro[4.5]dec-8-yl)acetamide 1h

[0806] Compound 1g (500 mg, 0.94 mmol) was dissolved in tetrahydrofuran (8 mL) and ethanol (8 mL), and 10% palladium on carbon (containing 55% water) (200 mg, 0.19 mmol) was added. The reaction was stirred at room temperature under a hydrogen atmosphere for 1 hour. The reaction solution was filtered through celite, and the organic phase was concentrated under reduced pressure to give the crude title compound 1h (373 mg, yield: 99%), which was used directly in the next reaction without purification.

[0807] MS m / z(ESI):396.4[M+1].

[0808] Step 7

[0809] N-(2-((4-(2,4-dimethylpyridin-3-yl)phenyl)amino)-2-oxo-1-(1,4-dioxaspiro[4.5]dec-8-yl)ethyl)-1-methyl-1H-pyrazole-5-carboxamide 1i

[0810] Compound 1h (107 mg, 270.5 μmol) and 1-methyl-1H-pyrazole-5-carboxylic acid (47.8 mg, 378.8 μmol, Shanghai Leyan) were dissolved in N,N-dimethylformamide (3 mL), and N,N-diisopropylethylamine (70 mg, 541.1 μmol) and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (154.3 mg, 405.8 μmol) were added. The reaction was stirred at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system A to give the title compound 1i (130 mg, yield: 95.4%).

[0811] MS m / z(ESI):504.5[M+1].

[0812] Step 8

[0813] N-(2-((4-(2,4-dimethylpyridin-3-yl)phenyl)amino)-2-oxo-1-(4-oxocyclohexyl)ethyl)-1-methyl-1H-pyrazole-5-carboxamide 1j

[0814] Compound 1i (130 mg, 258.1 μmol) was dissolved in tetrahydrofuran (3 mL), 2N hydrochloric acid (2 mL) was added, and the reaction was stirred at room temperature for 2 hours. Saturated sodium bicarbonate solution was added to the reaction solution for neutralization, and the reaction solution was extracted with ethyl acetate (10 mL×3). The organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system A to give the title compound 1j (118 mg, yield: 99%).

[0815] MS m / z(ESI):460.2[M+1].

[0816] Step 9

[0817] N-(1-(4-(difluoromethylene)cyclohexyl)-2-((4-(2,4-dimethylpyridin-3-yl)phenyl)amino)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide 1k

[0818] Compound 1j (140 mg, 304.7 μmol) and 2-((difluoromethyl)sulfonyl)pyridine (117.7 mg, 609.3 μmol, Leyan) were dissolved in N,N-dimethylformamide (9 mL), and potassium tert-butoxide (1.83 mL, 1.83 mmol, 1 M THF solution) was added at -40°C. The reaction was stirred at -40°C for 3 hours. Saturated ammonium chloride solution was added to the reaction solution, and the reaction solution was extracted with ethyl acetate (20 mL×3). The organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system A to give the title compound 1k (130 mg, yield: 86.5%).

[0819] MS m / z(ESI):494.2[M+1].

[0820] Step 10

[0821] 3-(4-(2-(4-(difluoromethylene)cyclohexyl)-2-(1-methyl-1H-pyrazole-5-carboxamido)acetamido)phenyl)-2,4-dimethylpyridine 1-oxide 1

[0822] Compound 1k (130 mg, 263.4 μmol) was dissolved in dichloromethane (4 mL), and m-chloroperbenzoic acid (54.5 mg, 316.1 μmol) was added. The reaction mixture was stirred at room temperature for 40 minutes. Saturated sodium bicarbonate solution was added to the reaction solution, and the reaction solution was extracted with dichloromethane (10 mL×3). The organic phases were combined and concentrated under reduced pressure. The residue was purified by preparative HPLC (Waters-2545, column: YMC Triart-Exrs C18, 30×150 mm, 5 μm; mobile phase: aqueous phase (10 mmol / L ammonium bicarbonate) and acetonitrile, gradient ratio: acetonitrile 35%-45%, flow rate: 30 mL / min) to give the title compound 1 (15 mg, yield: 11.2%).

[0823] MS m / z(ESI):510.4[M+1].

[0824] 1 H NMR (500MHz, CD3OD): δ8.29(d,1H),7.81(dd,2H),7.50(d,1H),7.37(d,1H),7.22(d,2H),6.94(d,1H),5.36(t ,1H),4.12(s,3H),2.29(s,3H),2.21(t,1H),2.13(s,3H),2.05(d,2H),1.91(s,1H),1.62(d,1H),0.92(t,4H).

[0825] Example 2

[0826] N-(1-(4-(difluoromethylene)cyclohexyl)-2-((3-fluoro-1-(1-(5-fluoro-2-oxo-1,2-dihydropyridin-3-yl)-2-methoxyethyl)-1H-pyrazol-4-yl)amino)-2-oxoethyl)-4-methyl-1,2,5-oxadiazole-3-carboxamide 2

[0827] first step

[0828] 1-(5-Fluoro-2-methoxypyridin-3-yl)-2-methoxyethan-1-one 2b

[0829] Under ice-cooling, n-butyllithium (3.88 mL, 9.71 mmol, 2.5 M hexane solution) was added to a solution of isopropylmagnesium bromide (4.85 mL, 4.85 mmol, 1 M THF solution) in tetrahydrofuran (4 mL), and the reaction was stirred at 0°C for 15 minutes. A solution of 3-bromo-5-fluoro-2-methoxypyridine 2a (1 g, 4.85 mmol, Leyan) in tetrahydrofuran (1 mL) was added at -10°C, and the reaction was stirred for 2 hours. N-methoxy-N-methyl-2-methoxyacetamide (1.29 g, 9.71 mmol, Shanghai Titan) was then added, and the reaction was stirred at 0°C for 2 hours. Saturated ammonium chloride solution was added to the reaction solution, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic phases were combined and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using eluent System B to afford the title compound 2b (560 mg, 57.9% yield).

[0830] MS m / z(ESI):200.1[M+1].

[0831] Step 2

[0832] 1-(5-Fluoro-2-methoxypyridin-3-yl)-2-methoxyethan-1-ol 2c

[0833] Compound 2b (560 mg, 2.81 mmol) was dissolved in methanol (10 mL), and sodium borohydride (106.4 mg, 2.81 mmol) was added at 0°C. The reaction mixture was stirred at room temperature for 1 hour. Saturated ammonium chloride solution was added to the reaction solution, and the mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent System A to give the title compound 2c (540 mg, yield: 95.5%).

[0834] MS m / z(ESI):202.1[M+1].

[0835] Step 3

[0836] 5-Fluoro-3-(1-(3-fluoro-4-nitro-1H-pyrazol-1-yl)-2-methoxyethyl)-2-methoxypyridine 2e

[0837] Compound 2c (540 mg, 2.68 mmol) and 3-fluoro-4-nitro-1H-pyrazole 2d (422 mg, 3.22 mmol, prepared by the method disclosed in Intermediate 16 on page 71 of the specification of patent application "WO2022212538") were dissolved in tetrahydrofuran (20 mL), and triphenylphosphine (1.06 g, 4.03 mmol) and diisopropyl azodicarboxylate (814 mg, 4.03 mmol) were added at 0°C. The reaction was stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system B to give the title compound 2e (700 mg, yield: 83.0%).

[0838] MS m / z(ESI):315.2[M+1].

[0839] Step 4

[0840] 3-Fluoro-1-(1-(5-fluoro-2-methoxypyridin-3-yl)-2-methoxyethyl)-1H-pyrazol-4-amine 2f

[0841] Compound 2e (700 mg, 2.23 mmol) was dissolved in ethanol (10 mL) and water (2 mL), and iron powder (622 mg, 11.14 mmol) and ammonium chloride (596 mg, 11.14 mmol) were added. The reaction was stirred at 80°C for 16 hours. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system A to give the title compound 2f (490 mg, yield: 77.4%).

[0842] MS m / z(ESI):285.1[M+1].

[0843] Step 5

[0844] Benzyl (2-((3-fluoro-1-(1-(5-fluoro-2-methoxypyridin-3-yl)-2-methoxyethyl)-1H-pyrazol-4-yl)amino)-2-oxo-1-(1,4-dioxaspiro[4.5]dec-8-yl)ethyl)carbamate 2g

[0845] Compound 2f (340 mg, 1.20 mmol) and compound 1e (417.9 mg, 1.20 mmol) were dissolved in N,N-dimethylformamide (5 mL), and N,N-diisopropylethylamine (309.2 mg, 2.39 mmol) and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (681.8 mg, 1.79 mmol) were added. The reaction was stirred at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent System A to give the title compound 2g (700 mg, yield: 95.1%).

[0846] MS m / z(ESI):616.4[M+1].

[0847] Step 6

[0848] 2-Amino-N-(3-fluoro-1-(1-(5-fluoro-2-methoxypyridin-3-yl)-2-methoxyethyl)-1H-pyrazol-4-yl)-2-(1,4-dioxaspiro[4.5]dec-8-yl)acetamide

[0849] Compound 2g (700 mg, 1.34 mmol) was dissolved in tetrahydrofuran (5 mL) and ethanol (5 mL), and 10% palladium on carbon (containing 55% water) (200 mg, 0.19 mmol) was added. The mixture was stirred at room temperature under a hydrogen atmosphere for 1 hour. The reaction solution was filtered through celite, and the organic phase was concentrated under reduced pressure to give the crude title compound 2h (547 mg, yield: 99%), which was used directly in the next reaction without purification.

[0850] MS m / z(ESI):482.3[M+1].

[0851] Step 7

[0852] N-(2-((3-fluoro-1-(1-(5-fluoro-2-methoxypyridin-3-yl)-2-methoxyethyl)-1H-pyrazol-4-yl)amino)-2-oxo-1-(1,4-dioxaspiro[4.5]dec-8-yl)ethyl)-4-methyl-1,2,5-oxadiazole-3-carboxamide 2i

[0853] Compound 2h (620 mg, 1.29 mmol) and 4-methyl-1,2,5-oxadiazole-3-carboxylic acid (200 mg, 1.56 mmol, Shanghai Leyan) were dissolved in N,N-dimethylformamide (10 mL), and N,N-diisopropylethylamine (500 mg, 3.86 mmol) and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (734.4 mg, 1.93 mmol) were added. The reaction was stirred at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure and the residue was purified by silica gel column chromatography with eluent system A to give the title compound 2i (600 mg, yield: 78.8%).

[0854] MS m / z(ESI):592.5[M+1].

[0855] Step 8

[0856] N-(2-((3-fluoro-1-(1-(5-fluoro-2-methoxypyridin-3-yl)-2-methoxyethyl)-1H-pyrazol-4-yl)amino)-2-oxo-1-(4-oxocyclohexyl)ethyl)-4-methyl-1,2,5-oxadiazole-3-carboxamide 2j

[0857] Compound 2i (600 mg, 1.01 mmol) was dissolved in tetrahydrofuran (6 mL), and 2N hydrochloric acid (3 mL) was added. The reaction was stirred at room temperature for 1 hour. Saturated sodium bicarbonate solution was added to the reaction solution for neutralization. The reaction solution was extracted with ethyl acetate (10 mL×3). The organic phases were combined and concentrated un...

Claims

1. A compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, in: Ring A is selected from aryl, heteroaryl, cycloalkyl and heterocyclyl; Ring B is a cycloalkyl group or a heterocyclic group; R 1 is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkylalkyl group, and a heterocyclylalkyl group; R 2 is selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, -C(O)R a 、-C(S)R a 、-C(O)OR a and -C(O)NR b R c The alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl are each independently optionally substituted by one or more R A replace; R a , R b and R c are the same or different and are each independently selected from a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group and a heteroarylalkyl group; the alkyl group, the alkenyl group, the alkynyl group, the cycloalkyl group, the heterocyclyl group, the aryl group, the heterocyclylalkyl group, the arylalkyl group and the heteroarylalkyl group are each independently optionally replaced by one or more R A replace; Or, R b and R c Together with the nitrogen atom to which it is attached, it forms a heterocyclic group, which is optionally substituted by one or more R A replace; R 3 A hydrogen atom or n4 is 0, 1, 2 or 3; n5 is 0, 1, 2 or 3; R 3a , R 3b , R 3c and R 3d are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, hydroxyl, cyano, amino, nitro, -(CR x R y ) s OR d 、-(CR x R y ) s NR e R f 、-C(O)R d 、-C(S)R d 、-C(O)OR d 、-C(S)OR d 、-OC(O)R d 、-OC(O)NR e R f 、-C(O)NR e R f 、-C(S)NR e R f 、-NR g C(O)R d 、-NR g C(S)R d 、-NR g C(O)OR d 、-NR g C(S)OR d 、-NR g C(O)NR e R f 、-NR g C(S)NR e R f 、-S(O) v R d 、-S(O) v OR d 、-S(O) v NR e R f 、-NR g S(O) v NR e R f 、-NR g S(O) v R d and P(O)R h R i The alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl are each independently optionally substituted by one or more R B replace; Or, R 3a and R 3b and the connected carbon atoms together form a cycloalkyl or heterocyclic group, wherein the cycloalkyl and heterocyclic groups are each independently optionally substituted by one or more R B replace; Or, R on the same carbon atom 3a and R 3b Together they form = O; R d , R e and R f are the same or different and are each independently selected from a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group and a heteroarylalkyl group; the alkyl group, the alkenyl group, the alkynyl group, the cycloalkyl group, the heterocyclyl group, the arylalkyl group, the heterocyclylalkyl group, the arylalkyl group and the heteroarylalkyl group are each independently optionally replaced by one or more R B replace; Or, R e and R f Together with the nitrogen atom to which it is attached, it forms a heterocyclic group, which is optionally substituted by one or more R B replace; R g is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkylalkyl group, and a heterocyclylalkyl group; R h and R i are the same or different and are each independently selected from a hydrogen atom, a hydroxyl group, an alkyl group, an alkenyl group, an alkynyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, an alkoxy group, a haloalkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group and a heteroaryl group; wherein the alkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, the aryl group and the heteroaryl group are each independently optionally replaced by one or more R B replace; R 4 =O or =S; Or, R 4 connected to ring A to form a heterocyclic group or heteroaryl group fused to ring A; the heterocyclic group and heteroaryl group are each independently optionally substituted by one or more R 7 replace; R 5 For R 5a ; or R 5 does not exist; R 5a is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group, and a heteroarylalkyl group; X is a key or CR m R n ; R m and R n are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, hydroxyl, cyano, amino and nitro; wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl are each independently optionally replaced by one or more R 0 replaced by; R A , R B , R 6 and R 7 are the same or different and are each independently selected from halogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, hydroxyl, cyano, amino, nitro, -(CR x R y ) s OR 10 、-(CR x R y ) s NR 11 R 12 、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)NR 11 R 12 、-C(O)NR 11 R 12 、-NR 13 C(O)R 10 、-NR 13 C(O)OR 10 、-NR 13 C(O)NR 11 R 12 、-S(O) v R 10 、-S(O) v OR 10 、-S(O) v NR 11 R 12 、-NR 13 S(O) v R 10 , oxo, =S, =NR 14 , =CR 15 R 16 and P(O)R 17a R 17b wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl are each independently optionally substituted by one or more R 0 replaced by; Or, two R 6 and the atoms to which they are attached together form a cycloalkyl or heterocyclic group, wherein the cycloalkyl and heterocyclic groups are each independently optionally substituted by one or more R 0 replace; R 8 and R 9 are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, -OR 10 、-C(O)R 10 、-C(O)OR 10 and cyano, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl are each independently optionally substituted by one or more R 0 replace; Or, R 8 and R 9 and the carbon atoms to which it is connected together form a cycloalkyl or heterocyclic group, wherein the cycloalkyl and heterocyclic groups are each independently optionally substituted by one or more R 0 replace; R 10 , R 11 and R 12 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, an arylalkyl group and a heteroarylalkyl group; the alkyl group, the alkenyl group, the alkynyl group, the cycloalkyl group, the heterocyclyl group, the arylalkyl group, the heterocyclylalkyl group, the arylalkyl group and the heteroarylalkyl group are each independently optionally replaced by one or more R 0 replace; Or, R 11 and R 12 Together with the nitrogen atom to which it is attached, it forms a heterocyclic group, which is optionally substituted by one or more R 0 replace; R 13 is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkylalkyl group, and a heterocyclylalkyl group; R 14 is selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, hydroxyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, cycloalkyloxy and heterocyclyloxy; wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, cycloalkyloxy and heterocyclyloxy are each independently optionally replaced by one or more R 0 replace; R 15 and R 16 are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, -C(O)alkyl, -C(O)Oalkyl and cyano, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl are each independently optionally replaced by one or more R 0 replace; Or, R 15 and R 16 Together with the carbon atom to which it is attached, it forms a cycloalkyl group or a heterocyclic group, wherein the cycloalkyl group and the heterocyclic group are each independently optionally substituted by one or more R 0 replace; R 17a and R 17b are the same or different and are each independently selected from a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a hydroxyl group, an alkoxy group, a haloalkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group and a heteroaryl group; wherein the alkyl group, the alkenyl group, the alkynyl group, the alkoxy group, the cycloalkyl group, the heterocyclic group, the aryl group and the heteroaryl group are each independently optionally replaced by one or more R 0 replace; R 0 are the same or different and are each independently selected from oxo, =S, =NR 18 , =CR 19 R 20 , halogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, hydroxy, cyano, amino, nitro, -(CR x R y ) s OR 21 、-(CR x R y ) s NR 22 R 23 、-C(O)R 21 、-C(O)OR 21 、-OC(O)R 21 、-OC(O)NR 22 R 23 、-C(O)NR 22 R 23 、-NR 24 C(O)R 21 、-NR 24 C(O)OR 21 、-NR 24 C(O)NR 22 R 23 、-S(O) v R 21 、-S(O) v OR 21 、-S(O) v NR 22 R 23 and-NR 24 S(O) v R 21 wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl are each independently optionally substituted by one or more R t replace; R 18 is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a hydroxyl group, an alkoxy group, a haloalkoxy group, a cycloalkyl group, a heterocyclyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl group, a heterocyclylalkyl group, a cycloalkyloxy group, and a heterocyclyloxy group; R 19 and R 20 are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl and heteroarylalkyl; Or, R 19 and R 20 Together with the carbon atom to which it is attached, it forms a cycloalkyl group or a heterocyclic group, wherein the cycloalkyl group and the heterocyclic group are each independently optionally substituted by one or more R t replace; R 21 , R 22 and R 23 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclic group, an aryl group and a heteroaryl group; the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group and the heteroaryl group are each independently optionally replaced by one or more R t replace; Or, R 22 and R 23 Together with the carbon atom to which it is attached, it forms a heterocyclic group, which is optionally substituted by one or more R t replace; R 24 is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxyalkyl group, a cycloalkyl group, a heterocyclyl group, a cycloalkylalkyl group, and a heterocyclylalkyl group; Each R t are the same or different and are each independently selected from the group consisting of oxo, =S, =NH, halogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkoxy, haloalkoxy, cyano, nitro, hydroxy, amino, -NHalkyl, -N(alkyl), -C(O)alkyl, -C(O)OH, -C(O)Oalkyl, -C(O)NH, -C(O)NH(alkyl), -C(O)N(alkyl), -S-alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; R x and R y are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, hydroxy, cyano, amino, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl and heterocyclylalkyl; s is 0, 1, or 2; n1 is 0, 1 or 2; n2 is 0, 1, 2, 3, 4 or 5; n3 is 0, 1, 2, 3, 4 or 5; v is 0, 1, or 2.

2. The compound of general formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, which is a compound of general formula (M), general formula (M-1) or general formula (M-2) or a pharmaceutically acceptable salt thereof: in: Ring A, Ring B, R a , R 3 , R 6 -R 9 , n2 and n3 are as defined in claim 1.

3. The compound of general formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 or 2, which is a compound of general formula (X), general formula (X-1) or general formula (X-2) or a pharmaceutically acceptable salt thereof: in: Ring C is a nitrogen-containing heterocyclic group; q is 0, 1, 2, 3, 4, or 5; R 7c is a hydrogen atom or R 7 ; G 1 , G 2 , G 3 and G 4 Each independently is O or S; R 25 Selected from R d , OR d and NR e R f ; Ring B, R B , R a , R d , R e , R f , R 3b , R 6 -R 9 and n2 as defined in claim 1.

4. The compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, which is a compound represented by the general formula (VII), the general formula (VII-1) or the general formula (VII-2) or a pharmaceutically acceptable salt thereof: in: R 7c is a hydrogen atom or R 7 ; R Q Selected from hydrogen atoms, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl and -C(O)C 1-6 alkyl; R bb is a hydrogen atom or R B ; R a , Ring B, R B , R d , R 3b , R 6 -R 9 and n2 as defined in claim 1.

5. A compound represented by general formula (C), general formula (C-1) or general formula (C-2) or a pharmaceutically acceptable salt thereof, in: R 7d , R 7e and R 7f are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen and an alkyl group; R 2c , R 2d , R 2e , R 2f and R 2g are the same or different and are each independently a hydrogen atom or a deuterium atom; or, R 2f and R 2g and the atoms to which they are attached together form a cycloalkyl group; R 3b is an alkyl group or a cycloalkyl group, wherein the alkyl group is optionally substituted by one or more substituents selected from the group consisting of a cycloalkyl group, a cycloalkyloxy group, an alkoxy group and a haloalkoxy group; R bb is a hydrogen atom or an alkyl group; R 3e is a hydrogen atom or an alkyl group.

6. The compound of general formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 or 2, which is a compound of general formula (E) or general formula (E-1) or a pharmaceutically acceptable salt thereof, in: R B1 is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group and a cycloalkyl group; R B3 is selected from the group consisting of a hydrogen atom, a halogen, an alkyl group, a haloalkyl group, an alkoxy group and a cycloalkyl group; R 7c is selected from the group consisting of a hydrogen atom, a halogen, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkoxy group, a haloalkoxy group, a cycloalkyl group and a cyano group; Ring B, R a , R 3c , R 6 、n2、R 8 and R 9 As defined in claim 1.

7. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 and 6, wherein R a is optionally replaced by one or more R A Substituted 5- or 6-membered heteroaryl; R A are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 haloalkoxy, 3 to 6-membered cycloalkyl and cyano; preferably, R a Selected from 8. The compound of general formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein ring A is phenyl or a 5- or 6-membered heteroaryl group; preferably, ring A is selected from phenyl, pyrazolyl, pyridyl and pyridazinyl.

9. A compound of the general formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 2, 7 and 8, wherein R 3 for n4 is 0 or 1; n5 is 0 or 1; R 3a is a hydrogen atom; R 3b Selected from C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl and 3 to 6 membered cycloalkyl; R 3c and R 3d The same or different, and each independently selected from C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy C 1-6 Alkyl, C 1-6 Haloalkyl, -C(O)R d 、-C(S)R d 、-NR g C(O)R d 、-NR g C(S)R d 、-C(O)NR e R f 、-C(S)NR e R f 、-NR g C(O)NR e R f 、-NR g C(S)NR e R f , 5 or 6-membered heterocyclic group and 5 or 6-membered heteroaryl; the 5 or 6-membered heterocyclic group and the 5 or 6-membered heteroaryl are each independently optionally substituted by one or more R B Replacement; R d Selected from C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered heterocyclic group and 3 to 8 membered cycloalkyl C 1-6 alkyl; the 3 to 8 membered heterocyclic group and the 3 to 8 membered cycloalkyl C 1-6 The alkyl groups are each independently optionally substituted with one or more R B Replacement; R e and R f are the same or different and are each independently selected from a hydrogen atom, a C 1-6 Alkyl, C 1-6 Haloalkyl and 3 to 6-membered cycloalkyl; R g is a hydrogen atom; R B are the same or different and are each independently selected from halogen, C 1-6 Alkyl, C 1-6 Preferably, R 3 Selected from 10. The compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 and 6 to 9, wherein ring B is a 4- to 10-membered cycloalkyl group or a 4- to 10-membered heterocyclic group; preferably, ring B is selected from 11. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 and 6 to 10, wherein R 8 and R 9 are the same or different and are each independently selected from hydrogen atoms, halogens and C 1-6 Alkyl; or, R 8 and R 9 and the carbon atoms to which they are connected together form a 3- to 6-membered cycloalkyl group; preferably, R 8 and R 9 are the same or different and are each independently a hydrogen atom or a halogen.

12. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 and 6 to 11, wherein R 6 Selected from halogen, C 1-6 Alkyl and C 1-6 haloalkyl; and / or n2 is 0 or 1.

13. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 12, wherein R 3b C 1-6 alkyl or 3 to 6-membered cycloalkyl; preferably, R 3b It is methyl or cyclopropyl.

14. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 13, wherein R d Selected from C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 Alkoxy C 1-6 Alkyl; preferably, R d Selected from ethyl, methoxymethyl, 15. A compound or a pharmaceutically acceptable salt thereof, which is selected from any of the following compounds:

16. A compound represented by the general formula (Ca), (C-1a) or (C-2a) or a salt thereof, in: R 7d , R 7e , R 7f , R 3b , R 3e and R bb As defined in claim 5.

17. A compound represented by the general formula (EA) or (E-1A) or a salt thereof, in: Ring B, R 6 、n2、R 8 , R 9 , R 3c , R 7c , R B1 and R B3 As defined in claim 6.

18. A compound or a salt thereof selected from the following compounds:

19. A method for preparing a compound represented by general formula (C), general formula (C-1) or general formula (C-2) or a pharmaceutically acceptable salt thereof, the method comprising: The compound represented by the general formula (Ca) or its salt undergoes a condensation reaction with the compound represented by the general formula (Bb) or its salt to obtain the compound represented by the general formula (C) or its pharmaceutically acceptable salt; The compound represented by the general formula (C-1a) or its salt undergoes a condensation reaction with the compound represented by the general formula (Bb) or its salt to obtain the compound represented by the general formula (C-1) or its pharmaceutically acceptable salt; The compound represented by the general formula (C-2a) or its salt undergoes a condensation reaction with the compound represented by the general formula (Bb) or its salt to obtain the compound represented by the general formula (C-2) or its pharmaceutically acceptable salt; in: R w is OH or halogen; preferably, R w for OH; R 2c , R 2d , R 2e , R 2f , R 2g , R 3b , R 3e , R bb , R 7d , R 7e and R 7f As defined in claim 5.

20. A method for preparing a compound represented by general formula (E) or (E-1) or a pharmaceutically acceptable salt thereof, the method comprising: in: The compound represented by the general formula (EA) or a salt thereof and R w C(O)R a The compound or its salt undergoes a condensation reaction to obtain a compound represented by general formula (E) or a pharmaceutically acceptable salt thereof; The compound represented by the general formula (E-1A) or a salt thereof and R w C(O)R a The compound or its salt undergoes a condensation reaction to obtain a compound represented by the general formula (E-1) or a pharmaceutically acceptable salt thereof; in: R w is OH or halogen; preferably, R w for OH; R a , Ring B, R 6 、n2、R 8 , R 9 , R 3c , R 7c , R B1 and R B3 As defined in claim 6.

21. A pharmaceutical composition comprising a compound according to any one of claims 1 to 15 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.

22. Use of a compound according to any one of claims 1 to 15 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to claim 21 in the preparation of a medicament for treating and / or preventing a disease or condition mediated by IL-17; preferably, wherein the IL-17 is IL-17A.

23. Use of a compound according to any one of claims 1 to 15 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to claim 21 in the preparation of a medicament for treating and / or preventing cancer, inflammation or an autoimmune disease; preferably, the inflammation or autoimmune disease is selected from arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, suppurative hidradenitis, rheumatoid arthritis, juvenile atopic arthritis, spondyloarthritis, uveitis, bone erosion, intraperitoneal abscesses and adhesions, inflammatory bowel disease, Crohn's disease, allograft rejection, psoriasis, Angiogenesis, atherosclerosis, asthma, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, Behcet's syndrome (Behcet's disease), ulcerative colitis, Behcet's disease, Wegener's granulomatosis, sarcoidosis, systemic sclerosis, insulin-dependent diabetes mellitus, septic shock syndrome, Alzheimer's disease, inflammatory eye disease, palmoplantar pustulosis (PPP), atopic dermatitis, chronic obstructive pulmonary disease (COPD), and Helicobacter pylori-associated gastritis, preferably selected from psoriasis, rheumatoid arthritis, spondyloarthritis and multiple sclerosis, more preferably psoriasis.

Images